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SUMMARY
1. The pharmacological actions of adenosine and adenosine S’-triphosphate (ATP) are 
reviewed. The current knowledge of purinoceptor subtj^es involved in mediating the 
actions of adenosine and ATP are summarised and the factors affecting the actions of 
purines are discussed.
2. The ontogeny of responses to adenosine, ATP and related analogues was studied in 
the rat duodenum, urinary bladder and vasa deferentia. In rat duodenum and rat urinary 
bladder responses to adenosine and ATP mediated by Pi- and P2-purinoceptors 
respectively were present as early as posmatal day 2, the earliest day tested. In rat vasa 
deferentia responses to adenosine and ATP were not observed until posmatal day 15.
3. In rat duodenum adenosine and adenosine 5'-(P,y-methylene) triphosphonate 
(AMPPCP) were inhibitory, their potency being less than the adult at 5 days, lowest at 10 
days and highest at 25 days. The effects of adenosine and AMPPCP were mediated by 
Pl-puiinoceptors as their responses were antagonized by 8-(p-sulphophenyl)theophylline 
(8-SPT). The Pi-puiinoceptor action of AMPPCP was not due to its degradation to 
adenosine as it was resistant to degradation in this tissue. .
4. The adenosine analogues, N6-cyclopentyladenosine (CPA), 5'-N-ethyl- 
carboxamidoadenosine (NECA) and 2-p-((carboxyethyl)phenethylamino)-5'-carbo- 
xamidoadenosine (CGS21680) were also inhibitory on rat duodenum, the order of 
potency of the adenosine agonists was NECA ^  CPA > AMPPCP = adenosine > 
CGS21680, and 1,3-dipropyl-8-cyclopentylxanthine (DPCPX) antagonized CPA and 
AMPPCP at a' concentration of InM whereas equivalent antagonism of NECA and 
adenosine required a concentration of IpM. This suggests the presence of a mixture of 
Ax and A2 receptors in this tissue, with CPA and AMPPCP acting on the Ai and NECA
and adenosine acting on the A% receptors. The low potency of CGS21680 in this tissue 
suggests that the A2 receptor is of the A2b subtype.
5. In rat duodenum low concentrations of ATP were inhibitory at every age studied and 
its potency increased with age, however higher concentrations of ATP (3pM and above) 
were excitatory until day 15 after which no contractions to ATP were seen. Both 
relaxations and contractions were mediated by P2Y-purmoceptors as 2-
methylthioadenosine 5'-triphosphate (2MeSATP) was much more potent than ATP or 
adenosine 5'-(a,p-methylene) triphosphonate (AMPCPP) at mediating these effects. 
These ATP-induced contractions were not inhibited by indomethacin (25pM) or by 
tetrodotoxin (IpM) and are therefore not due to prostaglandin synthesis or to ATP- 
induced release of transmitter substances from nerves.
6 . In rat urinary bladder adenosine was inhibitory and was more potent in the neonate 
than in the adult. The adenosine analogues NECA, CPA and CGS21680 were also 
inhibitory with an order of potency of NECA »  adenosine > CPA = CGS21680. A 
concentration of DPCPX of IpM was required to antagonize responses to NECA and 
adenosine suggesting the presence of A2 receptors in this tissue. The low potency of 
CGS21680 would suggest that the A2 receptors are of the A2b subtype.
7. ATP and AMPPCP were excitatory on rat urinary bladder, their actions mediated by 
P2X-purinoceptors. The potency of the nucleotides initially increased with age but then 
declined, being highest between posmatal days 10 and 25. The ATP- and AMPPCP- 
induced contractions were not enhanced by DPCPX (IpM) which suggests that in this 
tissue AMPPCP was acting only via P2-purinoceptors and had no Pi agonist activity. 
That AMPPCP was active on the Ai receptors in the duodenum but inactive on the A2 
receptors in the bladder implies that it has selectivity for the Ai subtype.
8. The changes in potency for adenosine and ATP in both rat duodenum and urinary 
bladder are not due to changes in the rate of degradation of the purines as both the rate 
and pattern of breakdown was similar in adult and neonatal animals.
9. In rat vasa deferentia adenosine inhibited nerve-mediated contractions from posmatal 
day 15 (the earliest day at which nerve-mediated responses could be observed), and its 
potency decreased with age. The Pi-purinoceptor agonists CPA and NECA also
inhibited nerve-mediated contractions with an order of potency of CPA = NECA >
I
adenosine. InM DPCPX antagonized the inhibitory effect of CPA whereas IpM DPCPX 
was required to antagonize responses to adenosine and NECA suggesting that CPA acts 
via Ai and NECA and adenosine act via A2 receptors. CPA was inactive as an inhibitor
of contractions induced by exogenous ATP or noradrenaline (lOpM) whereas adenosine 
and NECA inhibited these contractions with NECA > adenosine at mediating this effect. 
These results show that the rat vas deferens contains both presynaptic Ai receptors and 
postsynaptic A2 receptors, and that adenosine acts on the latter population to inhibit 
nerve-mediated contractions.
10. ATP contracted rat vasa deferentia from posmatal day 15 and its potency increased 
with age up to day 25. The development of the response to ATP was similar to nerve- 
mediated contractions, which were also observed at day 15 and increased with age. In 
contrast, contractions to noradrenaline were present from day 10 (the earliest day tested) 
and decreased with age.
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CHAPTER 1: INTRODUCTION
15
1.1. GENERAL INTRODUCTION
For many years adenosine 5'-triphosphate (ATP) has been recognised as an important 
intracellular metabolic intermediate. Cells have complex mechanisms for 
synthesizing and conserving ATP and one might therefore expect that release of ATP 
to the extracellular milieu would rarely occur (Arch & Newsholme, 1978). The 
demonstration of neuronal release of ATP from sensory nerves following antidromic 
stimulation of sensory nerve fibres in the skin of rabbit ear challenged this idea 
(Holton, 1959) and there is now wide acceptance that ATP is released from a variety 
of sources including neurones (Su, 1975), platelets (Mills et al., 1968), endothelial 
and smooth muscle cells (Pearson & Gordon, 1979). It was in the late 1920*s that the 
physiological importance of extracellular adenine nucleotides and nucleosides started 
to emerge, culminating in the current view that ATP and adenosine can influence 
many biological processes (for review see Williams, 1987).
In 1929, Drury and Szent-Gyorgyi examined the effects of heart, brain, kidney and 
spleen extracts on the mammalian heart. They found that tissue extracts, when 
injected intravenously into whole animals induced bradycardia and reduced the 
contractile force of the heart. There was also a lowering of arterial pressure which in 
part was due to arterial dilatation. The active compound responsible for these effects 
was extracted and identified as adenylic acid (adenosine 5-monophosphate, AMP), 
however since the effect of tissue extract was delayed upon administration into the 
animal and the fact that adenosine was found to produce identical effects, they 
concluded that the activity of AMP was due to its subsequent dephosphorylation in 
the animal to adenosine (Drury & Szent-Gyôrgyi, 1929).
The physiological significance of purines was not fully appreciated until 1963 when 
Berne suggested that adenosine was a metabolic modulator. He proposed that high
16
concentrations of adenosine were released in hypoxic conditions and that adenosine 
acted in such a way as to reduce metabolic demand and/or increase oxygen 
availability e.g. by reducing heart rate and inducing coronary vasodilatation (Berne. 
1963). The idea of adenosine as a metabolic regulator is now widely excepted and its 
effects on the cardiovascular system have been well documented (for review see, 
Olsson & Pearson, 1990). The action of adenosine on the cardiovascular system will 
be discussed further in I.5.I.I. however it is of interest to note that despite intensive 
research into the development of physiologically active adenosine analogues 
adenosine itself is the only currently available therapeutic agent. Adenosine is used in 
the treatment of supraventricular tachycardia, however its use is often limited as it 
produces pain upon administration (Pantely & Bristow, 1990; Bowmer & Yates, 
1989).
Not only is adenosine recognised as having important actions on the cardiovascular 
system it has also been shown to have an important modulatory role in the central 
nervous system (CNS). Adenosine has a net inhibitory effect on the CNS and, for 
example, it can inhibit the release of various neurotransmitters including 
acetylcholine, dopamine, 5-hydroxytryptamine (5-HT), noradrenaline y-aminobutyric 
acid (GABA) and glutamate (Fredholm & Hedqvist 1980; Hollins & Stone, 1980; 
Corradetti et al., 1984 and AUgaier'et al., 1987). Pharmacologically, adenosine is 
seen as an anxiolytic agent (Williams, 1983) a sedative and anticonvulsant 
(Dunwiddie & Worth, 1982), and as it can inhibit the release of excitatory amino 
acids such as aspartate and glutamate it may be useful in the prevention of neuronal 
damage that usually accompanies cerebrovascular stroke and neurodegenerative 
disorders such as Huntington's chorea (Bowmer & Yates, 1989).
Adenosine has been implicated as an important mediator in acute renal failure 
(Churchill & Bidani, 1982) and adenosine antagonists appear to offer some protection
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against the damaging effects of adenosine (Jacobson et al., 1991). Adenosine 
however can have beneficial actions in the kidney as damage to the kidney often 
results in the launch of an inflammatory response. Inflammatory cells release a 
number of factors that can cause tissue damage including cytokines and free radicals. 
Adenosine is an immunosuppressor and acts to limit the inflammatory response and 
reduce tissue damage (Samet, 1985; Cronstein et al., 1990). Thus there may be a fine 
balance between the physiological and pathological effects of adenosine in disease.
The physiological importance of ATP emerged from the realisation that the 
autonomic nervous system did not comprise entirely of cholinergic and adrenergic 
neurones. Although there was early evidence that stimulation of nerves in both gut 
and bladder could give rise to responses that were resistant to the muscarinic 
antagonist atropine, it was still felt that these uncharacteristic responses could be 
explained in the context of adrenergic and cholinergic transmitters. In 1963, it was 
found that intramural nerve stimulation of the guinea-pig taenia coli produced a 
relaxation that was resistant to blockade by the adrenergic neurone blocker 
guanethidine (Bumstock et al., 1963) and it soon became apparent that in a large 
number of smooth muscle preparations nerve stimulation gave rise to responses that 
were resistant to both adrenergic and cholinergic antagonists and these nerves were 
subsequently classified as "non-adrenergic, non-cholinergic". A wide variety of 
substances have been proposed as putative neurotransmitters released from non- 
adrenergic non-cholinergic nerves including 5-HT, histamine, GABA, bradykinin and 
substance P (SP). Although these substances may well be neurotransmitters released 
from some non-adrenergic, non-cholinergic nerves e.g. 5-HT and SP have been found 
to be present in enteric neurones of the gastrointestinal tract, there is increasing 
evidence that ATP is the neurotransmitter released from non-adrenergic, non- 
cholinergic neurones directly iimervatihg the smooth muscle of the intestine and 
bladder (for review see Bumstock, 1981). Studies have shown that ATP closely
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mimicks the response to non-adrenergic, non-cholinergic nerve stimulation in 
gastrointestinal and bladder preparations from a number of different animals, both in 
terms of the type of the response seen (contraction or relaxation) and the time course 
of the response (Bumstock et. al., 1972b).
Where strong evidence has been obtained for the release of ATP from non- 
adrenergic, non-cholinergic nerves these have been classified as "purinergic" 
(Bumstock, 1972). However in order for ATP to be classified as a neurotransmitter it 
should fulfill certain criteria: it should be synthesized and stored in nerve terminals; 
be released upon nerve stimulation; post-junctional responses to exogenously applied 
putative transmitter should mimic nerve stimulation; enzymes should be present to 
inactivate the transmitter and/or an uptake system for the transmitter or its breakdown 
products, and dmgs which inhibit or potentiate responses to putative transmitter 
should have the same effect on nerve stimulation (Eccles, 1964). Although most of 
these criteria have been met, the lack of selective ATP receptor antagonists have 
meant that a definite role for ATP as a neurotransmitter cannot be assumed.
1.2. SYNTHESIS AND RELEASE OF ADENINE NUCLEOTIDES
Evidence for neuronal storage of ATP has come from studies with the fluorescent dye 
quinacrine, which binds to ATP. Quinaciine fluorescence has been demonstrated in a 
number of nerves including those which supply the annococcygeus muscle 
(Bumstock et al., 1978a) and gastrointestinal tract (Crowe & Bumstock, 1981). The 
use of radiolabelled tracers such as [3H] adenosine has provided further evidence for 
the storage of ATP in tissues such as the guinea-pig taenia coli (Su et al., 1971).
19
There is now direct evidence for the release of ATP. Originally release of ATP was 
detected using the incoiporation of radiolabelled compounds such as [3H] adenosine 
into nerve endings however this method has now been largely replaced by the 
luciferin-luciferase firefly assay which is extremely sensitive and specific for ATP 
and can usually detect ATP before any degradation of the nucleotide occurs (White et 
al., 1981). Release of ATP has been demonstrated from a number of tissues including 
the gastointestinal tract (Su et al., 1971), urinary baldder (Bumstock et al., 1978c), 
blood vessels and vas deferens (von Kiigelgen & Starke, 1991) and from the rat 
phrenic nerve (iSilinsky, 1975).
13. METABOLISM OF ADENOSINE AND ADENINE NUCLEOTIDES
In establishing that adenosine and ATP have physiological functions and in the case 
of ATP to have a role as a neurotransmitter it is essential to elucidate the mechanisms 
by which these adenine derivatives are degraded or otherwise removed from their site 
of action.
1.3.1. Sources and fate of adenosine
Adenosine can be formed intracellularly in response to ATP-consuming reactions.
I
ATP is sequentially dephosphorylated to adenosine 5'-diphosphate (ADP) and 
adenosine 5-monophosphate (AMP) by cytosolic enzymes adenosine triphosphatases 
and myokinase respectively. AMP can then be metabolized to adenosine by cytosolic 
5'-nucleotidase. Intracellular adenosine can then be transported out of the cell; 
degraded further to inosine, hypoxanthine and uric acid by adenosine deaminase.
20
purine nucleoside phosphorylase and xanthine dehydrogenase respectively; can be 
recycled to AMP through either adenosine kinase or the purine salvage pathway or it 
can be sequestered through binding to S-adenosylhomocysteine (SAH) (reviewed by 
Olsson & Pearson, 1990). In order for intracellular adenosine to have physiological 
actions it must be released from the cell.
Adenosine can also be formed extracellularly by the metabolism of adenine 
nucleotides. Adenosine formed extracellularly can be taken up into cells via a 
combination of simple diffusion and facilitated diffusion (Paterson & Kolassa, 1981). 
Facilitated diffusion is carrier mediated and the carrier for adenosine appears to 
transport other nucleosides, which are therefore competitive inhibitors of this 
transport, and is symmetrical mediating both the uptake and release with identical 
kinetics (Jarvis et al., 1982; Wohlhueter & Plagemann, 1982). Several inhibitors of 
the adenosine uptake system have been produced e.g. dipyridamole, 6-S-Ô?- 
nitrobenzylthio)guanosine (NBTGR) and 6-S-(p-nitrobenzylthio)inosine (NBMPR) 
(Cass et al., 1974; Paterson & Oliver, 1971). Dipyridamole has limited use as 
although it is a potent uptake inhibitor in most species it appears to be much less 
effective in the rat (Hopkins & Goldie, 1971). Also dipyridamole is not a selective 
uptake inhibitor as it has other actions such as phosphodiesterase inhibition (Pearson 
& Gordon, 1985). The effectiveness of NBMPR also appears to be species dependent 
as whilst nucleoside uptake by human erythrocytes is sensitive to nM concentrations 
of NBMPR (Jarvis & Young, 1980), in rat erythrocytes only a relatively small 
percentage of transport activity is sensitive to nM concentrations of NBMPR (Jarvis 
& Young, 1986).
Adenosine can be metabolized to inosine (which is pharmacologically inactive) by 
adenosine deaminase. Adenosine deaminase was originally thought to be a cytosolic 
enzyme, because it did not readily sediment on ultracentrifugation implying that it
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was a soluble enzyme. It is now apparent that adenosine deaminase is also an 
ectoenzyme often located near to ecto-5'-nucleotidase and bound to the cell 
membrane through a glycoprotein (Daddona & Kelley, 1978). Adenosine deaminase 
can therefore exist in two forms: the ‘C  form which is catalytically active and has a 
molecular weight of around 40KD and the 'A' form which is a complex of the 
catalytic component bound to the adenosine deaminase binding protein and has a 
molecular weight of around 200KD (Ma & Fisher, 1968). The proportion of ecto- 
adenosine deaminase varies depending on the tissue studied however it apears to be 
important in the brain and gastrointestinal tract (Centelles et al., 1988; Franco et al., 
1988). Inhibitors of adenosine deaminase have been synthesized and include 
deoxycoformycin and erythro-6-amino-9-(2-hydroxy-3-nonyl)purine hydro- chloride 
(EHNA) (Henderson et a., 1977; Agarwal, 1982).
1.3.2. Adenine nucleotide metabolism
As mentioned earlier, adenosine can be formed from metabolism of extracellular 
adenine nucleotides. In 1950, Binet and Bumstein reported that exogenous ATP was 
degraded during a single passage through the lung capillary bed. The rapidity of this 
action suggested that metabolism was taking place extracellularly by ectoenzymes on 
the surface of cells (for review see Pearson & Gordon, 1985). Although there have 
been a few reports that adenine nucleotides can cross the cell membrane e.g. in 
neonatal heart cell (Chaudry & Baue, 1980) their overall negative charge tends to 
prohibit their entry into cells thus making intracellular catabolism unlikely. Also 
studies with Berg reagent (diazotized sulphanilic acid) which attacks exposed proteins 
has suggested that the enzymes are ectoenzymes (De Pierre & Kamovsky, 1974). 
Extracellular ATP has been shown to be catabolized sequentially to ADP, AMP and 
adenosine by ecto ATPase, ADPase and 5-nucleotidase respectively. The
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ectonucleotidases are often thought to be activated by Mg2+ or Ca2+ but it has been 
shown that chelation of Mg2+ inhibits nucleotide degradation whereas chelation of 
Ca2+ does not (Pearson et al., 1980). Ectonucleotidases are now known to be present 
on most eukaryotic cells including cardiac myocytes, skeletal muscle cells and 
synaptosomes however most of the research on these ectoenzymes has been done on 
vascular cells such as pig aortic smooth muscle cells and endothelial cells (Cusack et 
al., 1983; Pearson et al., 1985).
Studies on smooth muscle cells using non-terminally substituted phosphorothioates 
ATPpS and ADPaS have confirmed the existence of separate ectonucleotidases that 
recognise ATP and ADP, as the ectonucleoside diphosphatase selectively catabolizes 
ADPaS whereas the ectonucleoside triphosphatase selectively catabolizes ATPpS. 
ADPaS and ATPpS exist as diastereoisomeric pairs and it has been shown that 
nucleoside triphosphatases and diphosphatases preferentially degrade Rp ATPpS and 
Sp  ADPaS respectively. The apparent contrasting stereo-selectivity of the 
triphosphatase and diphosphatase is due to an artefact of the S and R nomenclature as 
in each case the favoured isomer presents the same molecular conformation to the 
enzyme. This stereoselectivity also suggests that the enzymes recognise a Mg2+- 
nucleotide complex at their active sites as Mg2+ preferentially binds to oxygen rather 
than to sulphur (Pearson & Cusack, 1985; Pearson, 1986). In endothelial cells the 
ecto ATPase and ADPase exhibit some stereoselectivity as L-ATP and L-ADP are 
poorer substrates than the natural D-enantiomers. 5-nucleotidase however appears to 
be extremely stereoselective as L-AMP has an affinity of less than 1% of that of AMP 
itself (Cusack et al., 1983).
There appear to be distinct differences between ectonucleotidases on smooth muscle 
cells and those on endothelial cells. Smooth muscle 5-nucleotidase has a 10-fold 
lower affinity for AMP than the endothelial cell enzyme. Also the smooth muscle
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cell enzyme has been found to catabolize the phosphorothioate AMPS, whereas 
endothelial cells cannot (Pearson et al., 1985). Although 5 -nucleotidase on smooth 
muscle and endothelial cells is inhibited by ADP, production of adenosine from ATP 
in smooth muscle cells is immediate and rapid, whilst on endothelial cells most of the 
ATP is metabolized to AMP before any significant conversion of AMP to adenosine 
occurs i.e. 5-nucleotidase activity is very low until most of the ADP has disappeared 
(Gordon et al., 1989; Gordon et al., 1986). The reason for this difference in kinetics 
is not clear but it has been suggested that this anomaly is due to differential delivery 
of intermediates at the surface of smooth muscle cells possibly with the 
ectonucleotidases forming a complex, whereas on endothelial cells there is no 
evidence of surface effects (Slakey et al., 1990; Gordon et al., 1989). Therefore 
smooth muscle cells have a significantly greater capacity to produce adenosine fi’om 
either ATP or ADP however overall endothelial and smooth muscle cells have a 
similar capacity to hydolyze ATP. This inconsistancy is due to smooth muscle cells 
being significantly slower at metabolizing extracellular adenosine and it has also been 
demonstrated that smooth muscle cells lack the high affinity adenosine transport 
system found on endothelial cells (Pearson et al., 1978).
Ectonucleotidase activity has also been described in visceral smooth muscle: in the 
guinea-pig taenia coli and urinary bladder. The enzymes in the taenia showed similar 
stereoselectivity to endothelial cells in that the unnatural enantiomers, L-ATP and L- 
ADP were degraded very slowly and virtually no degradation of L-AMP was 
observed (Welford et al., 1986). In both the guinea-pig taenia coli and urinary 
bladder metabolism of adenosine was very slow with around 70% remaining after 60 
minutes (Welford et al., 1986; Welford et al., 1987) these kinetics being similar to 
those in arterial smooth muscle cells where the capacity to metabolize adenosine is 
low (Gordon et al., 1989).
24
The rapid degradation of ATP to adenosine by smooth muscle cells makes 
pharmacological analysis of the actions of ATP difficult, as it reduces the potency of 
ATP and the major metabolite adeposine is often active in the preparation being 
studied. Therefore the production of selective ectonucleotidase inhibitors would 
enhance the study of ATP and would also be of use in determining whether or not 
ATP is a neurotransmitter. .
I
A number of compounds have been observed to modify ectonucleotidase activity. 
Degradation of ATP by guinea-pig bladder has been shown to be inhibited by 
suramin and ethacrynic acid. However suramin is also a purinoceptor antagonist and 
ethacrynic acid has a variety of effects on smooth muscle thus making them 
unexceptable in pharmacological studies (Hourani & Chown, 1989). Inosine 
nucleotides have been shown to antagonize the breakdown of nucleotides in porcine 
smooth muscle cells (Pearson et al.» 1980) and adenosine 5'-(a,p- 
methylene)diphosphonate (AMPCP) and thymidine 5'-diphosphate have been 
reported to be powerful inhibitors of intestinal 5'-nucleotidase (Burger & Lowenstein, 
1970). The stable ATP analogues adenosine 5'-(p,y-methylene)triphosphonate 
(AMPPCP) and adenosine 5'-0-(3-thiotriphosphate) (ATPyS) can inhibit the 
catabolism of ADP, however these analogues also have direct effects on smooth 
muscle which would therefore restrict their use (Pearson, 1986). At present no 
selective inhibitors of ectonucleotidase activity exist, their development would 
undoubtably aid research into the physiological importance of ATP.
1.4. PURINOCEPTORS
Adenosine and adenine nucleotides exert their effects via receptors, known as 
purinoceptors. In 1978, Bumstock proposed that purinoceptors could be subdivided
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into Pi- and P2-purinoceptors based mainly on the order of potency of adenosine and 
adenine nucleotides. He proposed that for Pi-purinoceptors the order of potency was
adenosine > AMP > ADP > ATP and methylxanthines could antagonise their actions. 
For P2-puiinoceptors the order of potency was reversed with ATP > ADP > AMP >
adenosine and methylxanthines were without effect (Bumstock, 1978). Subsequent 
studies have supported this subdivision. Cusack and Blanker (1979) noted that whilst 
the guinea-pig taenia displayed stereoselectivity towards the L-enantiomer of the 
azido analogue of adenosine (2-azido-L-adenosine) it showed little stereoselectivity 
towards 2-azido-L-adenosine 5'-triphosphate suggesting that the two analogues are 
acting on separate receptors and Satchell and Maguire demonstrated that whilst 8- 
bromoadenosine and 2 '-deoxyadenosine were virtually inactive on the guinea-pig 
taenia coli, 8-bromoadenosine 5'-triphosphate and 2'-deoxyadenosine 5-triphosphate 
both induced relaxations, and that the adenosine uptake inhibitor dipyridamole did not 
potentiate the responses to the ATP analogues (Satchell & Maguire, 1982). There is 
strong evidence to suggest that adenosine and ATP act on separate receptors and this 
view has now been widely accepted.
1.4.1. Pi-purinoceptor
Bumstock (1978) proposed that for Pi-purinoceptors the order of potency of 
adenosine and adenine nucleotides was adenosine > AMP > ADP > ATP, and that 
methylxanthines could antagonize their effects.
It was found that adenosine acted by either stimulating or inhibiting adenylate cyclase 
and so the Pi-purinoceptor was subdivided into A% or Ri, which mediated inhibition 
of adenylate cyclase, and A2 or Ra, which stimulated adenylate cyclase (Van Calker 
et al., 1979; Londos et al., 1980). Since it was felt that the Ri /Ra subdivision which
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was based solely on adenosines effects on adenylate cyclase and the assumption that 
an intact ribose moeity was required for activity was too limiting, the Ai /A2
subdivision has now been widely accepted. It is now known that adenosine can act on 
Ai receptors through other effector mechanisms including potassium (K+) channels
(Belardinelli et al., 1988), calcium (Ca2+) channels (Ribeiro & Sebastiao, 1986), 
phospholipase A2 (Schimmel & Elliot, 1988) or phospholipase C and guanylate 
cyclase (Petcoff & Cooper, 1987 and Hill & Kendall, 1987). Adenosine has also 
been found to act at a third, intracellular, site termed the "P-site", however its 
physiological significance is not known (Londos & Wolff, 1977). The subdivision of 
the Pi-purinoceptor into Ai and A2 has been further supported by the development of
adenosine analogues and their differential potency values on various preparations, and 
by the development of selective adenosine antagonists (see table 1)
Adenosine has been modified in a number of ways to yield Pi receptor agonists, 
however ribose moeity modifications are rarely tolerated by Pi-purinoceptors (Taylor 
et al., 1986) the exception being substitution at the 5- position e.g. 5-N- 
ethylcarboxamidoadenosine (NECA) and 5-N-cyclopropyl-carboxamidoadenosine 
(NCPCA) where it has been shown that these analogues are potent A2 agonists (Collis
& Brown, 1983). NECA however is not selective being approximately equipotent at 
both the Ai and A2 receptor (Bruns et al., 1986). Other ribose substitutions e.g. 2',5'- 
dideoxyadenosine lead to a loss of activity at Pi-purinoceptors however 2',5'- 
dideoxyadenosine has been found to be a potent agonist at the "P-site" (Nimit et al.,
1982).
Most modifications have been made at the adenine moeity particularly at the C-2 and 
N6-amino group. Substitutions at the C-2 position include 2-chloroadenosine 
(2CAD0) (Williams & Risley, 1980), 2-azidoadenosine, 2-phenylaminoadenosine 
(CV1808) (Marumoto et al., 1975) and 2-p-((carboxyethyl)phenethylamino)-5'-N-
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carboxamidoadenosine (CGS21680) (Hutchison et al., 1989). Substitution at the N6- 
amino group has led to the development of potent agonists. These include 
substitution of either antipode of amphetamine to produce N6- 
(phenylisopropyl)adenosine (PIA). The phenylisopropyl 2-position is chiral and the 
diasteieoisomers L-PIA and D-PIA have been synthesised and have been useful in P%-
purinoceptor classification. Other N6- modified analogues include 
cyclohexyladenosine (CHA) and cyclopentyladenosine (CPA) (for review see 
Jacobson, 1990) (see figure 1 for the structural formulae of some Pi-purinoceptor 
agonists).
\A ,\A , Ai receptor
The Ai receptor is thought to be present mainly presynaptically and is known to be 
important particularly in the CNS where it acts to inhibit the release of a variety of 
neurotransmitters including acetylcholine, dopamine, noradrenaline, GABA and 5-HT 
(Daly, 1982; Harms et al., 1978; Stone, 1981 and Williams, 1984). The Ai receptor
is also present postsynaptically where it has been shown to contract some smooth 
muscle preparations including rat colon (Bailey et al., 1992), guinea-pig aorta 
(Stoggall & Shaw, 1990) and guinea-pig trachea (Farmer et al., 1988) and has been 
shown to be located on guinea-pig atria where it mediates the potent negative 
inotropic action of adenosine (Collis, 1983).
N6-substitution greatly enhances Ai activity and from binding studies the adenosine
analogues CHA (Bruns et al., 1980), CPA (Moos et al., 1985) and L-PIA (Bruns et 
al., 1986) have been found to be selective Ai agonists with CPA being the most 
selective of the ligands. The Ai receptor also displays stereoselectivity as L-PIA is
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Figure 1. Pi-purinoceptor agonists
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around 100 times more potent then D-PIA however care should be taken when using 
D-PIA to study Pi-puiinoceptors as it is structurally similar to amphetamine and often 
has an amphetamine-like action (Collis, 1983).
A 2  receptor
A2 receptors are thought to be mainly present postsynaptically where they have been 
shown to mediate the relaxation of a number of smooth muscle preparations including 
the rat and guinea-pig aorta (Rose'-Meyer & Hope, 1990 and Stoggall & Shaw, 1990) 
and guinea-pig trachea ( Farmer et al., 1988). There is recent evidence though that in 
the CNS A2 receptors are present both pre- and postsynaptically (Phillis, 1990).
N6-substituted analogues have little activity at A2 receptors and the A2 receptor 
exhibits poor stereoselectivity with L-PIA being only 5 fold more potent then D-PIA 
(Brown & Collis, 1982). The ribose modified analogues NECA and NCPCA have 
been found to be up to 50 times more potent than L-PIA and CHA on A2 smooth 
muscle preparations such as guinea-pig aorta (Collis & Brown, 1983) however NECA 
is also a potept agonist at Ai receptors (Bruns et al., 1986). In early studies 
radioligand binding to A2 receptors could only be successfully achieved if a selective 
Ai agonist (e.g. CPA) was used in conjunction with NECA (Bruns et al., 1986)
however in recent years the development of C-2 substituted analogues has led to the 
discovery of A2 selective agonists.
CV1808 was found to be 8 fold more selective for A2 receptors than A% receptors and
CGS21680 a 2-substituted NECA analogue has been shown to be more than 140 fold 
selective for A2 receptors (Hutchison et al., 1989; Jarvis et al., 1989; Balwierczak et 
al., 1991). Studies with CV1808 and CGS21680 have produced confusing results
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since in some A2 preparations where NECA is more potent than CHA or CPA,
CV1808 and CGS21680 are poor agonists e.g. in rat hippocampus (Lupica, 1990). It 
has therefore been proposed that the A2 receptor can be further subdivided into A2a 
(high affinity receptor) and A2b (low affinity receptor) and it appears that whilst 
CGS21680 is a potent agonist at the A2a receptor e.g. in rat striatum (Wan et al.,
1990) and coronary arterial smooth muscle (Balwierczak et al., 1991) it is almost 
inactive at A2b receptors e.g. in dog saphenous vein and guinea-pig aorta (Hargreaves 
et al., 1991). The A2a high affinity receptor, like the Ai receptor, is susceptible to 
GTP as GTP abolishes the binding of CGS21690 to A2a receptors in rat striatum 
(Parkinson & Fredholm, 1990).
1.4.1.3. A 3  receptor
A third adenosine receptor the A3 receptor has also been proposed on the 
observations that the potency of adenosine analogues does not always fit into the "Ai" 
or "A2" classification. Jahnel and Nawrath (1989) showed that in guinea-pig atria the 
order of potency of adenosine analogues at producing negative inotropic effects was 
L-PIA = NECA > D-PIA > adenosine. Also Ribeiro and Sebastiao (1985) noted that 
presynaptic adenosine receptors on frog sartorius muscle had an order of potency of 
L-PIA = CHA = NECA > 2CAD0, again not fitting the Ai or A2 category. It has
also been noted that these atypical receptors appeared to be linked to a second 
messenger system other than adenylate cyclase (Ribeiro & Sebastiao, 1986). Whilst 
agonist profiles in these preparations do not follow the existing Pi-puiinoceptor 
subclassification there are some similarities. In guinea-pig atria L-PIA was almost 
100 times more potent than D-PIA which would indicate the presence of an Ai 
receptor (Jahnel & Nawrath, 1989), and in frog sartorius muscle the Ai selective 
antagonist 1,3-dipropyl 8-cyclopentylxanthine (DPCPX) was a potent antagonist of
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the effects of the adenosine analogues (Sebastiao & Ribeiro, 1989) again providing 
evidence for the presence of an Ai receptor. It is also now known that A% receptors
can be linked to a number of different second messenger systems and so the 
observation that adenosine does not act via adenylate cyclase in these tissues is not 
evidence against the existence of an A% receptor.
\A A A  "P-site"
I
It has been found that when high concentrations (mM) of adenosine are used 
adenosine can act on what has been termed the P-site (Londos & Wolff, 1977). The 
P-site is thought to be an intracellular binding site as it is insensitive to P%- 
purinoceptor antagonists such as 8-p-(sulphophenyl)theophylline (8-SPT) but strongly 
inhibited by adenosine uptake inhibitors such as dipyridamole (Collis & Brown,
1983). Both adenosine and 2CAD0 are agonists at this site and are thought to 
mediate their effect by interacting with the catalytic unit of adenylate cyclase thereby 
inhibiting the enzyme (Londos & Wolff, 1977). 5'- and N6- substituted adenosine 
analogues such as NECA, NCPCA and L-PIA however are inactive at this site (Daly, 
1982).
Since high concentrations of adenosine are required to activate this site and as 
intracellular adenosine concentration is regulated by adenosine deaminase this site is 
unlikely to have a major physiological role.
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IAA.5. ATP as a P 1-agonist
There have been a number of studies which have suggested that ATP can act via Pi- 
purinoceptors however it was originally thought that this Pi-activity was dependant 
on the breakdown of ATP to adenosine by ectonucleotidases. There is now 
considerable evidence that ATP can have a direct action on Pi-purinoceptors and that 
the stable ATP analogue, AMPPCP, is also a P% receptor agonist. It has been shown 
that ATP and AMPPCP can have inhibitory effects on guinea-pig atrium which were 
not significantly reduced by adenosine deaminase, or by 5 '-nucleotidase but were 
antagonized by theophylline (Collis & Pettinger, 1982; Moody et al., 1984). In the 
guinea-pig ileum ATP and AMPPCP have also been shown to inhibit contractile 
responses to transmural nerve stimulation and again these effects were not affected by 
adenosine deaminase but were antagonized by theophylline or 8-SPT (Moody et al., 
1984; Wiklund et al., 1985). Some authors have proposed that this direct action of 
adenine nucleotides represents a third purinoceptor which they have termed the P3-
purinoceptor (Forsyth et al., 1991). The existence of this third receptor is still under 
dipute, however, these observations highlight the care needed when investigating 
purinoceptors as the stable analogue AMPPCP cannot be assumed to be a selective 
P2-purinoceptor agonist.
IA 2 .6 ,  P i-purinoceptor antagonists
In 1970 Sattin and Rail observed that two xanthines caffeine and theophylline 
blocked adenosine-induced increases in cAMP (Sattin & Rail, 1970) which led to the 
proposal that xanthines were adenosine antagonists. Although xanthines have been 
shown to have other effects such as phosphodiesterase inhibition (which would act to 
increase cAMP levels) and at high concentrations an increase in Ca2+ influx, their
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main action is that of antagonizing the effects of adenosine (Choi et al., 1988). The 
naturally occuring xanthines such as caffeine and theophylline are non-selective for 
adenosine recej)tor subtypes however modifications of these xanthines has led to the 
development of selective adenosine receptor antagonists (reviewed by Jacobson, 
1990). 8-phenyltheophylline (8-PT) was the first adenosine anatagonist with 
nanomolar potency however it has poor solubility which has hampered its use (Bruns 
& Fergus, 1989). Production of 8-p-(sulphophenyl)theophylline (8-SPT) increased 
the solubility of the xanthine derivative and it was suggested from binding studies in 
the rat CNS that 8-SPT was also a selective Ai antagonist (Bruns et al., 1986).
Further studies, however, on isolated guinea-pig preparations found that 8-SPT could 
not discriminate between Pi-puiinoceptor subtypes in smooth muscle (Collis et al.,
1987). The conflicting results between the rat CNS and guinea-pig smooth muscle 
may be due to the difference in experimental protocol i.e. functional approach as 
opposed to binding assay, or could be due to differences between rat and guinea-pig 
tissues since marked species differences in the affinity of compounds for adenosine 
Ai binding sites has also been observed (Ukena et al., 1986b).
Replacement of the 8-phenyl moiety with a cyclopentyl group to give 8- 
cyclopentyltheophylline (CPT) increases solubility and improves Ai selectivity and
the dipropyl homologue of CPT: l,3-dipropyl-8-cyclopentylxanthine (DPCPX) is one 
of the most selective Ai antagonists to date (Bruns, 1990). Studies of antagonism of
the effects of adenosine by DPCPX in smooth muscle have shown that for 
preparations which possess Ai receptors (e.g. guinea-pig atria) DPCPX  gives a pA% 
value of around 8.0 , whereas for tissues which have a predominance of Az receptors 
(e.g. guinea-pig aorta and trachea) the pA2 is around 6.5. These results are 
significantly different to those obtained using 8-SPT which gives pA2 values of 
around 6.6  for guinea-pig atria, aorta and trachea (Collis et al., 1989). Again
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however DPCPX exhibits species differences with it having a higher affinity for rat 
rather than guinea-pig atria (Collis et al., 1988) (see figure 2 for the structural 
formulae of 8-SPT and DPCPX).
The development of A2 selective antagonists has not been so successful. The 
triazoloquinoxanthine, 9-chloro-2-(2-furyl)-5,6-dihydro[l,2,4]-triazolo[l,5-c]quinaz- 
olin-5-imine (CGS15943) has been suggested to be an A2 antagonist (Ghai et al., 
1987; Balwierczak et al., 1991) however it does not show marked selectivity. The 
Parke-Davies compound N-[2-(dimethyl-amino)ethyl]-N-methyl-4-(2,3,6,7-tetra- 
hydro-2,6-dioxo-l,3-dipropyl-lH-purin-8-yl)benzene-sulfonamide (PD115199) is a 
potent antagonist in rat striatal membranes (Bruns et al., 1987) but has lower affinity 
in dog saphenous vein and guinea-pig aorta, since the A2 receptor has putatively been 
subdivided into A2a (in the striatum) and A2b (in many peripheral tissues) it appears 
that PD 115199 is a selective A%a antagonist (Hargreaves et al., 1991).
1.4.2. P2-purinoceptor
ATP has been modified in a number of ways to develop analogues that are useful in 
investigating P2-purinoceptors (see figure 3). Modifications include: adenine C-2
modifications such as 2-methylthioadenosine 5'-tnpbosphate (2MeSATP), 2- 
chloroadenosine 5'-triphosphate (2C1ATP) and 2-azidoadenosine 5'-triphosphate (2- 
azidoATP); modifications to the polyphosphate chain such as replacement of 
inteiphosphate oxygen linkages with a methylene or imido link to give adenosine 5 '- 
(a,p-methylene)triphosphonate (AMPCPP), adenosine 5'-(p,y-methylene)triphos- 
phonate (AMPPCP) and adenosine 5'(P,y-amido)triphosphonate (AMPPNP) and 
replacement of an anionic oxygen in the polyphosphate chain with a sulphur or 
fluoride to give adenosine 5'-0-(l-thiotriphosphate) (ATP-a-S), adenosine
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Figure 2, Pi-purinoceptor antagonists
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Figure 3. Po-purinoceptor agonists
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5'-0-(2-thiotriphosphate) (ATP-P-S), adenosine 5'-0-(3-thiotriphosphate) (ATP-y-S) 
and adenosine 5-(2-fluorodiphosphate) (ADPpp). Where possible, enantiomers of 
these various analogues have also been synthesized and used in the classification of 
P2-purinoceptors (reviewed by Jacobson, 1990).
Following the Subdivision of purinoceptors into Pi- and P2-purinoceptors it became 
increasingly apparent that the P2-purinoceptor did not form a homologous group. 
ATP could mediate either contraction or relaxation and the development of ATP 
analogues highlighted differences in agonist potency orders between these two types 
of response. These differences led Bumstock and Kennedy to propose that the P2- 
purinoceptor could be subdivided into two putative subtypes P2X (usually mediating 
contraction) and ? 2Y (usually mediating relaxation) (Bumstock & Kennedy, 1985).
Subsequently it was noted that two more subtypes existed and these were putatively 
termed P2T- and P2z-purinoceptors (Gordon, 1986). These purinoceptor subtypes 
have now been generally accepted and so each will be reviewed in tum (see table 2).
IA 2 ,\ .  P2X-purinoceptor
ATP was found to contract some smooth muscle preparations e.g. guinea-pig bladder,
I
and relax others e.g. guinea-pig taenia coli and it was generally thought that the 
receptor mediating contraction was the ? 2x-punnoceptor whilst that mediating 
relaxation was the P2Y-purinoceptor. A more accurate description of P2X- 
purinoceptors arose from studies using ATP analogues where it was found that 
analogues which had a methylene link substituted in the polyphosphate chain such as 
AMPPCP and AMPCPP were much more potent than ATP itself (Brown et al., 1979; 
Kasakov & Bumstock, 1983). Since phosphonate analogues were known to be
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resistant to degradation by ectonucleotidases, the increased potency of these 
analogues suggested that the P2x-pu^oceptor is sensitive to the metabolism of ATP 
and related analogues (Welford et. al., 1987).
Generally P2x-purinoceptors exhibit only weak stereoselectivity as L-ATP is 
equipotent with ATP on a number of tissues including gumea-pig bladder (Bumstock 
et al., 1983). Cusack and Hourani (1984) however found that the enantiomer of 
AMPPCP, Lr AMPPCP, was much more potent than AMPPCP at contracting guinea- 
pig bladder. Although AMPPCP is fairly resistant to degradadtion by 
ectonucleotidases a small amount of degradation is seen when AMPPCP is incubated 
with guinea-pig bladder but there is no evidence of degradation of L-AMPPCP. The 
increased potency of L-AMPPCP over AMPPCP could therefore be a result of its
I
enhanced stability in the tissue (Cusack & Hourani, 1984).
Of the phosphorothioates, ATP-p-S and ATP-y-S are much more potent at contracting 
tissues such as guinea-pig bladder and vas deferens than ATP-a-S and ATP 
(Bumstock et al., 1984a). C-2 adenine-substituted compounds such as 2C1ATP and 
2- azidoATP are equipotent with ATP at P2x-purinoceptors (Bumstock et al., 1983). 
ADP-P-F, a relatively stable ADP analogue has virtually no activity on P2x- 
purinoceptors (Hourani e t al., 1988).
1A 2 .2, P2Y-purinoceptor
The P2Y-purinoceptor generally mediates relaxation to ATP on tissues such as 
guinea-pig taenia coli and pig aorta (Bumstock et al., 1983; Martin et al., 1985). 
However type of response is not a useful tool in the classification of receptors as it is 
now known that P2Y-purinoceptors can also mediate contractile responses in some
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smooth muscle preparations (Bailey and Hourani, 1990).
Whilst susceptibility to dephosphorylation appears to limit the potency of ATP on 
smooth muscle preparations that possess P2X‘purinoceptors (Welford et al., 1987) it 
does not appear to limit the potency of ATP or ATP analogues on P2Y-purinoceptors 
as for example in the guinea-pig taenia coli 2MeS ATP is much more potent than ATP 
(Bumstock et al., 1983) but is degraded at the same rate as ATP (Welford et al.,
1986). In some tissues where P2Y-punnoceptors are present e.g. guinea-pig taenia 
coli, comparison of relative potencies of ATP, AMPCPP and AMPPCP is 
complicated by the fact that they each produce different maximum responses, 
however if dipyridamole (an adenosine uptake inhibitor) is included in the study then 
all three agonists produce similar maximum responses and ATP is then significantly 
more potent than either of the two phosphate modified analogues (Maguire &
I
SatcheU, 1979).
ADP-p-F, which is a relatively stable analogue, relaxes guinea-pig aorta and taenia 
coli, which possess P2Y-purinoceptors, but it is less potent than ATP. Since ADP-P- 
F has no P2x-purinoceptor activity it has been proposed that ÀDP-p-F is a selective 
P2Y-purinoceptor agonist (Hourani e t  al., 1988). Whilst it may be that ADP-p-F is a 
selective P2 receptor agonist there is evidence that at low concentrations it may have 
some Pi-purinoceptor activity (Wood e t al., 1989). The Pi-purinoceptor activity 
may however be an indirect action as it can be degraded to adenosine on some smooth 
muscle preparations (Hourani et al., 1988).
Unlike P2x-purinoceptors the P2Y-punnoceptor appears to be highly stereoselective 
with L-ATP being significantly less potent than ATP (Cusack & Planker, 1979). This 
stereoselectivity becomes more pronounced in the 2-substituted series with 2MeS-L- 
ATP being virtually inactive on most P2Y-purinoceptor preparations (Martin et. al.,
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1985). L-AMPPCP is also inactive on P2Y”purinoceptors making it a selective P2X" 
purinoceptor agonist (Hourani et. al., 1985). Stereoselectivity is also seen for the a- 
substituted phosphorothioate analogue with a 7-fold stereoselectivity exhibited 
towards the diastereomer at P2Y-purinoceptors but no stereoselectivity of the 
ATP-p-S is observed (Bumstock et al., 1984a).
1.4.2.3. P2T-purinoceptor
The P2T-purinoceptor is present on platelets and in contrast to other P2-purinoceptors
ADP is the natural agonist whereas ATP is a competitive antagonist at this receptor 
(Bom, 1962). Like P2Y“purinoceptors C-2 substitutions greatly enhance potency so
that 2-azidoadenosine 5'-diphosphate (2-azidoADP), 2-chloroadenosine 5'- 
diphosphate (2C1ADP) and 2-methylthioadenosine 5'-diphosphate (2MeSADP) are up 
to 10 times more potent than ADP (Cusack & Hourani, 1982). The P2'rpurinoceptor 
is also similar to the P2y receptor in that it displays stereoselectivity for the D- rather 
than the unnatural L-enantiomers and so L-ADP is inactive at P2T-purinoceptors 
(Cusack et al., 1979).
1.4.2.4. P2Z-purinoceptor
The observation that very high (mM) concentrations of ATP could induce 
permeabilisation in some cell lines such as mast cells, macrophages and lymphocytes 
led to the suggestion that another P2 receptor existed which was classified as the P2z- 
purinoceptor. It appears that the effective agonist at this receptor is the tetrabasic
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anion ATM- which is present as a minor equilibrium component when ATP is added 
to physiological buffers containing conventional levels of divalent cations (Cockcroft 
& Gomperts, 1979).
Analogues where the overall charge of ATP has been altered, such as the methylene 
diphosphonates AMPCPP and AMPPCP, are inactive. Other substitutions however 
are tolerated by the P2z-punnoceptor e.g. ATP-a-S, ATP-p-S, 2C1ATP and
2MeSATP havb comparable activity to ATP but such substitutions do not enhance 
potency. Some stereoselectivity is seen at the P2z-purinoceptor with L-ribose being 
inactive (Tatham et. al., 1988).
1.4.2.5. P2S~purinoceptor
Wiklund and Gustafsson (1988) found that ATP contracted guinea-pig ileum and the 
order of potency of purines mediating this response was -2MeSATP > ATP = ADP. 
The contractile effects of ATP were not antagonized by AMPCPP desensitization, a 
technique employed to antagonize responses to ATP on P2x-purinoceptors (Kasakov 
& Bumstock, 1983). These results would suggest that ATP is acting via P2Y- 
purinoceptors however contractile effects of purines are usually associated with P2X- 
purinoceptors and reactive blue 2 , which is thought to be a non-competitive 
antagonist selective for P2Y-purinoceptors, did not antagonize responses to ATP. The 
authors concluiled therefore that the receptor mediating contraction of guinea-pig 
ileum was not a P2X- or P2Y-purinoceptor and instead classified it as a P2S- 
purinoceptor (Wiklund & Gustafsson, 1988). However reactive blue 2 is only 
thought to be a selective P2Y“purinoceptor antagonist within a narrow concentration
range below lOOpM (Kennedy, 1990). In these experiments a very high 
concentration of reactive blue 2 (ImM) was used which is usually associated with
44
non-specific actions (Reilly et al., 1987). Also it has since been shown that P2Y- 
purinoceptors can mediate contraction in the gastrointestinal tract (Bailey & Hourani, 
1990). Therefore more evidence is required before it can be said that a fifth P2- 
purinoceptor subtype exists.
1.4.2.6. Nucleotide and pyrim idine receptors
Since the classification of P2-purinoceptors into P2X-» P2Y-» PlT- and P2Z- 
purinoceptors there have been reports that ATP can act on a separate receptor termed 
the "nucleotide" or P2U receptor. The receptor arose from observations that in some 
tissues which are thought to possess P2Y“purinoceptors 2MeSATP produces a lower 
maximum response than ATP or even in some cases was inactive. In many of the 
tissues that were unresponsive to 2MeSATP it was found that a pyrimidine, uridine 
5'- triphosphate (UTP) was equipotent with ATP, inosine 5'- triphosphate (TIP) was 
moderately potent and the phosphorothioate, ATPyS, was also a potent agonist at this 
receptor (Pfeilschifter, 1990; O’Connor et al., 1991). In some studies the existence of 
a receptor selective for UTP and not ATP has been reported (Hâussinger et al., 1987; 
von Kügelgen & Starke, 1990) and these have been termed pyrimidinoceptors (Seifert 
& Schultz, 1989).
1.4.2.7. P2 -purinoceptor antagonists
A number of drugs have been shown to be selective antagonists at the P2- 
purinoceptor.
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Arylazidoaminopropionyl-adenosine 5'-triphosphate (ANAPP3) has been claimed to 
be a P2-puiinoceptor antagonist by forming a covalent bond to the receptor. It has 
been found to antagonize responses to ATP on guinea-pig vas deferens (Hogaboom et 
al., 1980) and urinary bladder (Westfall et al., 1983). However whilst ANAPP3
antagonizes responses to ATP in guinea-pig vas deferens it produces an initial 
activation of the receptor acting as a P2-agonist. Also in the guinea-pig taenia coli 
there is evidence that it antagonizes responses to adenosine (Westfall et al., 1982). 
Thus ANAPP3 has limited use since it produces irreversible antagonism and is
therefore a non-competitive antagonist, and in some tissues it does not appear to be 
selective for P2-purinoceptors.
Reactive blue 2 has been shown to antagonize responses to ATP and 2MeSATP on
I
P2Y-purinoceptors on coronary arteries such as human and rat pulmonary arteries and 
rabbit mesenteric artery (Lui et. al., 1989a,b; Bumstock & Warland, 1987) and 
secretory cells (Rice & Singleton, 1989). However its selectivity has been questioned 
since it has also been shown to antagonize responses to ATP on P2X“Puiinoceptors in
guinea-pig urinary bladder (Choo, 1981) and Soltoff e t al., (1989) found that it 
blocked the response to ATM- in parotid acinar cells, suggesting that it can also 
antagonize P2Z“purinoceptor mediated effects.
The trypanocidal dmg suramin has been shown to antagonize responses to ATP in a 
variety of smooth muscle preparations. In the mouse vas deferens (Dunn & Blakeley,
1988), guinea-pig bladder (Hoyle et al., 1990) and rabbit ear artery (Leff et al., 1990) 
suramin has been shown to antagonize responses to ATP indicating that it is a P2X-
purinoceptor antagonist. In some cases the antagonism seen with suramin has been 
described as non-competitive since steep Schild plot slopes or a depression of 
maximum response has been observed (Hoyle et. al., 1990). Leff and colleagues 
(1990) however showed that the antagonism by suramin is time dependent, with low
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concentrations of the antagonist requiring long (3hr) incubation periods whereas high 
concentrations (ImM) require only a short incubation period (10 min.). By varying 
the time that suramin was incubated with the tissue competitive antagonism was 
achieved. Whilst suramin appears to be an antagonist selective for the P2- 
purinoceptor it does not display selectivity between P2X- and P2Y-purinoceptors as it 
has been shown that suramin can antagonize responses to ATP on preparations that 
possess P2Y-purinoceptors such as guinea-pig taenia coli (Den Hertog et al., 1989; 
Hoyle et al., 1990).
Desensitization of P2“purinoceptors has been the most commonly applied method to 
block responses to ATP. Initially ATP was used as the desensitizing agent however 
its efficacy was questionable (Ambache & Zar, 1970).
It was known' that ATP could induce prostaglandin synthesis, which might be 
expected to influence its action as a desensitizing agent, whereas analogues of ATP 
such as AMPCPP, where a methylene group has been substituted in the 
polyphosphate chain, do not display this property (Brown & Bumstock, 1981b). 
AMPCPP is also relatively resistant to degradation (Welford et al., 1986 & 1987) 
making it more suitable than ATP as a desensitizing dmg.
Repeated administration of AMPCPP has been shown to selectively inhibit responses 
to ATP in a number of tissues including guinea-pig vas deferens (Meldrum & 
Bumstock, 1983) guinea-pig urinary bladder (Kasakov & Bumstock, 1983) rat 
mesenteric bed (Ralevic & Bumstock, 1988) and rat portal vein (Reilly & Bumstock,
1987). Therefore the P2x-purinoceptor, mediating contraction of vascular and
visceral smooth muscle, is sensitive to desensitization by AMPCPP. In contrast, its 
success at blocking responses to ATP on P2Y-purinoceptors has been varied since in 
the guinea-pig taenia coli, rabbit portal vein and canine basilar artery repeated
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administration of AMPCPP does not lead to desensitization of relaxant responses, 
however in rabbit ileum and colon relaxant P2Y‘inediated responses are susceptible to 
desensitization (Bumstock & Kennedy, 1985; Shirahase et al., 1991).
Since the P2-purinoceptor antagonists that have been developed display limited 
selectivity between purinoceptor subtypes purinoceptor subclassification has been 
based on observations of agonist potency values. A more sound classification of 
receptor subtypes will be possible with the development of more selective 
antagonists.
1.5. ACTIONS OF ADENOSINE AND ADENINE NUCLEOTIDES
ATP and adenosine have been shown to have potent pharmacological actions on a 
variety of tissues, including parts of the cardiovascular system and gastrointestinal 
tract, urinary bladder and vasa deferentia. These will be reviewed in turn (for a 
summary of the pharmacological actions of adenosine and ATP see tables 3 and 4 
respectively).
1.5.1. Cardiovascular system 
1.5.11. Actions o f  adenosine
Adenosine has negative chronotropic, dromotropic and inotropic actions on the heart. 
It can act on the sinoatrial and atrioventricular nodal cells to induce bradycardia and 
heart block respectively, possibly by hyperpolarization of the cell membranes. It 
appears fi*om potency orders of adenosine analogues that these effects are mediated
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Table 3. Pharmacological actions of adenosine
Tissue Receptor Response Reference
Guinea-pig atrium Ai
Human coronary A2
artery
Porcine coronary Ai
artery A2
Guinea-pig aorta Ai
A2
Rat thoracic aorta A2
Guinea-pig trachea Ai 
A2
Rat duodenum
Rat bladder
Pi
Guinea-pig taenia A2 
coli
Pi
Rat vas deferens Ai
i  force contraction CoUis, 1983
Relaxation Ramagopal et al., 1988
Contraction
Relaxation
Contraction
Relaxation
Relaxation
Contraction
Relaxation
Relaxation
Relaxation
Inhibition
Mills & Gewirtz, 1990
Stoggall & Shaw, 1990 
Collis & Brown, 1983
Rose'Meyer & Hope, 
1990
Farmer et al., 1988 
Brown & Collis, 1982
Gaion et al., 1988
Bumstock et al., 1984
Dahlén & Hedqvist, 1980
Inhibition of NT Paton, 1981 
release
Table showing some pharmacological actions of adenosine in a variety of tissues. For 
brevity 'neurotransmitter' has been abbreviated to NT.
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Table 4. Pharmacological actions of ATP
Tissue Receptor Response Reference
Pig aorta P2Y Relaxation Martin et al., 1985
Rat pulmonary ?2X Contraction Liu et al., 1989b
artery P2Y Relaxation
Human pulmonary ?2X Contraction Liu et al., 1989a
artery P2Y Relaxation
Rabbit mesenteric ?2X Contraction Bumstock & Warland,
artery ?2Y Relaxation 1987
Rat portal vein ?2X Contraction Reilly & Bumstock, 
1987
Guinea-pig ileum P2Y/P2S Inhibition of 
f.s. respones
Wiklund & Gustafsson 
1988
Rat duodenum P2 Relaxation Manzini et al., 1985
Guinea-pig taenia 
coli
P2Y Relaxation Bumstock & Kennedy, 
1985
Rat colon P2Y Contraction Bailey & Hourani, 1990
Guinea-pig
bladder
P2X Contraction Hourani et al., 1985
Rat vas deferens P2X Contraction Bumstock & Kennedy,
1985
Table showing some pharmacological actions of ATP on a variety of tissues. For 
brevity 'field stimulated' has been abbreviated to f.s.
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via Al receptors as CPA is more potent than NECA at inducing bradycardia and at 
the atrioventricular node the order of potency for adenosine analogues is CPA > L- 
PIA > NECA (Heller & Olsson, 1985; reviewed by Olsson & Pearson, 1990).
The negative inotropic action of adenosine is well documented. Adenosine and 
adenine nucleotides have been shown to decrease the force of contraction of atria via 
Ai receptors (Collis, 1983; Borea et al., 1989). This negative inotropic effect of
adenosine has been shown to be accompanied by a decrease in action potential 
duration and an increase in potassium (K+) conductance of the myocardial cell 
membrane (Meszaros et al., 1984; Jahnel & Nawrath, 1989). Although the reduction 
in atrial contractility is mainly due to activation of K+-charmels, adenosine can also 
act via Ai receptors on L-type Ca2+ chaimels to reduce the inward C2+ current and 
hence reduce contractility in this way (Borea et al., 1989). In ventricular myocardium 
adenosine has only limited effects and it has been suggested that only a small 
population of adenosine receptors exist on this tissue (Clarke & Coupe, 1989). It has 
since been shown however that adenosine can inhibit the positive inotropic effects of 
catecholamines in ventricular myocardium by inhibiting the increase in the slow 
inward Ca2+ current induced by catecholamines i.e. it has an indirect negative 
inotropic effect (Bohm et al., 1985). This action of adenosine has been ascribed to 
activation of Ai receptors as although A2 receptors have also been found to be 
present, activation of A2 receptors results in an increase in cAMP concentration 
without any influence on contractility (Behnke et al., 1990). This indirect 
antiadrenergic action of adenosine could be physiologically important since it would 
protect the heart from excessive inotropic stimulation.
Adenosine is also a potent vasodilator having a direct inhibitory action on the 
vascular smooth muscle. The order of potency of adenosine and adenosine analogues 
at relaxing coronary vessels is generally NECA > L-PIA > adenosine and studies on
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guinea-pig aorta give a pA2 value of 6.6 for the Ai selective antagonist DPCPX 
which suggest that adenosine mediates vasodilatation via A2 receptors (Ramogopal et 
al., 1988; Collis et al., 1989). Also the A2 selective agonist CGS21680 has been
found to be a potent agonist at relaxing many coronary aterial smooth muscle 
preparations which is further evidence for it being mediated via A2 receptors
(Balwierczak et al., 1991). There is some debate as to whether the receptors are 
located on the vascular smooth muscle or on endothelial cells as it has been shown 
that removal of the endothelium reduces relaxant responses to adenosine and its 
analogues in guinea-pig aorta (Rose'Meyer & Hope, 1990). There is also evidence to 
suggest the coexistance of Ai (mediating constriction) and A2 (mediating dilatation)
receptors on some coronary vessels (Stoggall & Shaw, 1990) however the 
physiological importance of this is not known as it is sometimes only unmasked when 
the A2-mediated response has been blocked (Mills & Gewirtz, 1990).
Although the action of adenosine on blood vessels is predominantly that of 
vasodilatation adenosine has been shown to be a potent vasoconstrictor in the kidney. 
Its vasoconstrictor action in this tissue acts to limit renal blood flow and therefore 
reduce glomerular filtration rate and reduce energy demand, hence it again acts as a 
"metabolic regulator" (for review see Spielman & Arend, 1991). Vasoconstrictor 
responses have also been demonstrated in the pulmonary artery of sheep however this 
is due to the stimulation by adenosine of cyclooxygenase and the subsequent release 
of prostaglandins (Biaggioni et al., 1989).
Actions o f  ATP
ATP is not thought to have important actions on the heart. It has been shown that 
ATP can reduce the force of contraction of atria however it is less potent than
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adenosine at producing this effect and it has therefore been proposed that it is acting 
via Pi-puiinoceptors. Originally this Pi-purinoceptor action of ATP was attributed to
its breakdown to adenosine via ectonucleotidases however because AMPPCP, a stable 
ATP analogue was found to have an identical Pi-puiinoceptor action it has been 
proposed that ATP can have a direct action on Pi-purinoceptors in guinea-pig atrium 
(Collis & Pettinger, 1982).
In a number of blood vessels ATP has been found to be a potent vasodilator, however 
ATP can induce vasodilatation or vasoconstiction depending on the vessel studied, 
species used, presence or absence of endothelium and basal tone. On guinea-pig and 
pig aorta, rabbit portal vein, rat pulmonary artery and vein ATP has been shown to 
relax with 2MeSATP being much more potent than ATP suggesting that this effect is 
mediated by P2Y-purinoceptors. Removal of the endothelium abolishes these
relaxations and in rat pulmonary artery and vein ATP then contracts the tissue via 
P2x-purmoceptors present on the smooth muscle (Bumstock & Kennedy, 1985; 
Martin et al., 1985; Lui et al., 1989a). The endothelial-dependent vasodilation is 
thought to be mainly due to the release of endothelium-derived relaxing factor 
(EDRF) (now known to be nitric oxide (NO) which relaxes smooth muscle by 
stimulating guanylate cyclase (Palmer et al., 1987; Murad, 1986). ATP can also 
stimulate cyclooxygenase resulting in the release of prostacyclin (PGI2) which could 
contribute to the vasodilation (Needham et al., 1987). POI2 release is not thought to
be of prime importance in physiological vasodilatation as the enzyme cylcooxygenase 
is only stimulated when intracellular calcium concentration, [Ca2+]i, reaches a 
threshold concentration of 0.8}:^) As ATP causes an initial increase in [Ca2+]j of up 
to a few (due to the release of Ca2+ from intracellular stores) after which a 
steady-state elevation of 300-400n^ is maintained (via opening of Ca2+ channels) 
this implies that the activation of cyclooxygenase would only be transient, whereas 
production of NO would be sustained (Pearson & Gordan, 1989).
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Therefore in mpst blood vessels with resting tone and intact endothelium ATP causes 
vasodilatation. There are however exceptions to this as in a number of vessels such as 
rat portal vein, rat pancreatic and dog carotid arteries the predominant response to 
ATP is a Pix-pnrinoceptor mediated vasoconstriction even when the endothelium is 
present (Sjoberg & Wahlstrom, 1975; Pearson & Gordon, 1989). The 
vasoconstriction via P2X-purinoceptors is thought to involve the opening of Ca2+
channels as removal of extracellular calcium often results in the attenuation of the 
contractile response (Rembold et al., 1991). '
The response to ATP can also be dependent on the tone of the vessel e.g. in the 
mesenteric bed of the rat at resting tone, ATP and ATP analogues constrict with an 
order of potency of AMPCPP > 2MeSATP > ATP suggesting that this effect is 
mediated by P2x-purinoceptors. However if the vessel is precontracted then
2MeSATP and ATP cause relaxation. Removal of the endothelium abolishes the 
vasodilator responses suggesting that they are due to stimulation of P2Y-purinoceptors 
on the endothelial cells (Ralevic & Bumstock, 1988).
The physiological importance of ATP under normal circumstances is not known 
although there is evidence to suggest that it plays an important role in cardiovascular 
disease. ATP has been proposed as an excitatory cotransmitter released from 
sympathetic nerves in some vascular beds (Taylor & Parsons, 1989) and certain 
pathological conditions such as ischaemia are known to stimulate catecholamine 
release which would therefore be expected to give a concomittant increase in ATP 
release. ATP is present in the cytoplasm of all cells in particular platelets contain a 
high concentration of adenine nucleotides in their dense granules (Bom, 1956) and 
during platelet activation and aggregation both ATP and ADP are released into the 
circulation (Mills et al., 1968). Endothelial cells are another likely source of adenine 
nucleotides and it has been shown that brief exposure of cultured endothelial cells to
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proteases, such as thrombin or elastase leads to the selective release of adenine 
nucleotides in biologically active concentrations (Pearson & Gordon, 1979). Also 
since the relative vasodilator or vasoconstrictor action of ATP has often been 
associated with the presence of intact endothelium, in certain cardiovascular disease 
states where there is damage to the endothelium ATP may have an important role in 
the pathological reactivity of the vessel.
1.5.2. Urinary bladder
The partial atropine-resistance of the contractions induced in the bladder by 
stimulation of parasympathetic nerves was first noted by Langely and Anderson 
(1895) although it was still thought that this atropine-resistant component was 
cholinergic in nature. It was suggested that the muscarinic receptors involved were 
atropine resistant or that the concentrations of atropine able to diffuse into close 
proximity with the receptors was not sufficient to antagonize the effects of high local 
concentrations of acetylcholine released during cholinergic nerve stimulation. 
Ambache and 'Zar (1970) however found that in guinea-pig bladder there was no 
histological evidence for atropine not being able to diffuse into the pericellular space 
and that eserine which was able to fi:eely diffuse into this area failed to potentiate the 
atropine-resistant twitches. Also by using single pulses and therefore keeping the 
quantal release of acetylcholine to a minimum they found that the atropine-resistant 
component still existed. They therefore proposed the presence of a non-cholinergic 
excitatory innervation. Bumstock et al. (1972a) showed that in both rat and guinea- 
pig bladder exogenous ATP produced a rapid but transient contraction, similar to that 
seen for non-cholinergic nerve stimulation. Quinacrine cdn bind to nucleic acids and 
adenine nucleotides causing bright fluorescence (Crowe & Bumstock, 1981), 
therefore the presence of quinacrine-positive fibres would suggest the presence of
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ATP. Bumstock and colleagues demonstrated the presence of quinacrine-positive 
fibres in the detmsor muscle of the urinary bladder and went on to show that non- 
adrenergic non-cholinergic nerve stimulation caused a three to twelve fold increase in 
ATP release which could be blocked by tetrodotoxin and that desensitization of the 
bladder to ATP in some preparations produced a reduction in the response to nerve 
stimulation (Bumstock et al., 1978b). On the basis of these results it was proposed 
that ATP was the non-adrenergic non-cholinergic transmitter.
Some workers have disputed the proposal that ATP is the transmitter as contractions 
to ATP are often weak when compared to those fi*om nerve stimulation and 
desensitization to ATP does not always inhibit the non-cholinergic response 
(Ambache & Zar, 1970). Various polypeptides have been suggested as putative 
transmitters in the bladder including SP and vasoactive intestinal polypeptide (VIP). 
However whilst immuno-histologically these peptides have been found to be present 
within the neurones of the genito-urinary tract, chymotrypsin, a proteolytic enzyme 
which degrades both SP and VIP, does not antagonize atropine-resistant contractions 
(Mackenzie & Bumstock, 1984). 5-HT has also been suggested as a putative 
transmitter in the bladder however there is evidence that 5-HT acts via 5-HT3
receptors to induce the release of both acetylcholine and ATP (Chen, 1990).
The production of stable ATP analogues has reinforced the proposal that ATP is the 
non-cholinergic excitatory transmitter as both AMPPCP and AMPCPP are potent 
agonists at contracting rat and guinea-pig bladder and their responses resemble more 
closely those to nerve stimulation. The increased potency of these analogues suggests 
that ATP is rapidly broken down in the bladder and is therefore only seen as a weak 
agonist (Brown et al., 1979) and this proposal has been supported by degradation 
studies in this tissue (Welford et al., 1987). Studies have shown that desensitization 
of P2-purinoceptors with A ^ C P P  and L-AMPPCP attenuates subsequent responses
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to ATP and to non-adrenergic, non-cholinergic nerve stimulation (Kasakov & 
Bumstock, 1983; Hourani, 1984). The stable ATP analogues AMPCPP and 
AMPPCP are more potent than ATP and 2MeSATP in contracting urinary bladder 
suggesting that ATP acts via P2x-punnoceptors in this tissue (Bumstock et al., 1983).
From electrophysiological studies it appears that nerve stimulation of rat and guinea- 
pig detmsor muscle can elicit a biphasic response: a fast contraction followed by a 
slow atropine-sensitive contraction. The fast contractiou is thought to involve the 
opening of receptor operated Ca2+ channels and is generally thought to be mediated 
by P2-purinoceptors (Fujii, 1988; Bhat et al., 1989). The second phase of the 
response, the slow atropine-sensitive contraction has been shown to be dépendit on
V
the excitability of the detmsor muscle, hence if the tissue is spontaneously active then 
the response is increased. It appears that for rodent urinary bladder the predominant 
innervation is non-cholinergic and that the main action of acetylcholine is to modify 
the excitability'of the tissue (Brading & Williams, 1990). Support for the importance 
of purinergic transmission in small mammals has also come from binding studies. 
[3H] ATP binding has been demonstrated in rabbit urinary bladder where it appears 
that there is a high density of receptors (Levin et al., 1983). However, although these 
binding studies were carried out at OoC to limit the hydrolysis of ATP it is possible 
that some hydrolysis may still occur. More substantial evidence for the existence of 
P2-purinoceptors in urinary bladder has arisen from the observation that pHJ
AMPCPP, an ATP that is resistant to degradation by ectonucleotidases, binds 
specifically to rat bladder detmsor muscle (Bo & Bumstock, 1989).
Whilst there is considerable evidence for a non-cholinergic excitatory response in 
most mammals, studies on human tissues have been less clear. Experimentally, it is 
difficult to selectively field stimulate intramural nerves in human urinary bladder 
without also directly stimulating the smooth muscle and therefore it is often difficult 
to assess whether or not a non-cholinergic component is present (Hoyle et al., 1989).
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Although some studies have provided evidence for non-cholinergic innervation of 
human detrusor muscle these have often been performed on bladder obtained from 
patients undergoing surgery for disorders of the lower urinary tract and 
pharmacological studies on healthy bladder tissue dispute the presence of a non- 
cholinergic component (Sibley, 1984). Thus it appears that normally the predominant 
innervation in human bladder is cholinergic, however in diseased tissues a non- 
cholinergic component becomes apparent which suggests that it may play a role in the 
pathogenesis of urinary tract disease (Andersson, 1984).
As previously mentioned ATP is only a weak agonist in mammalian bladder 
suggesting that it is rapidly degraded by ectonucleotidases present on the smooth 
muscle cells. ATP is sequentially degraded to adenosine and adenosine has been 
shown to reduce the basal tone of the bladder and contractions to non-cholinergic 
nerve stimulation. Since adenosine is more potent than ATP at inhibiting nerve 
mediated responses and theophylline antagonizes the effects of adenosine it suggests 
that adenosine acts via Pi-purinoceptors (Dahlén & Hedqvist, 1980; Brown et al.,
1979). The physiological importance of the inhibitory effects of adenosine on urinary
I
bladder are not known as they have not been extensively studied but presumably 
adenosine would counteract excessive ATP stimulation and therefore act as a negative 
feedback mechanism.
1S3, Gastrointestinal tract
1.5.3.1. Stomach
In rat gastric coipus strip ATP and non-adrenergic, non-cholinergic nerve stimulation 
elicit a biphasic response: relaxation, followed by a rebound contraction (Hunt et al..
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1983). Such a response to ATP has also been demonstrated in rat gastric fundus 
where it was shown that the relaxant response was related to the tone of the 
preparation. At normal tone ATP and ATP analogues caused an initial relaxation 
followed by contraction of the fundic strip with an order of potency of 2MeSATP > 
ATP > AMPPCP these contractile responses being reduced by indomethacin. When 
the tone was raised by a submaximal dose of carbachol, ATP induced a larger 
relaxation foUôwed by a small contraction. Again indomethacin reduced the 
contractile response to ATP and the putative P2-purinoceptor antagonist, reactive blue 
2, inhibited the relaxant responses (Lefebvre & Bumstock, 1990).
Even though responses to ATP are similar to those elicited by non-adrenergic, non- 
cholinergic nerve stimulation in many stomach preparations and quinacrine-positive 
fibres have been observed in the mesenteric ganglia of rabbit stomach (Crowe & 
Bumstock, 1981), the proposal that ATP is the non-adrehergic, non-cholinergic 
transmitter in the stomach has not been widely accepted mainly because 
desensitization to ATP has been shown not to reduce relaxations evoked by 
transmural nerve stimulation (Baer & Frew, 1979) although as previously mentioned 
the use of ATP as a desensitizing agent has produced ambiguous results (Ambache & 
Zar, 1970).
Adenosine is also inhibitory on stomach preparations and there have been suggestions 
that the relaxations evoked by ATP are mediated by adenosine (Okwuasaba et al., 
1977). As well as inducing smooth muscle relaxation adenosine can inhibit gastric 
acid secretion via Ai receptors present on parietal cells (Westerberg & Geiger, 1989)
and there is evidence that the increase in mucosal blood flow associated with 
increased acid secretion is also mediated by adenosine as the Pi-purinoceptor 
antagonist, 8-PT, can inhibit this response (Gerber & Guth, 1989).
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\ , 5 3 ,2 , Sm all intestine
In rat duodenum it has been shown that non-adrenergic non-cholinergic nerve 
stimulation results in a transient relaxation followed by a rebound contraction both of 
which are mimicked by ATP. The rebound contraction appears to be due to 
prostaglandin synthesis as indomethacin abolishes this response (Manzini et al., 
1985). Further support for ATP being the non-adrenergic, non-cholinergic 
transmitter in the duodenum comes from observations that nucleoside 
pyrophosphatase ( which degrades ATP to AMP), reactive blue 2 and Pz-purinoceptor 
desensitization by ATP all antagonize responses to ATP and to non-adrenergic, non- 
cholinergic nerve-stimulated responses (Manzini et al., 1985 and 1986). It has even 
been suggested that the relaxation followed by rebound contraction could play an 
important role in peristalsis. There is not however total acceptance that ATP is the 
non-adrenergic, non-cholinergic transmitter in the duodenum as Serio et al. (1990) 
have disputed the antagonistic action of reactive blue 2  on non-adrenergic, non- 
cholinergic nerve stimulated responses and have also shown that desensitization by 
AMPCPP fails to significantly modify nerve-mediated responses. Histologically VIP 
has been shown to be present in the gut and it has been proposed as a putative 
transmitter however it produces a sustained relaxation which is unlike that to nerve 
stimulation and chymotrypsin antagonizes responses to VIP but has no effect on 
nerve-mediated or ATP-induced responses (Manzini et al., 1985).
On the duodenum adenosine is also inhibitory and appears to act via Pi-purinoceptors 
as 8-PT antagonizes responses to adenosine but has no effect on relaxations to ATP 
(Gaion et al., 1988; Furukawa & Nomoto, 1989).
I
In the ileum the evidence for ATP being the non-adrenergic, non-cholinergic 
transmitter is much weaker than that for the duodenum. It has been shown that
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adenosine and adenine nucleotides can relax the small intestine from a number of 
species including rabbit and guinea-pig however it has been demonstrated that they 
act by inhibiting acetylcholine release (Wiklund et al., 1985). ATP appears to act via 
Pi- rather than P2-purinoceptors and some workers have suggested that ATP can act 
following degradation to AMP (Moody et al., 1984) whilst others have shown that 
ATP can have a direct action on Pi-puiinoceptors (Wiklund & Gustafsson, 1986).
Also whilst non-adrenergic, non-cholinergic nérve stimulation in the rat duodenum is 
sensitive to ATP desensitization and the enzyme nucleotide pyrophosphatase, non- 
adrenergic, non-cholinergic nerve stimulation in the rat ileum is insensitive to these 
two treatments suggesting that ATP is not the neurotransmitter in ileal tissue 
(Manzini et al., 1986).
In addition to its inhibitory effect on acetylcholine release in the enteric nervous 
system adenosine has been shown to inhibit peptidergic transmission in guinea-pig 
ileum. The order of potency of adenosine and its analogues at inhibiting tachykinin 
release was CPA > NECA > CV1808 and the Ai selective antagonist, DPCPX, gave a 
pA2 of around 8 which would suggest that the Pi-purinoceptor is of the Ai subtype 
(Christofi et al., 1990).
Adenosine, as well as having an inhibitory effect on gastric motility has been shown 
to lower cAMP levels of epithelial cells in the small intestinal mucosa via an Ai 
receptor (Reymaim & Gniess, 1988). The absorptive function of epithelial cells is 
modulated by cAMP and the elevation of mucosal cAMP is a major factor in the 
pathophysiology of diarrhea (for review see Fondacaro, 1986). Thus an Ai selective
agonist may be of use in antidiarrheal therapy.
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I.5.3.3. Taenia coli
The guinea-pig taenia coli has been central to the development of the purinergic 
hypothesis as it was noted as early as 1966 that stimulation of intramural nerves gave 
rise to relaxation followed by rebound contraction that was resistant to sympathetic 
blocking drugs (Bennett et al., 1966). Many workers have smce confirmed the non- 
adrenergic relaxation in the guinea-pig taenia and it has been shown that ATP mimics 
the nerve-mediated response (Tomita & Watanabe, 1973). Lucifeiin-luciferase 
studies have demonstrated the release of ATP from intramural nerves (Bumstock et 
al., 1978c) although release can only be seen when a superfusion assay is used 
possibly because ATP is rapidly degraded in this tissue (White et al., 1981). Other 
direct evidence for ATP being the non-adrenergic, non-cholinergic transmitter has 
come from observations that nucleotide pyrophosphatase antagonizes both the 
inhibitory response to ATP and to field stimulation of intramural nerves (Satchell, 
1981).
Adenosine can also relax guinea-pig taenia coli however relaxations to adenosine are 
much slower than those to ATP and field stimulation (Cusack & Planker, 1979) and 
whereas theophylline antagonizes responses to adenosine it has no effect on those to 
ATP (Brown & Bumstock, 1981a). Whilst it has been suggested that both ATP and 
adenosine relax the taenia by hypeipolaiizing the smooth muscle membrane it appears 
that the two act via separate mechanisms. Electrophysiological studies have shown 
that the ATP-induced hyperpolarization is due to a Ca2+-depend^t increase in K+- 
permeability as removal of extracellular Ca2+ abolishes the response and the K+ 
conductance is increased when the extemal K+ concentration is reduced. The 
response to adenosine however is not modified by a reduction in extemal K+ and less 
effected by Ca2+ removal suggesting that the adenosine hyperpolaization is not due to
62
a Ca2+-dependent increase in permeability (Ferrero & Frischknecht, 1983). A similar 
electrophysiological response to adenosine has also been observed in the guinea-pig 
caecum (Hoyle et al., 1988).
Therefore in the guinea-pig taenia coli there is substantial evidence for ATP being the 
non-adrenergic, non-cholinergic transmitter (reviewed by White, 1988). In this tissue 
it appears that ATP acts via P2Y-purinoceptors as 2MeSATP is 30-50 times more 
potent than ATP (Satchell & Maguire, 1982). Adenosine is inhibitory in the taenia 
coli however its effects appear to be mediated by A2 receptors (Bumstock et al., 
1984b).
1 ,5 3 A . Anococcygeus
The anococcygeus is a thin, paired smooth muscle recieving a dense adrenergic 
excitatory innervation (Gillespie, 1972). There is also evidence of a non-adrenergic, 
non-cholinergic inhibitory innervation to this tissue for which ATP has been proposed 
to be the neurotransmitter. Quinacrine-positive fibres have been demonstrated in the 
rat and rabbit anococcygeus and after blockade of adrenergic nerves with 
guanethidine intramural nerve stimulation results in a rapid relaxation which is 
accompanied by an increase in ATP release (Bumstock et al., 1978a). The direct 
action of ATP is often complicated as for exainple in the rabbit it relaxes (Sneddon et 
al., 1982) whereas in the rat it contracts (Carpenter & Joshi, 1980). Contractions 
however appear to be due to prostaglandin synthesis as they can be blocked by 
indomethacin which then unmasks a relaxant response similar to that seen with 
intramural nerve stimulation (Bumstock et al., 1978a). Other authors have disputed 
the proposal that ATP is the non-adrenergic, non-cholinergic neurotransmitter in this 
tissue, as the putative P2-purinoceptor antagonist ANAPP3 is without effect on
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responses to nerve stimulation (Sneddon et al., 1982), and it has since been proposed 
that nitric oxide (NO), or a substanôe releasing NO is the transmitter released from 
non-adrenergic, non-cholinergic nerves in the anococcygeus (Gillespie et al., 1989).
Adenosine is inhibitory on rat anococcygeus and can reduce the contractile responses 
of the anococcygeus muscle to adrenergic nerve stimulation. From the order of 
potency of adenosine analogues it appears that adenosine acts via Ai receptors to 
mediate this effect as L-PIA > NECA > adenosine and it has therefore been suggested 
that adenosine acts presynaptically to inhibit neurotransmitter release (Stone, 1983). 
Suiprisingly if the tone of the anococcygeus is raised then adenosine and adenosine 
analogues induce contraction of the tissue with NECA, L-PIÀ and adenosine being 
virtually equipotent. This would suggest a postsynaptic excitatory action of the 
agonists, although the class of receptor mediating this response is unclear as the Pi- 
purinoceptor antagonists theophylline and 8-PT do not antagonize contractions to 
adenosine and its analogues suggesting that they are not acting via Pi-purinoceptors 
(Stone, 1983).
1.5.4. Vas deferens
The smooth muscle of vas deferens is densely innervated by sympathetic fibres of the 
hypogastric nerve. Electrical field stimulation of the vas deferens results in a biphasic 
response: an initial rapid contraction followed by a slower tonic contraction. The 
tonic component appears to be adrenergic as it can be mimicked by noradrenaline and 
is abolished by ai-adrenoceptor antagonists such as prazosin ^ d  by treatment with 
reserpine (Ambache & Zar, 1971). It has been suggested that the initial phasic 
component is due to the release of ATP as exogenous ATP closely mimicks the fast 
contraction and it can be abolished by desensitization of P2-purinoceptors by
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AMPCPP (Meldnun & Bumstock, 1983). From electrophysiological studies it has 
been shown thàt nerve stimulation in the vas deferens elicits an excitatory junction 
potential (e.j.p.). Exogenous ATP has been shown to induce an e.j.p. whereas 
exogenous noradrenaline does not, also field stimulated e.j.p.s are abolished by the 
P2“purinoceptor antagonist ANAPP3 and by desensitization of P2-puiinoceptors with
AMPCPP (Sneddon & Westfall, 1984; Sneddon & Bumstock, 1984). Further support 
for the hypothesis that both noradrenaline and ATP are coreleased from sympathetic 
nerves came from studies by Westfall and colleagues who showed that [3H] purines 
were released from adrenergic nerves in guinea-pig vas deferens and subsequent 
studies in this tissue showing the release of ATP upon nerve stimulation (Westfall et 
al., 1978; Lew & White, 1987). The fact that 6-hydroxydopamine can eliminate both 
phases of the contractile response to nerve stimulation substantiates this proposal 
(Trachte et al., 1989). There is increasing evidence that a third transmitter substance 
may be involved in the vas deferens as neuropeptide Y (NPY) is also released upon 
nerve stimulation and this release can be blocked by tetrodotoxin. Stjame and 
Lundberg (1986) have suggested that NPY acts on postsynaptic receptors initially to 
potentiate the feffects of noradrenaline and ATP, however as the concentration of 
NPY increases it appears to act on presynaptic receptors to inhibit transmitter release. 
Prostaglandins of the E series can also modulate transmitter release in the vas 
deferens, and can be released upon nerve stimulation. Studies have shown that PGE2
inhibits the release of ATP in the rabbit vas deferens but that it enhances or has no 
effect on the release of noradrenaline. This is interesting as it implies that although 
ATP and noradrenaline may be coreleased they appear to be released from separate 
stores (Trachte et al., 1989).
Whilst the response to exogenous ATP closely resembles that of the phasic response 
to nerve stimulation there are slight differences. Low concentrations of ATP produce 
only rapid transient contractions but as the concentration of exogenous ATP is
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increased a slow tonic contraction is also seen. The initial phasic response is 
abolished by the P2-purinoceptor antagonist ANAPP3 but this antagonist has little
effect on the second component (Fedan et al., 1982). It appears that the twitch-like 
contraction is due to the release of Ca2+ from intracellular stores as ryanodine can 
inhibit this response. The second, tonic contraction is susceptible to blockade by 
nifedipine a Ca2+-channel blocker suggesting that it is due to the opening of Ca2+ 
channels in the smooth muscle cell membrane. This biphasic response is not unlike 
that to electrical field stimulation as ryanodine selectively inhibits the first 
(purinergic) component whereas ' nifedipine selectively inhibits the second 
(adrenergic) component (Bourreau et al., 1991). It has been noted that two distinct 
responses to field stimulation can only be observed when stimulating at a low 
frequency (2Hz) (Ellis & Bumstock, 1990) perhaps at high frequency stimulation, the 
concentration of ATP is such that a tonic contractile response predominates therefore 
making it difficult to observe a rapid contractile response.
It has been proposed that ATP acts via P2x-purinoceptors on vas deferens (Bumstock 
& Kennedy, 1985) however it has subsequently been suggested that the agonist 
recognising the receptor is ATP4- rather than ATP, since as the concentration of 
Mg2+ present in the buffer solution was increased the concentration of ATP required 
to stimulate contraction also increased (Fedan et al., 1990).
Adenosine is inhibitory on the vas deferens and has been shown to reduce pH] 
noradrenaline release during nerve stimulation (Fredholm et al., 1982). L-PIA is 
approximately 100 times more potent at inhibiting field stimulated responses and 
CHA is also a potent agonist whereas the A2 agonist CV1808 is without effect 
therefore suggesting that adenosine is acting on presynaptic Ai receptors to inhibit 
neurotransmitter release (Paton, 1981; Major et ^ ., 1989). Some workers have 
shown that ATP can also inhibit neurogenic contractions and have suggested that
66
ATP is metabolized to adenosine to produce this inhibitory effect (Clanachan et al., 
1977). Since it is known that noradrenaline can feedback via a 2-adienoceptors to
inhibit its own release it has been proposed that a similar negative feedback 
mechanism exists for ATP, and that ATP is rapidly metabolized in the vas deferens to 
adenosine which then acts on presynaptic Ai receptors to inhibit transmitter release.
The presynaptic inhibition by both noradrenaline and adenosine does not appear to be 
selective for their respective transmitter substances as adenosine and noradrenaline 
each inhibit both components of the contractile response and both appear to exert 
greater inhibition over the first (purinergic) phase of the response (Sperlagh & Vizi, 
1988; Major et al., 1989). Whether adenosine is important physiologically is not 
certain as in some species autoinhibition by noradrenaline appears to be quantitatively 
more important (Stjame & Astrand, 1985; Sperlagh & Vizi, 1988).
1.6. ONTOGENY OF PURINOCEPTORS
There have been limited studies on the development of purinoceptors. Radioligand 
binding studies have provided information on the development of Ai receptors in
guinea-pig and rat brain in particular the forebrain and cerebellum. In guinea-pig 
forebrain it appears that Ai receptors are present as early as embryonic day 36 and
receptor number appears to be fairly stable with only a transient increase in receptor 
number just before birth. In guinea-pig cerebellum however, Ai receptor binding is
low until just prior to birth when a dramatic increase in binding is observed which 
then continues to increase up to adulthood (Morgan et al., 1990). A similar 
development is seen in rat forebrain and cerebellum with Ai receptor binding
changing very gradually in the forebrain whereas binding in the cerebellum increases 
markedly after birth (Marangos et al., 1982; Geiger et al., 1984).
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Studies on the development of peripheral purinoceptors have also been reported. In 
the cardiovascular system adenosine has been shown to have pharmacological effects 
on 5 day old guinea-pig heart with adenosine being more potent at reducing coronary 
resistance in neonatal heart than in the adult (Matheme et al., 1990). In the 
gastrointestinal tract responses to ATP have been observed in rat duodenum the day 
after birth suggesting that functional P2-purinoceptors are present at this time. In this
study responses to adenosine however did not become apparent until day 14 
suggesting that Pi-purinoceptors develop later (Furukawa & Nomoto, 1989). It has
been proposed that ATP is the non-adrenergic, non-cholinergic neurotransmitter in 
many areas of the gastrointestinal tract (for review see Bumstock, 1972) and non- 
adrenergic, non-cholinergic nerve-mediated effects have been observed before birth 
in rat stomach (Ito et al., 1988) and in mouse and rabbit small intestine (Gershon & 
Thompson, 1973). Also quinacrine fluorescence, which indicates the presence of 
purinergic nerves, is also observed before birth in rabbit ileum and stomach (Crowe & 
Bumstock, 1981).
ATP has also been proposed as the non-cholinergic excitatory transmitter in urinary 
bladder (Bumstock et al., 1978b) and "purinergic" responses are apparent at birth 
(Keating et al., 1990). Studies have shown that purinergic innervation and 
responsiveness to ATP is greater in 1 day old urinary bladder than in adult tissue 
which would indicate that the purinergic component is more important in the neonate 
than in the adult (Keating et al., 1990; Zderic et al., 1990; Sneddon & McLees, 1991). 
The importance of ATP in neonatal tissue has also been demonstrated in rat vas 
deferens where ATP has been proposed as the co-transmitter (Meldrum & Bumstock, 
1983). In this tissue purinergic responses have been observed three weeks after birth 
(the earliest age that could be tested) whereas adrenergic responses were absent at this 
age (MacDonald & McGrath, 1984).
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1.7. AIM OF THE THESIS
The aim of the thesis was to study the development of purinoceptors in peripheral 
tissues in the rat to assess the importance of purinergic responses in the neonate and 
the differences between neonatal and adult preparations. The rat duodenum was 
chosen as in this tissue ATP causes relaxation (Manzini et al., 1985) and it is known 
that in general P2Y-purinoceptors mediate relaxation whereas P2x-purinoceptors 
mediate contraction of smooth muscle (Bumstock & Kennedy, 1985). The rat urinary 
bladder and vas deferens were chosen as a models to study the development of Pzx-
purinoceptors, as in these tissues ATP causes contraction (Brown et al., 1979; 
Meldrum & Bumstock, 1983). Adenosine is inhibitory in rat duodenum, urinary 
bladder and vasa deferentia (Gaion et al., 1988; Dahlén & Hedqvist, 1980; Fredholm 
et al., 1982) and so the development of Pi-purinoceptors could be followed in each. 
As degradation and/or uptake of ATP and adenosine can influence their 
pharmacological potency, the developmental changes in the degradation of these 
purines were investigated to see if there was a correlation between the ontogeny of 
pharmacological responses and metabolism of the purines.
Also the purinoceptor subtypes mediating responses to adenosine and ATP in these 
tissues were further characterized using adenosine and ATP analogues and the Pi- 
purinoceptor antagonists 8-SPT and DPCPX.
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CHAPTER 2. METHODS
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2.1. ANIMALS
Wistar rats were obtained from the University of Surrey Breeding Unit. Litters of 
neonatal rats were crossfostered at bhtii andxulled to 8 rats per mother. Day of birth 
was designated as day 1 and neonatal rats were weaned around day 20 .
Wistar rats, adult male (200-250g), neonatal male and female 2, 5,10, 15, 20,25 and 
30 days old (see figure 4. for table of corresponding mean weights vs age) were killed 
by cervical dislocation and decapitation. The abdomen was opened up and the 
duodenum, urinary bladder and vasa deferentia removed.
2.1.1. Rat duodenum
The duodenum was dissected out by cutting at the base of the pylorus and at 1.5cm 
(adults) or 0.5cm (2-30days old) from this point. The tissues were cleared of any 
connective tissue and washed thoroughly with Krebs solution by passing Krebs buffer 
through the lumen using a plastic Pasteur pipette (1ml). Cotton threads (Silko, 60 
gauge) were tied round each end of the segment of duodenum so that the lumen was 
sealed.
There was a marked difference between neonatal and adult rat duodenum. Neonatal 
rat duodenum was thin and almost transparent in appearance and the muscle was 
extremely fragile. Initially adult rat duodenum had been prepared by threading the 
cotton through the muscle wall, however whilst this was possible for adult tissues this 
technique could not be used for neonatal duodenum due to the fragility of the tissue.
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Figure 4. Neonatal weight vs age.
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Figure showing the increase in neonatal weight with age. Each 
point is the mean of at least 4 determinations and the vertical bars 
(apparent only when they are greater than the symbol size) show 
s.e.mean.
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2.1.2. Rat urinary bladder
The rat urinary bladder was excised and cleared of any connective tissue and the 
sphincter was removed by a lateral cut across the base of the sac. Either side of the 
bladder sac was then cut so that the bladder could be opened up as a flat sheet.. The 
sheet of bladder was pinned out on a bed of inert wax (Cottrell & Co. modelling wax) 
and a 10 X 2 mm detrusor strip was then prepared and cotton threads (Silko, 60 
gauge) tied at each end of the strip. This tissue was maintained in Krebs buffer 
during the preparation. There was little difference in urinary bladder from adult and 
neonatal rats except that neonatal rat urinary bladder was overall smaller in size, the 
size increasing with age.
2.1.3. Rat vasa deferentia
The vasa deferentia were dissected out by cutting just .below the epididymis and 
above the urethra. The tissues were very carefully freed of any connective tissue, 
ensuring that the forceps were not allowed to come into contact with the vas deferens 
(so that the nerves innervating the vas deferens were not damaged) and washed with 
Krebs buffer. Cotton threads (Silko, 60 gauge) were tied at either end of the vas 
deferens so that the lumen was sealed. There was no marked difference between 
adult and neonatal vas deferens except in the overall size of the tissues.
2.2. HISTOLOGICAL ANALYSIS OF RAT DUODENUM
Rat duodenum from 5 and 10 day old rats were fixed in 10% neutral buffered 
formalin for 1 week. Tissues were placed in a metal processing container for
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embedding in paraffin wax using a Histokinette automatic tissue processor. The 
embedding process consisted of three phases: dehydration; clearing and impregnation, 
after which the tissue containers were transfered to a third wax bath from which the 
tissue was blocked out. Sections were cut every 100pm ^t a thickness of 5pm using 
an LKB Historange. The sections were mounted on slides, stained with Ehrlich's acid 
haematoxylin and eosin and examined at a magnification of x400 using a Vickers 
M15 c microscope.
2.3. PHARMACOLOGICAL STUDIES
I
The tissues were mounted in 10ml organ baths containing Krebs solution of the 
following composition (mM): NaCl 118, KCl 4.8, MgS0 4  1.2, CaCli 2.5, KH2PO4
1.2, NaHCOs 25 and glucose 11. The Krebs solution was aerated with 95% O2 : 5% 
CO2 and maintained at 35-360C by means of a water jacket surrounding the organ 
bath. Resting tensions of Ig (adult duodenum and bladder), 0.5g (20-30 day old 
duodenum, adult and neonatal vas deferens) and 0.2g (2-15 day old duodenum) were 
applied to the tissues and isometric responses were recorded with a Grass FT03 
transducer and displayed on a Grass 79D polygraph. Some of the studies on the vas 
deferens were recorded with Harvard UFl transducers, amplified with Washington 
120 biological amplifiers and recorded on Washington 4(X)MD chart recorders. 
When nerve-mediated responses were required tissues were field stimulated by linear 
platinum electrodes: 0.3mm diameter, 7.0cm length; 1.5cm apart. Tissues were 
allowed to equilibrate for 45 minutes before the addition of drugs.
All concentratibn-response curves were obtained non-cumulatively, with 5 washouts 
of the organ baths between doses, and potency estimates of each agonist were
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obtained from regression analysis of the linear region of individual concentration 
response curves. Where figures show mean of n determinations: there is one determination 
per tissue.
2.3.1. Rat duodenum
2 3 A .I .  Inhibitory responses
The rat duodenum was spontaneously active however the size of spontaneous 
contractions were variable and tended to decrease with time making relaxant 
responses to agonists difficult to quantify. Therefore the rat duodenum was pre­
contracted with carbachol so that inhibitory responses could be easily measured. A 
concentration-response curve to carbachol was constructed so that a suitable dose for 
pre-contracting the tissue could be chosen (see figure 5). O.lpM carbachol gave a 
contraction that was approximately 40% of the maximum response and it produced 
steady rhythmic contractions. It was therefore chosen as the pre-contracting dose. At 
the start of each experiment contractions to carbachol tended to be irregular therefore 
tissues were challenged with three doses of O.lpM carbachol prior to any addition of 
purines. After this steady contractions to carbachol were obtained. Inhibitory 
responses were quantified by pre-contracting the duodenum with O.lpM carbachol 
and challenging with purine (contact time 1 minute) 1.5 minutes (adults) or 1 minute 
(20-30 days old) later. The reason for the time difference between adding purine to 
neonatal or adult rat duodenum was because contractions to carbachol (O.lpM) 
tended to reach a steady state quicker in the neonate than in the adult however 
neonatal contractions were found to fade after around 2 minutes. Contractions to 
carbachol were measured from the peak of spontaneous activity to the highest point of 
carbachol contraction. Relaxations were measured as the reduction in this peak 
height and expressed as % inhibition of carbachol contraction. The dose cycle for
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Figure 5. Concentration-response curve for carbachol on adult and 15
day old rat duodenum
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Concentration-response curve for carbachol on (a) adult and (b) 15 day old rat 
duodenum (n=l). Responses expressed as % of maximum contraction with 
carbachol.
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addition of agonists was 10 minutes, and no tachyphylaxis was observed to either 
carbachol or any of the purines used. For ontogenetic studies potency was expressed 
as pECss, the negative logarithm of the EC35.
For studies with the Pi-purinoceptor antagonists, concentration-response curves for 
purines were obtained as previously described and tissues were then incubated for 30 
minutes with either 8-p-(sulphophenyl)theophylline (8-SPT) (1-lOOpM) or 1,3- 
dipropyl-8-cyclopentylxanthine (DPCPX) (InM-lpM). Dose-ratios were calculated 
from the ratio of the EC50 values in the absence and presence of antagonist, and 
dissociation constants (Kd) values) were calculated as the molar concentration of the 
antagonist divided by the dose-ratio -1 . Concentration-response curves to adenosine 
5'-(P,Y-methylene) triphosphonate (AMPPCP) and N6-cyclopentyladenosine (CPA) 
were also constructed in the absence and presence of lOpM hexaméthonium. 
Inhibition of nicotinic receptors by hexaméthonium (lOpM) was confirmed by the 
ability of hexaméthonium at this concentration to inhibit responses to the nicotinic 
agonist dimethylphenylpiperazinium (DMPP).
2 3 ,1 2 ,  Excitatory responses
Excitatory responses of neonatal duodenum were observed by adding purine (contact 
time 1 minute) without pre-contracting the tissue, dose-cycle 10 minutes. 
Contractions were expressed as % of contraction to carbachol (O.lpM). After 
concentration-response curves to purines had been obtained tissues were incubated 
with 25pM indomethacin for 45 minutes and the concentration-response curves were 
repeated in the presence of indomethacin. Inhibition of cyclooxygenase by 
indomethacin was confirmed by the ability of indomethacin (25pM) to inhibit
I
contraction induced by arachidonic acid (O.lmM) in 5 day old rats. To investigate
77
whether the ATP-induced contractions were neurogenic, concentration-response 
curves to ATPi on 5 day old rat duodenum were obtained and then repeated after 
incubation of the tissues with tetrodotoxin (IpM) for 30 minutes. Inhibition of nerve- 
mediated transmitter release by tetrodotoxin was confirmed by blockade of the 
contractile responses to field stimulation of the tissues. Tissues were field stimulated 
by a Grass S48 stimulator at 70V, 15Hz, 1ms pulse width with a train duration of 5s.
Potency values of excitatory responses were expressed as the pECss, the negative 
logarithm of the EC35.
2.3.2. Rat urinary bladder
Concentration-response curves to purines were obtained. Excitatory responses to 
ATP and AMPPCP were observed by adding the agonists direct to the bladder 
(contact time 30s, dose-cycle 10 minutes). The rat urinary bladder had a steady basal 
tone and excitaltory responses were expressed as % of maximum contraction induced 
by KCl (120-180mM). In the ontogenetic studies potency was expressed for 
AMPPCP and ATP as the PEC35 or pECis respectively, the negative logarithm of the 
EC35 and EC 15 respectively. Inhibitory responses to adenosine, 5-N- 
ethylcarboxamidoadenosine (NECA), CPA and 2-p-((carboxyethyl)- 
phenethylamino)-5'-carboxamidoadenosine (CGS21680) were expressed as % 
inhibition of carbachol contraction, where the agonists had been added 30s before 
carbachol (3pM). 3pM carbachol was chosen as it gave a contraction approximately 
50% of the maximum contraction to carbachol (figure 6).« Potency was expressed as 
the PEC35, the negative logarithm of the EC35.
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Figure 6. Concentration-response curve for carbachol on adult and 15
day old rat urinary bladder
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Concentration-response curve for carbachol on (a) adult and (b) 15 day old rat 
urinary bladder (n=l). Responses expressed as % of maximum contraction with 
carbachol.
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Studies with the Pi-purinoceptor antagonist DPCPX were performed by incubating 
the tissues for 30 minutes with the antagonist after concentration-response curves to 
the purines had been obtained. Concentration-response curves were than repeated in 
the presence of DPCPX. Dose-ratios were calculated from the ratio of the EC50 
values in the absence and presence of antagonist, and dissociation constants (Kd 
values) were calculated as the molar concentration of the antagonist divided by the 
dose-ratio -1.
2.3.3. Rat vasa deferentia
Concentration-response curves to ATP and noradrenaline were obtained, contact time 
1 minute, dose-cycle 10 minutes for each agonist. Contractions were measured as % 
of maximum response induced by KCl (120-180mM). Concentration-response curves 
of the inhibitory effects of adenosine and its analogues on contractions to exogenous 
ATP and noradrenaline were measured by pre-incubating the vasa deferentia with the 
Pl-agonists for 1 minute before the addition of ATP or noradrenaline (lOpM). 
Nerve-mediated contractions were obtained by field stimulating the tissues by means 
of a Grass S48 stimulator with twin pulses of 1ms duration, 75ms delay at 70V. To 
verify that the contractions induced by field stimulation were neurogenic the 
inhibitory effect of tetrodotoxin (IpM) on these responses was tested. Concentration- 
response curves for the inhibitory effects of adenosine and its analogues on nerve- 
mediated contractions were measured by field stimulating the. rat vasa deferentia at a
I
frequency of O.lHz and adding the purine to the bath (contact time 1 minute) when 
the responses to nerve stimulation had stabilized. Field-stimulated contractions were 
expressed as % of maximum contraction induced by KCl (120-180mM) and the 
inhibitory effects of the Pi-purinoceptor agonists on field stimulated contractions
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were expressed as the % reduction of the nerve-mediated response. Potency was 
expressed as the pECso, the negative logarithm of the EC50.
In experiments with DPCPX, control concentration-response curves to the purines 
were constructed, followed by incubation of the tissues with the antagonist before 
repeating the concentration-response curves in the presence of DPCPX. Dose-ratios 
were calculated from the ratio of EC50 values in the absence and presence of 
antagonist, and dissociation (Kd values) were calculated as the molar concentration of 
the antagonist divided by the dose-ratio - 1. Control studies where concentration- 
response curves were repeated after a 30 minute incubation period with vehicle alone 
were also performed to see if the responsiveness of the tissues to purines changed 
during this time.
2.4. DEGRADATION STUDIES
2.4.1. Sample preparation
Rat duodenum and urinary bladder were prepared as described in section 2.1.1. and
2.1.2. respectively. The rates of degradation of purines by each tissue were studied 
by incubating the tissue in a solution of Krebs buffer containing the purine.
Tissues were incubated in Krebs buffer (gassed with 95% O2 : 5% CO2 and 
maintained at 35oC) for 3 hours with the buffer being changed every 15 minutes. The 
tissues were then tied to the end of a 21 gauge needle and placed in a vial containing 
2.5ml Krebs buffer. The needles were connected up to 95% O2 • 5 % CO2 gas supply
I
by removing the plastic Leur cormection and cormecting up to P.V.C. portex tubing
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(1mm diameter), which kept the tissues aerated and ensured thorough mixing of the 
Krebs buffer. All vials were placed in a water bath so that the buffer was maintained 
at 350c. lOOpl aliquots of Krebs buffer were removed at time 0 (when the tissues 
were added to the vials) and 20 minutes later to see if there was any release of 
endogenous nucleotides by the tissues. The samples were placed on ice and then 
frozen (-200C) for later analysis by high performance liquid chromatography 
(h.p.l.c.). Following these basal measurements tissues were transfered to a second 
vial containing purine (lOOpM) in 2.5ml Krebs buffer and lOOpl aliqouts were 
removed at 0, 5,10,15 and 20 minutes so that the degradation of the purine could be 
followed. The samples were stored on ice and frozen for separation and 
quantification of purines and metabolites by h.p.l.c. The design of the apparatus was 
such that evaporation of Krebs solution was kept to a minimum as all vials were 
loosely capped. In order to ensure that the purine being tested was stable in Krebs 
buffer at 350C and that no loss occurred through evaporation lOOpM purine was 
added to Krebs buffer (final volume 2.5ml), vials were aerated and maintained at 
350C and lOOpl aliquots removed at 0 and 20 minutes for analysis by h.p.Lc. Control 
studies were also performed to check for leakage of nucleotidases. lOOpM purine 
was added to buffer that had previously contained the tissue and lOOpl aliquots 
removed at 0 and 20 minutes for analysis by h.p.l.c.
2.4.2. Analysis of purine metabolism by h.p.l.c.
The lOOpl aliquots obtained from the above studies were stored frozen ( -20oC) until 
required for analysis by h.p.l.c., when they were thawed out and thoroughly mixed by 
vortexing.
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50pl samples were analysed with a Waters h.p.l.c. and were injected onto a Techspere 
5pm ODS Ci8 column, eluted with O.IM KH2PO4 /  8mM tetrabutylammonium 
hydrogen sulphate (pH 6.0) (solvent A) and a 60:40 mixture of solvent A and 
acetonitrile (pH 6.73) (Solvent B), using a non-linear gradient (0-2.5 min 0% B, 2.5- 
5.0 min 0-20% B, 5-10 min 20-40% B, 10-13 min 40-100% B, 13-18 min 100% B) at 
a flow rate of 1.2ml per minute. This gradient gave good separation of the 
nucleotides being studied and the catabolites adenosine 5-diphosphate (ADP), 
adenosine 5 -monophosphate (AMP), adenosine and inosine (see figure 7). The 
purines were detected by u.v. absorbance at 259nm, and quantified from the height of 
their absorbance peaks, which was linearly related to their concentration (figure 8).
2.5. MATERIALS
Adenosine, ATP, ADP, AMP, inosine, AMPPCP, adenosine 5'-(a,P-methylene) 
triphosphonate (AMPCPP), NECA, carbachol, indomethacin, tetrodotoxin, 
hexaméthonium, DMPP, arachidonic acid and tetrabutylammonium hydrogen 
sulphate were obtained from Sigma Chemical Co., U.K. Ltd. 2MeSATP, 8-SPT, 
DPCPX, CPA and CGS21680 were obtained from Research Biochemicals Inc., 
Buffer salts (analytical grade), solvents (h.p.l.c. grade), Ehrlich's acid haematoxylin 
and eosin were obtained from BDH, Ltd and 95% O2: 5% CO2 was supplied by 
B.O.C. The Techsphere 5pM ODS Cig column was obtained from H.P.L.C. 
Technology. U.K.
Stock solutions of adenosine, adenine nucleotides, 2MeSATP and AMPPCP were 
made up in distilled water. As these compounds are known to be hydroscopic the 
final concentration of drug was confirmed by measuring the u.v. absorbance of the 
stock solution together with the extiction coefficients for each compound at its
K
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optimum wavelength (optimal wavelength and extinction coefficients are shown in 
table 5). A lOmM stock solution of CPA was made up using 20% ethanol after which 
all dilutions of this drug were made using distilled water. ImM DPCPX was 
prepared in 2% aqueous dimethylsulphoxide (DMSO) containing 6mM NaOH. 
Concentrations, of DPCPX from ImM to IpM were dissolved in 2% aqueous DMSO, 
6mM NaOH solution after which distilled water was used. Indomethacin was initially 
dissolved in ethanol and made up in 1/19 v/v ethanol/phosphate buffer. The pH of 
this solution was approximately 7.4 and the indomethacin solution should therefore 
be stable for 24 hours (Curry and Brown, 1982) however fresh solutions were 
prepared for immediate use before each experiment. Arachidonic acid was freshly 
made up in O.IM NaiCOg before each experiment. The solvents used for preparing
the drugs mentioned above had no effect oh the responses of the tissues at the 
concentrations finally used. All other drugs were dissolved in distilled water.
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Figure 7. Separation of adenosine and adenine nucleotides using h.p.Lc.
G R A D IE N T
V
20
Time (m inutes)
Separation of ATP (■ ), ADP (•  ), AMP (A), adenosine ) and inosine (▼) (100 pM) by 
h.p.l.c.
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Figure 12. U.V. absorbance of purines vs. purine concentration
(a) (b)
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U.V.absorbance vs concentration of (a) ATP. (b) ADP. (c) AMP. (d) adenosine, 
(e) inosine. Absorbance expressed as height of peak (cm).
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Table S. Optimum wavelength and extinction coefficient for purines
Purine Optimum wavelength Extinction coefficient
nm at their optimal wavelenght
pH6-7ExlO-3Mcm"’
ATP 259 15.4
ADP 259 15.4
AMP 259 15.3
Adenosine 259 14.9
Inosine 259 7.1
2MeSATP 273 14.5
Table showing the /optimum wavelength for absorbance of purines and their 
respective extinction coefficients.
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CHAPTER 3. RESULTS.
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3.1. ONTOGENY OF RESPONSES TO PURINES ON RAT DUODENUM AND 
URINARY BLADDER
3.1.1. Adult rat duodenum
Adenosine 5'-triphosphate (ATP), adenosine, adenosine 5'-(P,y-methylene) 
triphosphonate (AMPPCP) and 2-methylthioadenosine 5'-triphosphate (2MeSATP) 
all produced relaxations of carbachol-contracted rat duodenum (figure 11). When the 
duodenum was prepared so that the lumen remained open ATP, AMPPCP and 
adenosine were virtually equipotent (figure 9a) however when the lumen were sealed 
the potency of ATP was increased 10-fold while the potency of AMPPCP and 
adenosine remained virtually unchanged (figure 9b and table 6). The order of 
potency for purines on the rat duodenum (where the lumen were sealed) was 
2MeS ATP > ATP > AMPPCP = adenosine.
3.1.2. Adult rat urinary bladder
ATP and AMPPCP both contracted adult rat bladder with AMPPCP being much more 
potent than ATP (figure 11). An EC35 value of 53pM was obtained for AMPPCP
however the maximum contraction induced by ATP did not reach 35% of the 
maximum response and so an EC15 value of 41pM was calculated (figure 10a). 
Adenosine inhibited the carbachol contraction of the rat bladder with an EC35 value 
of 57.8pM (figure 10b and 11).
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Table 6. Potency of purines on rat duodenum with lumen open or closed
Purine Potency (EC35) Potency (EC35)
lumen open lumen closed
2MeSATP O.OlpM
ATP 3.3pM. 0.3pM
AMPPCP 14.9pM 3.5pM
adenosine . 7.6pM 5.6pM
Table showing the potency of purines on rat duodenum when the duodenum was set 
up so that the lumen remained open or was sealed.
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Figure 9. Inhibitory effects of purines on adult rat duodenum
(a)lOO-i
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purine concentration pM
Inhibitory effects of ATP (■), adenosine (•) , AMPPCP (A) and 2MeSATP (♦) 
on adult rat duodenum, (a) duodenum set up so that lumen remained open, (b) 
duodenum tied at each end so that lumen was sealed. Each point is the mean of 
at least 7 determinations and the vertical bars show s.e.mean.
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Figure 10. Effects of purines on adult rat urinary bladder
(a)
!
60
40
2 0
0
10 1000.1 1
Purine concentration pM
40-
2 0 -
10 1 0 00 .1 1
Adenosine concentration jiM
Effects of purines on adult rat urinary bladder, (a) contractile effect of ATP (■ ) and 
AMPPCP (A), expressed as % maximal contraction induced by KCl (120-180rnM). 
(b) Inhibitory effect of adenosine expressed as % inhibition of contraction induced 
by carbachol (3pM). Each point is the mean of at least 7 determinations and the 
vertical bars (shown when greater than symbol size) show s.e.mean.
92
3.1.3. Neonatal rat duodenum
Low concentrations (0.1-lpM) of ATP relaxed rat duodenum between 2 and 15 days, 
whilst ATP at 3pM and above contracted this tissue, even when the tone had been 
raised with carbachol (figure 11). The potency of ATP in contracting rat duodenum 
and the maximal contractile response decreased with age (table 7 , figures 12 and 13a) 
until after day 15 when no contractions to ATP were observed even at a concentration 
of lOOpM. 2MeSATP also contracted the rat duodenum between 2 and 15 days and 
the development of the response mirrored that to ATP however 2MeSATP was 
always nearly 100 times more potent at contracting rat duodenum than ATP itself 
(table 7, figures 12 and 13b).
Indomethacin (25pM) blocked the contractions induced by O.lmM arachidonic acid 
(figure 14b) but did not significantly, reduce contractions induced by ATP in 2, 5 and 
10 day old rat duodenum (figure 11 and 14) or by 2MeSATP in 2, 5, 10 and 15 day 
old rat duodenum (figure 15).
Tetrodotoxin (IpM) blocked contractions to field stimulation (figure 16) but did not 
reduce contractions induced by ATP in 5 day old rat duodenum (figure 17).
At day 15, although ATP contracted the resting tissue, if the tone was raised by 
carbachol (O.lpM) relaxations to all concentrations (0.1-lOOpM) were also observed 
but it was much less potent than in the adult The potency of ATP at relaxing rat 
duodenum increased up to day 25 when it was equipotent with the adult (table 7, 
figure 13a). AMPPCP even at a concentration of lOOpM was never observed to 
contract the rat duodenum but its potency in causing relaxation varied with age. 
AMPPCP was much less potent than the adult at 5 days, was least potent at 10 days 
and most potent at 25 days (table 7, figure 13c).
93
Adenosine did not contract the duodenum at any age and its potency in causing 
relaxation was also less than the adult at 5 days, lowest at day 10 and highest at day 
25 (table 7, figure 13d).
Histological studies confirmed that both the circular and longitudinal muscle were 
present in 5 day old rat duodenum (data not shown).
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Figure 11. Representative traces of responses to purines on adult and
neonatal rat duodenum and urinary bladder
(a ) i !
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Representative traces showing effects of purines on adult and neonatal tissues, (a) Relaxant effects on adult 
rat duodenum pre-contracted with carbachol (O.lpM) of 2MeSATP (O.lpM) (A), ATP(lOpM ) (■  ), 
AMPPCP (lOpM) ( # )  and adenosine (lOpM) (^ ). (b) Effects on 5 day old rat duodenum: relaxant effects 
of ATP (O.lpM) (■ ) after precontraction with carbachol (O.lpM), and contractile effects on resting tissue 
of ATP (lOOpM) (□),2M eSA T P (lOOpM) (A), and of ATP (lOOpM) (□ )  following incubation with 
indomethacin (25pM) ( #  ). (c) Contractile effetcs of ATP (lOOpM) (■  ), AMPPCP (lOOpM) (#  ) and 
carbachol (3pM) (A ) on 5 day old rat bladder, and inhibitory effects o f adenosine (lOOpM) ( ^ )  on 
contraction induced by carbachol (3pM) (A ).
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Figure 12. Contractile effects of ATP and 2MeSATP on neonatal
rat duodenum
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Contractile effects of ATP (closed symbols) and 2MeSATP (open symbols) 
on 2 (■ ,□), 5 (e ,0 ), 10 (A, A) and 15 ($,% day old rat duodenum. Results 
are expressed as % contraction induced by carbachol (O.lpM). Each point 
is the mean of at least 5 determinations and the vertical bars show s.e.mean.
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Figure 13. Variations in potency of purines on rat duodenum with age
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Variations in potency of purines on rat duodenum with age. (a) contractile (□) and 
relaxant effects (■) of ATP. (b) contractile effects of 2MeS ATP (0 ) . (c) relaxant 
effects of AMPPCP (A), (d) relaxant effects of adenosine (e  ). Potency is 
expressed as pEC35 (negative logarithm of the concentration producing 35% of 
maximal response). Each point is the mean of at least 5 determinations and the 
vertical bars (shown when greater than symbol size) show s.e.mean.
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Figure 14. Contractile effects of ATP on neonatal rat duodenum 
and the effect of indomethacin on these responses
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Ontogeny of contractile responses to ATP (■) and arachidonic acid (#) in the rat 
duodenum in the absence (closed symbols) and presence (open symbols) of 
indomethacin (25pM). (a) 2 day old. (b) 5 day. (c) 10 day old. Each point is 
the mean of at least 5 determinations and the vertical bars (shown when greater 
than symbol size) show s.e.mean.
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F ig u re  15. The contractile effects o f 2M eSATP on neonatal rat 
duodenum
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Ontogeny of contractile effects of 2MeS ATP on rat duodenum in the absence 
(closed symbols) and presence (open symbols) of indomethacin (25pM). (a) 2 
day old. (b) 5 day old. (c) 10 day old. (d) 15 day old. Each point is the mean 
of at least 5 determinations and the vertici bars (shown when greater than symbol 
size) show s.e.mean.
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F ig u re  16. Representative traces o f responses to field stim ulation and to 
ATP in 5 day old rat duodenum in the absence and presence o f tetrodotoxin
( a )
( b )
FS
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ATP
0.2g
30s
ATP
0.2g
30s
Representative traces showing responses to field stimulation (70V, 15Hz, 1ms duration) 
and to ATP in (a) the absence and (b) the presence of tetrodotoxin (IpM).
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Figure 17. Effect of tetrodotoxin on contractile responses to ATP
on 5 day old rat duodenum
100-1
80-
60-
g
1 40-
2 0 -
10 1 0 01
ATP concentration pM
Contractile effects of ATP on 5 day old rat duodenum in the absence (closed 
symbols) and presence (open symbols) of tetrodotoxin (IpM). Results are 
expressed as % of carbachol (O.lpM) contraction. Each point is the mean of 
at least 5 determinations and the vertical bars show s.e.mean.
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3.1.4. Neonatal rat urinary bladder
ATP was always less potent than AMPPCP at contracting rat urinary bladder but the 
pattern of development for ATP and AMPPCP were very similar. At 2 days the 
potency of ATP and AMPPCP was similar to the adult, but between 5 and 15 days for 
ATP and 5 and 25 days for AMPPCP there was a marked increase in potency (table 8, 
figure 18).
Adenosine was more than 10 times as potent in inhibiting carbachol contractions 
between 2 and 25 days than it was in the adult (table 8, figure 19).
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Figure 18. Variation in potency of ATP and AMPPCP on rat urinary
bladder with age
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Variations with age in the potency of purines to contract rat urinary bladder, (a) 
ATP potency expressed as pEC15 (negative logarithm of the concentration 
producing 15% of maximal response), (b) AMPPCP potency expressed as pC35 
(negative logarithm of the concentration producing 35% of maximal response. 
Each point is the mean of at least 5 determinations and the vertical bars (shown 
when greater than symbol size) show s.e.mean.
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Figure 19, Variation in potency of adenosine on rat urinary bladder
with age
7 -
0 10 20 30 40 50 60
Age (days)
Variation in the potency of adenosine to inhibit rat urinary bladder with age. 
Potency is expressed as pEC35 (negative logarithm of the concentration 
producing 35% of maximal response). Each point is the mean of at least 5 
determinations and the vertical bars (shown when greater than symbol size) show 
s.e.mean.
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3.2. EFFECT OF 8-SPT ON RESPONSES TO PURINES ON RAT 
DUODENUM
ATP, adenosine, adenosine 5'-(a,p-methylene) triphosphonate (AMPCPP), AMPPCP 
and 2MeSATP all relaxed carbacholrcontracted rat duodenum. The order of potency 
of these purines was 2MeSATP > ATP > AMPCPP > AMPPCP = adenosine with 
EC50 values of 0.035pM, 1.9pM, 5.3pM, 37.8pM and 31.7pM respectively (figure 
20).
The responses to ATP, AMPCPP and 2MeSATP were not inhibited by lOOpM 8-p- 
(sulphophenyl)theophylline (8-SPT) (figure 21) whereas those to adenosine and 
AMPPCP were abolished by lOOpM 8-SPT (figure 22).
Low concentrations (l-5pM) of 8-SPT had no effect on responses to adenosine but 
lOpM, 20pM and 50pM 8-SPT shifted the concentration-response curves to the right 
with dose-ratios of 2.0,4.6 and 7.0 corresponding to calculated Kd values of lO.OpM,
5.6pM and 8.4pM respectively (figure 23).
Concentration-response curves for AMPPCP were shifted by low concentrations (2- 
5pM) of 8-SPT with lOpM 8-SPT almost completely abolishing responses to 
AMPPCP. 2pM 8-SPT gave a dose-ratio of 4.4 corresponding to a Kp value of
0.59pM (figure 24). A dose-ratio for 5pM 8-SPT was not calculated because in the 
presence of antagonist the concentration-response curve did not achieve 50% 
relaxation.
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Figure 20. Inhibitory effects of purines on rat duodenum
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Inhibitory effects of ATP (■ ), AMPCPP ( •  ), 2MeSATP (A ), adenosine (T ) and 
AMPPCP ( ^ )  on rat duodenum. Each point is the mean of at least 5 determinations 
and the vertical bars show s.e.mean.
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Figure 21. Effect of lOOpM 8-SPT on responses to ATP. AMPCPP
and 2MeSATP on rat duodenum
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Effects of purines on rat duodenum in the absence (closed symbols) or presence 
(open symbols) of 8-SPT. (a) ATP (m). (b) AMPCPP ( t) . (c) 2MeSATP (*). 
Each point is the mean of at least 5 dterminations and the vertical bars show s.e. 
mean.
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Figure 22. Effect of lOOpM 8-SPT on responses to adenosine and
AMPPCP on rat duodenum
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Effects of purines on rat duodenum in the absence (closed symbols) or presence 
(open symbols) of 8-SPT (lOOpM). (a) adenosine, (b) AMPPCP. Each point is 
the mean of at least 5 determinations and the vertical bars show s.e.mean.
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Figure 23. Effect of increasing concentrations of 8-SPT on relaxations
to adenosine in rat duodenum
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Effect of adenosine on rat duodenum in the absence (closed symbols) or presence 
(open symbols) of 8-SPT. (a) 5pM 8-SPT. (b) lOpM 8-SPT. (c) 20pM 8-SPT. 
(d) 50pM 8-SPT. Each point is the mean of at least 5 determinations and the 
vertical bars (shown when greater than symbol size) show s.e.mean.
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Figure 24. Effect of increasing concentrations of 8-SPT on relaxations
to AMPPCP in rat duodenum
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Effect of AMPPCP on rat duodenum in the absence (closed symbols) or presence 
(open symbols) of 8-SPT. (a) IpM 8-SPT. (b) 2pM 8-SPT. (c) 5pM 8-SPT. (d) 
lOpM 8-SPT. Each point is the mean of at least 5 determinations and the vertical 
bars show s.e.mean.
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33. EFFECT OF DPCPX ON RESPONSES TO PURINES
3.3.1. Rat duodenum
Adenosine, AMPPCP, N6-cyclopentyladenosine (CPA), 5'-N-ethylcarboxamido- 
adenosine (NECA) and 2-p-((carboxyethyl)phenethylamino)-5'-carboxamido- 
adenosine (CGS21680) all relaxed carbachol-contracted rat duodenum, the order of 
potency being NECA > CPA > AMPPCP = adenosine > CGS21680, the EC50 values 
of these compounds being 0.4pM, 0.7pM, ISpM, 28.5pM and 98.0pM respectively 
(figure 25).
1,3-dipropyl-8-cyclopentyl xanthine (DPCPX) (InM) had no significant effect on 
concentration-response curves to adenosine and NECA (figures 26a and b) but caused 
a parallel shift to the right of the concentration-response curves to AMPPCP and CPA 
giving dose-ratios of 6.7 and 5.7, corresponding to Kd values of O.lSnM and 0.2InM 
respectively (figures 26c and d).
At IpM DPCPX did cause shifts in the concentration-response curves to adenosine 
and NECA, giving dose-ratios of 6.3 and 6.7 corresponding to Kd values of 0.19pM
and O.lSpM respectively (figures 27a and b). At lOnM DPCPX caused a similar shift 
in the concentration-response curve to AMPPCP (figure 27c) however lOnM DPCPX 
produced an even greater shift and flattening of the concentration-response curve to 
CPA (figure 27d).
Dimethylphenylpiperazinium (DMPP) (O.l-lOOpM) caused relaxation of the rat 
duodenum, followed at high concentrations ty  contraction, and these effects were 
inhibited by lOpM hexaméthonium (figures 28a and b).. Hexaméthonium (lOpM) 
had no effect on contractions induced by carbachol, or on the concentration-response
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curves to AMPPCP or to CPA (figures 29a and b). AMPPCP and CPA both relaxed 
rat duodenum that had been precontracted with bethanechol (IpM) with CPA being 
more potent than AMPPCP with EC50 values of 0.26pM and 26.92pM respectively 
(figure 30).
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Figure 25. Effect of P ^-purinoceptor agonists on rat
duodenum
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Ï
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2 0 -
0.01 0.1 101 100
purine concentration pM
Inhibitory effects of adenosine (■), NECA (•), AMPPCP (A), 
CPA (4) and CGS21680 on rat duodenum. Each point is the 
mean of at least 7 determinations and the vertical bars show 
s.e.mean.
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Figure 26. Effect of InM DPCPX on responses to adenosine. NECA.
AMPPCP and CPA in rat duodenum
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Effects of purines on rat duodenum in the absence (closed symbols) or presence 
(open symbols) of InM DPCPX. (a) adenosine ± DPCPX. (b) NECA ± DPCPX. 
(c) AMPPCP ± DPCPX. (d) CPA ± DPCPX. Each point is the mean of at least 
7 determinations and the vertical bars show s.e.mean.
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Figure 27. Effect of IpM  DPCPX on responses to adenosine and
NECA and lOnM DPCPX on responses to AMPPCP and CPA in rat
duodenum
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Effects of purines on rat duodenum in the absence (closed symbols) or presence 
(open symbols) of DPCPX. (a) adenosine ± IpM DPCPX. (b) NECA ± IpM 
DPCPX. (c) AMPPCP ± lOnM DPCPX. (d) CPA ± lOnM DPCPX. Each point 
is the mean of at least 7 determinations and the vertical bars show s.e.mean.
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Figure 28. Representative traces of responses to DMPP in rat duodenum
in the absence and presence of hexaméthonium
( a )
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!
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30s
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Representative traces showing (a) Responses to IpM and lOOpM DMPP in the absence of 
hexaméthonium (lOpM). (b) Response to 100 pM DMPP in presence of hexaméthonium 
(lOpM).
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Figure 29. Effect of lOpM hexaméthonium on inhibitory responses to
AMPPCP and CPA in rat duodenum
(a) 100-1
80-
60-
40-
2 0 -
0.1 10 1001
AMPPCP concentration pM
(b)lOO-i
80-
60-
40-
10 1000.1 1
CPA concentration pM
Relaxation of the rat duodenum induced by purines in the absence (closed symbols) 
or presence (open symbols) of lOpM hexaméthonium, (a) AMPPCP ± hexa­
méthonium. (b) CPA ± hexaméthonium. Each point is the mean of at least 4 
determinations and the vertical bars show s.e.mean.
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F ig u re  30, Inhibitory responses induced by AM PPCP and CPA in rat 
duodenum precontracted with bethanechol
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Inhibitory effect of (a) AMPPCP and (b) CPA on rat duodenum precontracted 
with bethanechol (IpM). Each point is the mean of at least 4 determinations 
and the vertical bars show s.e.mean.
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3.3.2. Rat urinary bladder
Adenosine and NECA each inhibited contractions of the rat bladder induced by 
carbachol (3pM), and the order of potency was NECA »  adenosine with EC50
values of 1.6pM and 92pM respectively. CPA and CGS21680 also weakly inhibited 
carbachol-induced contractions but EC50 values could not be obtained due to their
low potency (figure 31).
DPCPX (IpM) shifted to the right the concentration-response curves to NECA and 
adenosine, giving dose-ratios of 5.7 and 6.3 corresponding to Kd values of 0.21pM
and 0.19pM respectively (figure 32). The concentration-response curve to adenosine 
was also flattened by DPCPX (IpM).
ATP and AMPPCP each contracted rat urinary bladder and these contractions were 
not enhanced, but slightly inhibited, by DPCPX (IpM) (figure 33). Vehicle alone 
had no significant effect on the concentration-response curve to ATP and only a slight 
enhancement of the concentration-response curve to AMPPCP was observed (figure 
34).
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Figure 31. Effect of P ^-purinoceptor agonists on rat urinary
bladder
80-,
60-
2 0 -
100
purine concentration pM
Inhibitory effects of adenosine (■), NECA (#), CPA (^) and 
CGS21680 (▼) on carbachol (3pM) contractions of rat urinary 
bladder. Each point is the mean of at least 4 determinations 
and the vertical bars show s.e.mean.
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Figure 32. Effect of IpM  DPCPX on responses to adenosine and
NECA in rat urinary bladder
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Inhibitory effects of purines on rat urinaiy bladder in the absence (closed symbols) 
or presence (open symbols) of IpM DPCPX. (a) adenosine ± DPCPX. (b) NECA 
± DPCPX. Inhibitory effects expressed as % inhibition of contraction induced by 
carbachol (3pM). Each point is the mean of at least 4 determinations and the 
vertical bars show s.e.mean.
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Figure 33. Effect of IpM  DPCPX on responses to ATP and AMPPCP
in rat urinary bladder
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Contractile effects of purines on rat urinary bladder in the absence (closed symbols) 
or presence (open symbols) of IpM DPCPX. (a) ATP ± DPCPX. (b) AMPPCP ± 
DPCPX. Contractions expressed as % maximal contraction induced by KCl (120- 
180mM). Each point is the mean of at least 5 determinations and the vertical bars 
(shown when greater than symbol size) show s.e.mean.
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Figure 34. Effect of vehicle alone on responses to
ATP and AMPPCP in rat urinary bladder
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«  2 0 -
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0.1 1 10 100
purine concentration pM
Contractile actions of ATP (■ ) and AMPPCP (• )  on rat urinary 
bladder in the absence (closed symbols) or presence (open symbols) 
of DMSO + 6mM NaOH solution (2:98). Each point is the mean of 
at least 6 determinations and the vertical bars show s.e.mean.
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3.4. ONTOGENY OF THE EFFECTS OF PURINES ON RAT VASA 
DEFERENTIA
3.4.1. Adult rat vasa deferentia
3.4.1.1. Effect o f  purines on fie ld  stimulated responses
Field stimulation of the adult rat vas deferens induced contractions which were 
abolished by tetrodotoxin (IpM) and adenosine, NECA and CPA each inhibited these 
nerve-mediated contractions with an order of potency of NECA = CPA > adenosine 
and EC50 values of O.OTpM, O.OSpM, and 16.98pM respectively (figures 35 and 36).
InM DPCPX had no effect on the responses to NECA and adenosine but IpM 
DPCPX shifted the concentration-response curves to the right giving dose-ratios of 
3.7 and 3.8 respectively corresponding to a Kp value of 0.37pM for both agonists
(figures 37 and 38). InM DPCPX gave a small shift of the concentration-response 
curve to CPA whereas 3nM DPCPX shifted the concentration-reponse curve to the 
right resulting in dose-ratios of 2.1 corresponding to Kd value of 2.7nM. IpM
DPCPX resulted in a dose-ratio of 84 although maximal responses to CPA could not 
be achieved due to its limited solubility (figure 39).
3.4.1.2. Effect o f  purines on responses to exogenous A TP  and noradrenaline
ATP and noradrenaline (lOpM) both contracted adult rat vasa deferentia. Adenosine 
dose-dependently inhibited the responses to ATP and noradrenaline with EC50 values
of 4.31pM and 13.56pM respectively (figure 40). NECA also dose-dependently 
inhibited responses to ATP and noradrenaline with EC50 values of 0.32pM and
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0.43pM respectively (figure 41). CPA did not inhibit contractions to ATP or 
noradrenaline (figure 40).
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Figure 35. Representative traces showing the inhibitory effects of 
adenosine, NECA and CPA on nerve-mediated responses in rat vasa 
deferentia
100pM ADO 
1
0.5g
60s
0 3 pM NECA 0-3 pM CPA
60s
Representative traces showing the inhibitory effects of adenosine (ADO) (100|xM), NECA 
(0.3pM) and CPA (0.3pM) on nerve-mediated responses in rat vasa deferentia.
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Figure 36. Inhibitory effects of purines on field stimulated rat vas 
deferens
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Inhibitory effects of adenosine (■ ), NECA ( •  ) and CPA (A ) on field stimulated 
rat vas deferens. Each point is the mean of at least 4 determinations and the vertical 
bars (shown when greater than symbol size) show s.e.mean.
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Figure 37. Effect of InM and IpM  DPCPX on responses to adenosine
on field stimulated rat vas deferens
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Inhibition of field stimulated responses on rat vas deferens by adenosine in the 
absence (closed symbols) or presence (open symbols) of DPCPX. (a) adenosine ± 
InM DPCPX. (b) adenosine ± IpM DPCPX. Each point is the mean of at least 4 
determinations and the vertical bars show s.e.mean.
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Figure 38. Effect of InM and IpM  DPCPX on responses to NECA on
field stimulated rat vas deferens
(a)120
100
0.01 0.1 101
NECA concentration pM
(b)lOO
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Inhibition of field stimulated responses on rat vas deferens by NECA in the absence 
(closed symbols) or presence (open symbols) of DPCPX. NECA ± InM DPCPX. 
(b) NECA ± IpM DPCPX. Each point is the mean of at least 4 determinations and 
the vertical bars (shown when greater than symbol size) show s.e.mean.
131
Figure 39. Effect of InM. 3nM and IpM  DPCPX on responses to CPA
on field stimulated rat vas deferens
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Inhibition of field stimulated responses on rat vas deferens by CPA in the absence 
(closed symbols) or presence (open symbols) of DPCPX. (a) CPA ± InM DPCPX.
(b) CPA ± 3nM DPCPX. (c) CPA ± IpM DPCPX. Each point is the mean of at 
least 4 determinations and the vertical bars show s.e.mean.
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Figure 40. Inhibitory effect of adenosine and CPA on contractions to 
exogenous ATP and NA on rat vas deferens
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Inhibitory effect of adenosine (■) and CPA (A) on contractions to 
(a) exogenous ATP and (b) exogenous NA on rat vas deferens. 
Each point is the mean of at least 4 determinations and the vertical 
bars show s.e.mean.
133
Figure 41. Inhibitory effect of NECA on contractions to exogenous
ATP and NA on rat vas deferens
(a)lOO
0.10.01 1 10
NECA concentration pM
0.01 0.1 1 10
NECA concentration pM
Inhibitory effect of NECA on contractions to (a) exogenous ATP and (b) exogenous 
NA. Each point is the mean of at least 4 determinations and the vertical bars show 
s.e.mean.
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3.4.2. Neonatal rat vasa deferentia
Contractions to ATP were first observed in 15 day old rat vas deferens after which the 
maximum lespone achieved by ATP increased up to day 25 when it was then more 
potent than in the adult (figure 42a). Noradrenaline contracted rat vas deferens as 
early as early as day 10 (the earliest day tested) after which the maximum response 
produced decreased with age (figure 42b). Nerve-stimulated responses showed a 
similar ontogenetic pattern to ATP as there was no response to nerve stimulation until 
day 15 after which the maximum response increased up to day 25 when it was 
equipotent with the adult (figure 42c).
The inhibitory effect of adenosine on nerve-mediated contractions was greatest at day 
15, the earliest day at which field stimulated responses were detected, and the potency 
of adenosine (expressed as the pECso) decreased with age until day 35 when it was 
equipotent with the adult (figure 43).
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Figure 42. Ontogeny of contractile responses to exogenous ATP and 
NA and of field stimulated responses on rat vas deferens
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Ontogeny of responses to (a) exogenous ATP, (b) exogenous NA and (c) nerve 
stimulated responses on rat vas deferens. Contractile responses expressed as % 
of maximum contraction by KCl (120 - 180 mM). Each point is the mean of at 
least 4 determinations and the vertical bars (shown when greater than symbol 
size) show s.e.mean.
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Figure 43. Ontogeny of inhibitory effect of adenosine on nerve- 
mediated responses on rat vas deferens
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Variation in potency of the inhibitory effect of adenosine on field stimulated 
responses in rat vas deferens with age. Potency expressed as pEC50 (negative 
logarithm of the concentration producing 50% of maximal response). Each 
point is the mean of at least 4 determinations and the vertical bars (shown when 
greater than symbol size) show s.e.mean..
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3.5. ONTOGENY OF THE METABOLISM OF PURINES
3.5.1. Rat duodenum: degradation of ATP
ATP was rapidly degraded by adult rat duodenum, with only 9.5% remaining after 20 
minutes. In adult rat duodenum the main products of ATP degradation were ADP, 
AMP and inosine. The concentration of ADP peaked within 5 minutes and then 
gradually decreased, whereas AMP concentration rose during the first 10 minutes 
after which it remained fairly constant. The concentration of inosine produced 
gradually increased with time with 45% of the ATP being converted to inosine within 
20 minutes (figure 44c).
The pattern of dephosphorylation of ATP varied only slightly with age, and 2 day old 
rat duodenum rapidly degraded ATP with only 9.7% of die ATP remaining after 20 
minutes. Again the concentration of ADP peaked within the first 5 minutes, the 
concentration of AMP remained fairly constant between 5 and 20 minutes and the 
amount of inosine produced gradually increased with time. However the amount of 
AMP detected at any given time was lower with 2 day old rat duodenum compared to 
the adult and adenosine was also detected with 2 day old rat duodenum whereas none 
was detected in the adult samples (figure 44a).
The ability of 15 day old rat duodenum to degrade ATP was lower than either 2 day 
old or adult rat duodenum and 25.8% of the ATP remained after 20 minutes. The 
concentration of ADP produced again peaked within 5 minutes after which it 
remained fairly constant rather than decreasing with time. The pattern of AMP, 
adenosine and inosine production was the same as for the 2  day old rat duodenum 
however the concentration of adenosine and inosine produced was much lower than at 
2 days old (figure 44b).
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The control studies where ATP was incubated with Krebs buffer for 20 minutes 
showed that no degradation of ATP occurred during this'time, however where ATP 
was incubated with Krebs that had previously contained duodenum the ATP was 
rapidly degraded within 20 minutes at all ages. For 15 day old and adult rat 
duodenum however virtually no adenosine nor inosine were detected and the 
concentration of ADP was still high after 20 minutes with 44.0% and 31.5% being 
detected for 15 day old and Mult rat duodenum respectively (figure 45b and c). For 
2 day old rat duodenum the loss of ATP was greater during the incubation time and
I
both adenosine and inosine were formed with 36% of the ATP being converted to 
inosine (figure 45a).
3.5.2. RAT DUODENUM: DEGRADATION OF AMPPCP
AMPPCP (lOOpM) was relatively resistant to degradation by adult rat duodenum 
with 86.5% remaining after a 20 minute incubation period. The main degradation 
products being AMP (5%) and inosine (9%) (figure 46a). Control studies showed 
that AMPPCP was completely stable in normal Krebs buffer and that only 3% was 
lost when incubated in buffer that had previously contained the tissue (figure 46b).
3.5.3. RAT DUODENUM: DEGRADATION OF ADENOSINE
I
Adenosine (l(X)pM) was rapidly degraded to inosine by 2 day old and adult rat 
duodenum with all of the adenosine being converted to inosine within 5 minutes and 
in both 2 day old and adult rat duodenum around 20% of the inosine produced was
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metabolized further during the 20 minute incubation period (figure 47). Control 
studies showed that no degradation of adenosine occurred during a 20 minute 
incubation in normal Krebs buffer but that adenosine (lOOpM) was completely 
degraded to inosine by Krebs that had previously contained the tissue (figure 48).
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Figure 44. Ontogeny of the metabolism of ATP by ra t duodenum
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Ontogeny of the degradation of ATP (lOOpM) (■) to ADP (•), AMP (A), adenosine 
( f  ) and inosine (T)by rat duodenum, (a) 2 day old rat duodenum, (b) 15 day old rat 
diiodenum. (c) adult rat duodenum. Each point is the mean of at least 4 determin­
ations and the vertical bars (shown when greater than symbol size) show s.e.mean.
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Figure 45. Ontogeny of the metabolism of ATP by enzymes
released into buffer from ra t duodenum
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Ontogeny of the denudation of ATP (lOOpM) (■) to ADP (•), AMP (A), 
adenosine (4 ) and inosine (▼ ) by enzymes released into buffer from rat 
duodenum, (a) 2 day old rat duodenum, (b) 15 day old rat duodenum, (c) adult rat 
duodenum. Each point is the mean of at least 4 determinations and the vertical bars 
(shown when greater than symbol size) show s.e.mean
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Figure 46. Metabolism of AMPPCP by adult ra t
duodenum
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Metabolism of AMPPCP (■) to AMP (A) and inosine (▼), by: (a) adult rat 
duodenum, n=3 (s.e. not greater than symbol size) and (b) enzymes 
released into buffer, n=l.
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Figure 47. Ontogeny of the metabolism of adenosine by ra t
duodenum
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Ontogeny of the degradation of adenosine (lOOpM) (■) to inosine ( • )  by rat 
duodenum, (a) 2 day old rat duodenum, (b) adult rat duodenum. Each point 
is the mean of at least 4 determinations and the vertical bars (shown when greater 
than symbol size) show s.e.mean.
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Figure 48, Ontogeny of the metabolism of adenosine by enzymes
released into buffer from the ra t duodenum
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Ontogeny of the degradation of adenosine (lOOpM) (■)to inosine (#) by enzymes 
released into buffer from rat duodenum, (a) 2 day old rat duodenum, (b) adult rat 
duodenum. Each point is the mean of at least 4 determinations and the vertical bars 
(shown when greater than symbol size) show s.e.mean
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3.5.4. RAT URINARY BLADDER: DEGRADATION OF ATP AND 
ADENOSINE
ATP was slowly degraded to ADP, AMP and adenosine by 2 day old, 10 day old and 
adult rat urinary bladder. At 10 days the concentration of ADP and AMP produced at 
any time was greater than that for 2 day old or adult urinary bladder. At no age was 
adenosine deaminated to inosine (figure 49). Control studies showed that ATP was 
also degraded by Krebs buffer that had previously contained tissue but that little or no 
adenosine was produced and that at 2 and 10 days the loss of ATP was less than when 
the tissue was present (figures 50). •
No loss of adenosine occurred during the 20 minute incubation period with either 2 
day old or adult rat urinary bladder (figure 51).
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Figure 49. Ontogeny of the metabolism of ATP by ra t urinary
bladder
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Ontogeny of the degradation of ATP (lOOjiM) (■) to ADP (•) , AMP (A), 
adenosine (4  ) and inosine (T ) by rat urinary bladder, (a) 2day old rat bladder, (b) 
10 day old rat bladder, (c) adult rat bladder. Each point is the mean of at least 4 
determinations and the vertical bars (shown when greater than symbol size) show 
s.e.mean.
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Figure 50. Ontogeny of the metabolism of ATP by enzymes
released into buffer from the ra t urinary bladder
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Ontogeny of the degradation of ATP (lOOpM) (■ ) to ADP ( •  ), AMP (A), 
adenosine (^) and inosine (▼) by enzymes released into buffer from rat urinary 
bladder, (a) 2 day old rat bladder, (b) 10 day old rat bladder, (c) adult rat bladder. 
Each point is the mean of at least 4 determinations and the vertical bars (shown 
when greater than symbol size) show s.e.mean.
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F igure 51. Ontogeny o f the m etabolism o f adenosine hv rat urinary
bladder
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Ontogeny of the degradation of adenosine (lOOpM) (■) to inosine ( • )  by rat 
urinary bladder, (a) 2 day old rat bladder, (b) adult rat bladder. Each point is the 
mean of at least 4 determinations and the vertical bars (shown when greater than 
symbol size) show s.e.mean.
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CHAPTER 4. DISCUSSION.
ISO
4.1. EFFECTS OF PURINES ON RAT DUODENUM AND URINARY 
BLADDER
The ontogeny of responses to purines in two tissues: the rat duodenum and urinary 
bladder was studied. These tissues were chosen because ATP has been shown to 
relax rat duodenum (Manzini et al., 1985) and might therefore be expected to possess 
P2Y“purinoceptors, whereas it contracts the urinary bladder via P2x-purinoceptors 
(Brown et al., 1979) and hence the development of both subclasses of ? 2- 
purinoceptor could be studied. In both these tissues adenosine has been shown to be 
inhibitory (Gaion et al., 1988; Dahlén & Hedqvist, 1980) and so the development of 
Pi-purinoceptors could be followed in each.
4.1.1. Adult rat duodenum
ATP, 2-Methylthioadenosine 5'-triphosphate (2MeSATP) and adenosine 5'-(P,y- 
methylene) triphosphonate (AMPPCP) were inhibitory on rat duodenum and one 
would expect that their actions were mediated via P2-purinoceptors (Bumstock & 
Kennedy, 1985). Adenosine was also inhibitory on rat duodenum its actions expected 
to be via Pi-purinoceptors (Bumstock, 1978). The rat duodenum was initially set up
by threading cotton through the duodenum so that the lumen remained open allowing 
free access of drug to both the internal and external muscle surfaces. This set up 
however was impractical for neonatal tissue due to the fragility of neonatal smooth 
muscle and so the methodology was altered and cotton tied around each end thereby 
closing the lumen. When the lumen was open ATP was almost equipotent with 
adenosine whereas when the lumen was closed the potency of ATP was increased 10- 
fold making it much more potent than adenosine (figure 9). It is known that ATP can 
be dephosphorylated to adenosine by ectonucleotidases present on smooth muscle
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cells (Welford et al., 1986; 1987) and the results obtained would suggest that ATP is 
relatively unstable in rat duodenum and that when the surface area of duodenum 
available to ATP is increased the ATP was degraded to adenosine. The degradation 
of ATP to adenosine may be pharmacologically significant as it has been 
demonstrated in other smooth muscle preparations, including guinea-pig ileum and rat 
duodenum, that ATP, in addition to its direct P2-puiinoceptor activity, can have an 
indirect action via Pi-puiinoceptors following the ectoenzymatic breakdown of ATP 
(Moody et al., 1984; Seiio et al., 1989).
AMPPCP has been shown to be resistant to degradation in smooth muscle 
preparations such as guinea-pig taenia coli and urinary bladder (Welford et al., 1986; 
1987) and indeed in the rat duodenum the potency of AMPPCP was only slightly 
increased when the lumen was closed suggesting that in this tissue only a small 
proportion of AMPPCP was degraded.
When the lumen of the duodenum was closed the potency of ATP and its analogues 
was 2MeSATP »  ATP > AMPPCP. This order of potency is similar to that seen in 
guinea-pig taenia coli and rabbit portal vein where it has been proposed that the 
effects of purines are mediated by P2Y-purmoceptors (Bumstock & Kennedy, 1985).
Therefore from the potency order of purines in the rat duodenum it appears that ATP 
and its analogues are acting via P2Y-purinoceptors to induce relaxation.
It has been proposed that ATP is the non-adrenergic, non-cholinergic 
neurotransmitter in the rat duodenum. For example, AT^ has been shown to mimic 
the response to non-adrenergic, non-cholinergic nerve stimulation, responses to both 
ATP and nerve stimulation are reduced by nucleotide pyrophosphatase, an enzyme 
which hydrolyzes ATP to AMP, and both responses are inhibited by reactive blue 2 
(l(X)pM), a putative P2-purinoceptor antagonist (Manzini et al., 1985). Other
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workers (Postorino et al., 1990; Serio et al., 1990) have disputed the proposal that 
ATP is the non-adrenergic, non-cholinergic transmitter in the duodenum as P2- 
purinoceptor desensitization by adenosine 5'-(a,p-methylene) triphosphonate 
(AMPCPP) has been shown to inhibit responses to ATP but not field stimulated 
responses. Also studies by Serio and colleagues (1990) challenged the antagonistic 
activity of reactive blue 2, as they found that whilst reactive blue 2 (10-l(X)pM) 
antagonized responses to ATP it had no effect on inhibitory responses to field 
stimulation. The conflicting results obtained with reactive blue 2 have been 
suggested to arise from the non-specific inhibitory actions of this drug when used in 
high concentrations.
Adenosine was inhibitory on the rat duodenum (section 3.1.3.) confirming the work 
of others on this tissue. In their studies it appeared that adenosine was acting via Pi- 
purinoceptors as its actions were antagonized by the Pi-puiinoceptor antagonists 
theophylline and 8-phenyltheophylline (8-PT) (Gaion et al., 1988; Mulé et al., 1989; 
Serio et al., 1989). Interestingly the potency of adenosine was not significantly 
altered when the lumen of the duodenum was closed. It has been reported that in rat 
duodenum adenosine is degraded by adenosine deamipase to inosine, which is 
pharmacologically inactive, at a relatively high rate (Franco et al., 1988). This might 
be expected to influence its pharmacological activity and indeed it was shown that the 
potency of adenosine was increased in the presence of the adenosine deaminase 
inhibitors erythro-9-(2-hydroxy-3-nonyl)adenine (EHNA) and deoxycoformycin and 
by an adenosine transport inhibitor, dilazep (Franco et al., 1988). The fact that 
sealing the lumen had no effect on the potency of adenosine, whereas it markedly 
increased the potency of ATP, would suggest that the luminal surface is not important 
in the degradation of adenosine.
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4.1.2. Adult urinary bladder
ATP and AMPPCP contracted rat urinary bladder with AMPPCP being much more 
potent than ATP (figure 10a). The contractile activity "of ATP and the increased 
potency of AMPPCP, relative to ATP, on rat bladder has previously been 
demonstrated (Bumstock et al., 1972a; Brown et al., 1979) and this order of potency 
would suggest that they are acting via Pix-puiinoceptors (Bumstock & Kennedy, 
1985). In the present study adenosine was found to be inhibitory on rat bladder and 
inhibited contractions to carbachol (figure 10b). The inhibitory effect of adenosine 
on rat urinary bladder has previously been reported when it was found that adenosine 
relaxed the smooth muscle and dose-dependently inhibited field stimulated 
contractions (Dahlén & Hedqvist, 1980).
There is considerable evidence that whilst the bladder of rat and guinea-pig receive a 
dense cholinergic iimervation field stimulated contractions of rat and guinea-pig 
urinary bladder are largely resistant to atropine (Brown et al., 1979; Dahlén & 
Hedqvist, 1980). It is now widely accepted that in smaller mammals there is a non- 
cholinergic excitatory component for which ATP has been proposed as the 
neurotransmitter (Bumstock et al., 1972a). The proposal that ATP is the non- 
cholinergic neurotransmitter has arisen from a number of observations. ATP has 
been shown to mimic responses to non-adrenergic, non-cholinergic nerve stimulation, 
although high concentrations (l(X)jiM) were required to produce this effect 
(Bumstock et al., 1972a). The work described in this thesis has also shown that ATP 
is not a potent agonist in the.rat urinary bladder, however the lack of potency of ATP 
could be due to the fact that it is readily degraded in this tissue (section 3.5.4.). The 
observation that AMPPCP, an ATP analogue resistant to degradation by 
ectonucleotidases (Welford et al., 1987) is much more potent than ATP at contracting 
the bladder would support this proposal and it has been shown by other workers that
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AMPPCP can mimic non-adrenergic, non-cholinergic nerve-mediated responses at 
much lower concentrations (Brown et al., 1979). Desensitization of P2-purinoceptors
by AMPCPP inhibits nerve-stimulated responses in rat and guinea-pig bladder which 
supports the hypothesis that ATP is the neurotransmitter (Kasakov & Bumstock, 
1983; Brading & Williams, 1990). Other workers, however, have observed that 
AMPCPP desensitization does not completely block nerve-mediated responses in rat 
urinary bladder, even at low frequency stimulation and have therefore proposed that a 
third component exists that is non-cholinergic and non-purinergic in nature (Luheshi 
&Zar, 1990).
Whilst there is now considerable evidence for ATP being the non-cholinergic 
neurotransmitter in smaller mammals, in human urinary bladder it appears that there 
is little or no non-cholinergic, putatively purinergic, component (Sibley, 1984). The 
lack of purinergic innervation in human urinary bladder is interesting since it has 
been shown that a high density of ATP receptors are present (Inoue & Brading, 
1991). There is however evidence for non-cholinergic nerve-mediated responses in 
human bladder from studies on diseased tissue, which could imply that the purinergic 
component is important in the pathogenesis of urinary tract disease (Hindmarsh et al., 
1977; Ruggieri et al., 1990). In this respect, studies on rat urinary bladder would 
have important implications clinically, as the main innervation is non-cholinergic the 
rat bladder could therefore be used as a screen for dmgs with potential application in 
various disease states.
4,13, Neonatal rat duodenum
Low concentrations (0.1-ljiM) of ATP relaxed 2 to 15 day old duodenum but higher 
concentrations (3pM and above) contracted the tissue even when the tone was raised
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with carbachol. 2MeSATP also contracted 2 to 15 day old rat duodenum and was 
much more potent than ATP however AMPPCP did not contract the tissue at any age 
tested thus suggesting that the contractile effect, like the inhibitory effect of purines, 
is mediated via P2Y-punnoceptors. The contractile actions of ATP and 2MeSATP
showed similar developmental profiles with both agonists being much more potent at 
2 days after which the potency decreased until after day 15 when no contractions 
were observed. In other regions of the gastrointestinal tract, such as guinea-pig taenia 
coli, "rebound" contractions have been observed following relaxations to purines and 
these contractions can be blocked by indomethacin suggesting that they are diie to 
prostaglandin synthesis (Bumstock et al., 1975). A recent ontogenetic study of purine 
action in rat duodenum also demonstrated contractions induced by ATP and ADP in 
neonatal tissue and showed that they could be inhibited by indomethacin (Furukawa 
& Nomoto, 1989). The results described in this thesis, demonstrating the lack of 
contractile effect of AMPPCP, would be consistent with the proposal that ATP can 
induce prostaglandin synthesis to cause contraction since it is known that that where a 
methylene group has been substituted on the polyphosphonate chain the ability of the 
agonist to induce prostaglandin synthesis is lost (Brown & Bumstock, 1981b). 
However the studies with ATP and 2MeSATP (section 3.1.3.) showed that 
contractions were not "rebound" contractions as they were not preceeded by a 
relaxant response (figure 11) and the contractile responses were not abolished by 
indomethacin (figures 14 and 15) implying that they are not due to prostaglandin 
synthesis. Also, in the rat duodenum it appears that AMPPCP acts via Pi- and not 
P2-purinoceptors, as responses to AMPPCP are antagonized by the Pi-puiinoceptor 
antagonist 8-/?-(sulphophenyl)theophylline (section 3.2.). No relaxations to ATP 
were observed in the study by Furukawa & Nomoto (1989) before day 15 however 
this was probably due to the fact that only high concentrations of ATP (10-l(X)pM) 
were used. Also they showed that the potency of ATP at contracting neonatal rat 
duodenum increased up to day 7 and then gradually decreased, which is in contrast to
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the results presented here which show a steady loss in potency from the day after 
birth. The reason for this discrepancy is unclear but may be due to anomalies in the 
methodology as the strain of rats, buffer solution and tension applied to the tissues 
were different.
P2Y-puiinoceptors are generally thought to mediate relaxation, although ATP has 
been reported to contract rat colon muscularis mucosae via P2Y-purmoceptors (Bailey 
& Hourani, 1990). It is unusual, however, that the type of response mediated by P2Y- 
purinoceptors in the rat duodenum should change from contractile to relaxant with 
age and that the P2Y-purinoceptor is able to mediate relaxation or contraction 
depending on the concentration of agonist. The possibility that ATP might be acting 
presynaptically to induce the release of a contractile neurotransmitter was 
investigated, however tetrodotoxin had no significant effect on contractions to ATP in 
neonatal rat duodenum thus confirming that the ATP-induced contraction of neonatal 
duodenum, like the relaxation seen in adult duodenum (Manzini et al., 1985), is a 
direct effect on smooth muscle.
It is known that the duodenum comprises of two distinct muscle layers: circular and 
longitudinal muscle. The circular muscle is thought to receive a non-adrenergic, non- 
cholinergic inhibitory innervation, stimulation of which results in relaxation of the 
tissue, whereas the longitudinal muscle receives an excitatory, cholinergic iimervation 
(Anuras et al., 1977; Cheung & Daniel, 1980). The lack of inhibitory effect of ATP 
cannot be due to the lack of development of the circular muscle since histological 
studies confirmed the presence of the circular muscle layer in 5 day old rat duodenum 
(section 3.1.3.). Also low concentrations of ATP and 2MeSATP did relax 2 to 15 day 
old rat duodenum suggesting that the circular muscle was functional at birth.
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The reason for inhibitory responses to low concentrations of ATP but excitatory 
responses to higher concentrations is not fully clear. It may be that the threshold 
concentration for ATP required to elicit contractions in 2 to 15 day old duodenum is 
higher than for the relaxant responses seen after day 15 and that ATP IpM and below 
during posmatal days 2 to 15 has no direct effect on P2-purinoceptors but instead is 
dephosphorylated to adenosine where it then acts indirectly via Pi-purinoceptors. 
This is supported by the observation that the inhibitory response to low 
concentrations of ATP on 5 day old rat duodenum is similar in onset and duration to 
that of adenosine, being much slower and more sustained than relaxations to ATP in 
adult rat duodenum (figure 11).
I
After day 15, ATP did not contract the duodenum and instead only relaxations were 
seen. The potency of ATP at relaxing rat duodenum increased up to day 25 when it 
was then equipotent with the adult. There is evidence that there is a high degree of 
co-ordination between gastrointestinal function in rats and major developmental 
changes that occur during the third week following birth (Henning, 1981). The 
establishment of the adult response of relaxation without contraction by day 20  and 
the potency of ATP being the same as in the adult by day 25 correlates with the 
suggestion that developmental changes occur during the third posmatal week. This 
time is a typical point of weaning and animals in this study were weaned between day 
20 and day 25 which suggests that weaning may act to modulate the responsiveness of 
the gastrointestinal tract.
The ontogenetic change in response to ATP at around day 15, from being contractile 
to relaxant, shows some parallels with the phylogenetic change observed in responses 
to ATP and to pon-adrenergic, non-cholinergic nerve stimulation seen from the smdy 
of a number of vertebrate species. Gastrointestinal preparations from lower 
vertebrates such as toad duodenum and ileum, lizard ileum and goldfish intestine have
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been shown to contract to both non-adrenergic, non-cholinergic nerve stimulation and 
to ATP whereas preparations from higher vertebrates such as guinea-pig stomach and 
taenia coli, human and guinea-pig colon, rat and mouse duodenum and ileum relax to 
both non-adrenergic, non-cholinergic nerve stimulation and to ATP (Bumstock et al., 
1972b; Sneddop et al., 1973). Indeed there is also an early postnatal change in the 
response to sympathetic nerve stimulation in the gastrointestinal tract of rabbits being 
cholinergic excitatory in the newborn rabbit changing to adrenergic, inhibitory with 
age (Day & Rand, 1961; Bum, 1968). This ontogenetic change in innervation 
parallels the evolution of the sympathetic nervous supply to the gut which develops 
from predominantly cholinergic, excitatory in fish, both cholinergic and adrenergic in 
amphibia and reptiles, to almost exclusively adrenergic in mammals, thus supporting 
the concept that ontogeny recapitulates phylogèny (Bumstock^ 1969).
AMPPCP at no age induced contraction of rat duodenum even at concentrations of 
lOOpM, instead relaxations to AMPPCP were observed at the earliest day tested, the 
day after birth. The potency of AMPPCP at relaxing rat duodenum varied with age 
with it being least potent at day 10 and most potent at day 25. The variation in 
potency of AMPPCP is unlikely to be due to changes in ectonucleotidase activity 
since it is resistant to degradation in other gastrointestinal preparations such as 
guinea-pig taenia coli (Welford et al., 1986) and has been shown to be stable in rat 
duodenum (figure 46). Adenosine also relaxed rat duodenum at every age tested and 
its potency at inducing relaxation was least at day 10 and highest at day 25. The 
changes in potency seen with adenosine were also not due to developmental changes 
in the metabolism or uptake of adenosine as although adenosine is rapidly 
metabolized by this tissue there was no significant difference in the degradation of 
adenosine in 2 day old and adult rat duodenum (section 3.5.3.). It is interesting to 
note that the ontogenetic profile for AMPPCP is different to that of ATP whereas it 
shows similarities with the development of the response to adenosine as both
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AMPPCP and adenosine were least potent at day 10 and most potent at day 25. This 
can be explained by the finding that AMPPCP acts via Pi- and not P2-purinoceptors 
in this tissue (section 3.2.).
The work presented here has clearly shown that purinergic responses via Pi- and P2Y- 
purinoceptors are present in the rat duodenum fi*om the day after birth and would 
suggest that purinergic responses are functionally important in both the adult and 
neonatal rat small intestine. The fact that functional purinoceptors are present at 
posmatal day 2 would support the proposal that a purinergic iimervation is present at 
birth in many species, as it correlates with the findings that in the rat stomach non- 
adrenergic, non-cholinergic nerve-mediated effects are observed before birth (Ito et 
al., 1988) and in the mouse and rabbit small intestine a non-adrenergic inhibitory 
response is present before birth (Gershon & Thompson, 1973). (Juinacrine 
fluorescence indicating the presence of purinergic nerves has also been observed 
before birth in the rabbit ileum and stomach (Crowe & Bumstock, 1981). The fact 
that Pi-purinoceptor inhibitory responses are present at birth may be physiologically
important as it has been reported that in the rat small intestine inhibitory adrenergic 
responses are not obvious until posmatal day 12 (Miyazaki et al., 1982).
4.1.4. Neonatal rat urinary bladder
ATP and AMPPCP both contracted 2 day old rat urinary bladder suggesting that 
functional P2x-pminoceptors are present from birth. The potency of ATP on P2x- 
purinoceptors in the neonatal bladder was greatest between 5 and 25 days and 
decreased thereafter. The loss in potency after day 25 could be due to a number of 
factors such as a reduction in receptor density in adult rat urinary bladder, a decreased
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sensitivity of the second messenger system involved, or the development of more 
active ectonucleotidases which would enhance the degradation of ATP and in turn 
reduce the concentration of ATP available at the receptor site. The changes in 
potency however are not due to developmental changes in ectonucleotidase activity as 
the potency of the slowly degradable ATP analogue, AMPPCP, followed the same 
developmental pattern as ATP, being much more potent in the neonate than in the 
adult and studies on the degradation of ATP demonstrated that there was no 
significant change in the metabolism of ATP by neonatal or adult urinary bladder 
(section 3.5.4.). Adenosine inhibited carbachol contractions on neonatal rat bladder 
and was always much more potent in the neonate than in the adult
The increased responsiveness to ATP in neonatal rat urinary bladder is analogous to 
rabbit urinary bladder where it has been demonstrated that the maximum response to 
ATP is greatest in 1 day old rabbit bladder, less in 1 week old bladder and least in 
adult rabbit urinary bladder (Zderic et al., 1990; Keating et al., 1990). The urinary 
bladder is thought to receive a cholinergic and non-cholinergic excitatory innervation 
and ATP has bçen proposed as the non-cholinergic neurotransmitter (Bumstock et al., 
1972a). The observation that ATP is more potent in the neonate would suggest that 
purinergic innervation is functionally more important in the neonate than in the adult, 
and indeed some studies have shown that field stimulated contractions of neonatal 
rabbit urinary bladder are more sensitive to desensitization by ATP than adult bladder 
(Keating et al., 1990). Care should be taken however when using ATP to desensitize 
P2-puiinoceptors, as ATP is rapidly degraded to adenosine by ectonucleotidases
present on bladder smooth muscle (Welford et al., 1987) and might therefore be 
acting on Pi-purinoceptors to inhibit smooth muscle contraction. Therefore the
increased susceptibility to desensitization by ATP in the neonate could be due to the 
increased potency of adenosine in neonatal urinary bladder rather than an 
enhancement in the purinergic innervation.
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Cholinergic agonists, such as bethanechol, have also been found to elicit responses in 
urinary bladder from birth (Zderic et al., 1990) and indeed in the studies reported here 
it has been shown that carbachol was able to contract rat urinary bladder at day 2 (the 
earliest day tested). Responses to a- and p- adrenergic agonists on the other hand are 
virtually absent at birth in rabbit urinary bladder but rapidly develop over the first 6 
weeks of life (Levin et al., 1981).
Inhibitory responses to adenosine were observed at day 2 suggesting that functional 
Pl-puiinoceptors are also present from birth. Between days 2 and 25 adenosine was
much more potent than in the adult and the physiological implications of this are 
unclear. Adenosine would act to oppose the excitatory actions of ATP and since ATP 
can be dephosphorylated to adenosine then one might expect adenosine to be the 
natural regulator of ATP-induced responses. Physiologically, the high inhibitory 
potency of adenosine in the neonate may account for the inability of young rats to 
urinate without maternal perianal stimulation. Purinergic innervation may be 
important in human bladder in various disease states (Andersson, 1984) and for 
example, an imbalance in the responsiveness to purines, such as an increased sensivity 
to ATP or lack of inhibitory control by adenosine could be involved in bladder 
voiding dysfunction.
4.2. EFFECT OF 8-SPT ON RESPONSES TO PURINES ON RAT 
DUODENUM
ATP is known to act directly on P2-purinoceptors however ATP is rapidly 
dephosphorylated, ultimately to adenosine, by ectonucleotidases present on smooth 
muscle (Welford et al., 1986; 1987), and this degradation can complicate studies of
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the actions of ATP and its analogues. Some analogues of ATP in which a bridging 
oxygen between the phosphate groups has been replaced by a methylene group, such 
as AMPCPP and AMPPCP, are much more resistant to degradation and are therefore 
useful in the study of Pz-purinoceptors (Moody & Bumstock, 1982; Welford et al.,
1986; 1987).
In the rat duodenum ATP, 2MeSATP, AMPCPP, AMPPCP and adenosine were all 
inhibitory with a potency order for the P2-purinoceptor of 2MeSATP > ATP > 
AMPCPP which would suggest that these analogues are acting via P2Y-purinoceptors 
(Bumstock & Kennedy, 1985).
8-SPT is a highly water soluble derivative of theophylline and is a potent P%- 
purinoceptor antagonist (Smellie et àl., 1979). It is preferable to theophylline as it 
has virtually no phosphodiesterase activity due to its inability to penetrate into cells 
(Heller & Olsson, 1985). 8-SPT (l(X)pM) did not shift the concentration-reqionse 
curve to ATP nor did it shift the concentration-response curve to 2MeSATP, which is 
known to be broken down at a similar rate as ATP on other smooth muscle 
preparations (Welford et al., 1986; 1987), which implies that they act solely on P2- 
purinoceptors in this tissue. Responsfes to AMPCPP, a stable ATP analogue, were not 
antagonized by 8-SPT (l(X)pM) also demonstrating that it acts solely as a P2- 
purinoceptor agonist, however the concentration-response curve for AMPCPP was 
steeper than those for ATP and 2MeSATP, a finding similar to that seen on guinea- 
pig taenia coli (Maguire & Satchell, 1979), and which is possibly due to its resistance 
to degradation. These results are in agreement with others who have shown that 
inhibitory responses to ATP on rat duodenum are not antagonized by the Pi-
purinoceptor antagonist 8-phenyltheophylline (8-PT) (Manzini et al., 1985; Serio et 
al., 1990).
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Responses to AMPPCP, another ATP analogue resistant to degradation by 
ectonucleotidases (Welford et al., 1986; 1987; Bailey & Hourani, 1990), surprisingly 
were abolished by 8-SPT (l(X)pM) which would suggest that it is acting on Pi- 
purinoceptors in the rat duodenum. H.p.l.c. analysis has confirmed that AMPPCP is 
resistant to degradation as 87% remained after a 20 minute incubation period with the 
tissue (section 3.5.2.). In a similar study only 9% of the ATP remained after this 
incubation period (section 3.5.1.) which would suggest that the negligable 
degradation of AMPPCP cannot account for its Fi-purinoceptor activity. Responses 
to adenosine were also abolished by 8-SPT (lOOpM) confirming previous reports that 
adenosine is acting as a Pi-purinoceptor agonist (Gaion et al., 1988).
The ability of AMPPCP to activate Pi-purinoceptors has been demonstrated in other 
smooth muscle preparations, however in these studies ATP was also shown to have a 
similar effect leading to controversy as to whether this action was due to degradation 
of the purines. In guinea-pig and frog atria ATP and AMPPCP have negative 
inotropic and chronotropic effects which have been shown to be antagonized by 
theophylline, potentiated by the adenosine uptake inhibitors dipyridamole and EHNA 
and reduced by adenosine deaminase, suggesting that they are acting on Pi- 
purinoceptors following degradation to adenosine (Bumstock & Meghji, 1981; 
Moody et al., 1984). Similar findings have been reported in guinea-pig ileum where 
the inhibitory effects of ATP and AMPPCP on transmurally stimulated ileum are 
antagonized by theophylline, potentiated by dipyridamole and reduced by adenosine 
deaminase (Moody & Bumstock, 1982; Moody et al., 1984). In the ileum AMPCPP 
did not appear to have any Pi effect which was attributed to a greater resistance to
degradation of this analogue. However whilst after a 30 minute incubation with the 
tissue 81% of AMPCPP remained compared to only 10% of AMPPCP, at 10 minutes 
both analogues had broken down to the same extent with 56% and 59% respectively, 
remaining at this time (Moody & Bumstock, 1982). Although it is not possible to
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recreate the enviroment at the receptor site, and therefore degradation of exogenous 
purine in the bathing medium is taken as an indication of what is occurring at the 
receptor, it would be expected that a 10 minute incubation period would reflect the 
extent of degradation of the purine in the vicinity of the receptor.
Other authors however have shown that degradation of ATP and AMPPCP is not a 
pre-requisite for Pi-puiinoceptor activity. Wiklund et al., (1985) demonstrated that in 
guinea-pig ileum, 8-SPT antagonized responses to adenosine, ATP and AMPPCP 
with similar pA2 values suggesting that all three agonists are acting on the same
receptor. However whilst adenosine deaminase abolished responses to adenosine it 
had no effect on responses to ATP suggesting that it is not degraded prior to its Pi 
action. They subsequently showed that adenosine 5'-(a,p-methylene) diphosphonate 
(AMPCP) and thymidine 5 -diphosphate, which inhibit the enzyme 5-nucleotidase 
and therefore ^ e  degradation of adenine nucleotides, were also without effect on 
responses to ATP suggesting that the action of ATP is not dependent on its 
degradation to adenosine (Wiklund & Gustafsson, 1986). In guinea-pig atrium 
responses to ATP and AMPPCP are sensitive to theophylline but are insensitive to 
adenosine deaminase again suggesting that they act p er  se (Collis & Pettinger, 1982). 
This inhibitory action of ATP and AMPPCP, which is sensitive to Pi-purinoceptor
antagonists but unaffected by drugs which modulate nucleotide metabolism, has been 
taken by some authors to represent a third purinoceptor subtype which has been 
termed the Pg-purinoceptor (Shinozuka et al., 1988; Forsyth et al., 1991). The
existence of this third receptor however has not been widely accepted and could be 
explained by the finding that AMPPCP is a direct Pi-purinoceptor agonist
In other tissues, for example dog saphenous vein (De Mey et al., 1979); guinea-pig 
taenia coli (Brown & Bumstock, 1981a) and rat aorta (Rose Meyer & Hope, 1990) 
where a mixture of Pi- and P2-purinoceptors exist, ATP and AMPPCP do not appear
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to have any Pi-puiinoceptor activity and instead act exclusively as P2-purinoceptor 
agonists.
In all of these studies ATP and AMPPCP appear to have similar actions unlike the 
present findings on rat duodenum where ATP appears to have only P2-purinoceptor 
activity whilst AMPPCP acts as a Pi-puiinoceptor agonist with no apparent P2 effect. 
A similar result has been demonstrated on rat colon muscularis mucosae where 
responses to AMPPCP were found to antagonized by 8-SPT whereas those to ATP, 
2MeS ATP and AMPCPP were not affected by the Pi-purinoceptor antagonist. In this
tissue the action of AMPPCP was concluded to be direct as it was highly resistant to 
degradation when compared to ATP (Bailey & Hourani, 1990).
Although from the results it appears that adenosine and AMPPCP act via Pi- 
purinoceptors it is not clear whether they act on the same receptor subtype. The 
results suggest that 8-SPT is 10 fold more potent against AMPPCP than adenosine as 
a dose-ratio of around 4.5 was observed for adenosine and AMPPCP at a 
concentration of 8-SPT of 20pM and 2pM respectively. 8-PT, a Pi-puiinoceptor 
antagonist similar to 8-SPT, has been reported to exhibit moderate Ai selectivity in 
ligand binding or adenylate cyclase based assay systems using rat tissues. 8-SPT also 
displays some selectivity in these systems although it is less marked than for 8-PT 
especially in ligand binding experiments (Bruns et al., 1986; Ükena et al., 1986a). In 
isolated tissue studies no Ai selectivity has been observed and on guinea-pig atria 
(which is thought to possess A% receptors) (Collis, 1983) and guinea-pig aorta and 
trachea (A2 receptors) (Brown & Collis, 1982; Collis &Brown, 1983) 8-PT and 8- 
SPT have been shown to cause equivalent degrees of antagonism of adenosine evoked 
responses with similar pA2 values (Collis et al., 1985; Collis et al., 1987; Collis et al.,
1989). It is possible that Ai selectivity is only apparent in rat tissues, as from binding
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studies it appears that Pi-purinoceptor antagonists have a higher affinity for rat rather 
than guinea-pig membranes (Ukena et al., 1986b) and indeed it has been shown that 
8-PT exhibits a 5-fold greater affinity for adenosine receptors in rat atria than in atria 
from guinea-pigs (Collis et al., 1988).
Since on rat duodenum 8-SPT was 10-fold more potent against AMPPCP than 
adenosine and the fact that 8-SPT can show Ai selectivity in some assay systems, this 
suggested that adenosine and AMPPCP were acting on separate Pi-purinoceptors: 
with adenosine acting on A2 receptors and AMPPCP acting on Ai receptors. This 
proposal was investigated using the Ai selective antagonist l,3-dipropyl-8- 
cyclopentykanthine (DPCPX).
43. EFFECT OF DPCPX ON RESPONSES TO PURINES
4.3.1. Rat duodenum
The Pi-purinoceptor antagonist DPCPX has been shown to be an A% selective 
antagonist with a dissociation constant on A% receptors in the nanomolar range, 
whereas on A2 receptors it has a dissociation constant in the micromolar range (Collis
et al., 1989; Shimada et al., 1991) and is therefore useful in the characterization of 
Pl-puiinoceptors.
In the duodenum adenosine, *N6-cyclopentyladenosine (CPA), 5-N-ethyl- 
carboxamidoadenosine (NECA), 2-p-((carboxyethyl)phenethylamino)-5'-carbox- 
amidoadenosine (CGS21680) and AMPPCP all caused relaxation with an order of
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potency of NECA > CPA > AMPPCP = adenosine > CGS21680. This order of 
potency did not fall clearly into that for Ai or A2 receptors (Bruns, 1990; Stiles,
1991), as NECA and CPA were equipotent. Similar results have been interpreted to 
imply the existence of a third class of adenosine receptor, which has been termed the 
A3 receptor (Ribeiro & Sebastiao, 1986), although this suggestion has not gained 
wide acceptance as the receptor has many similarities with the Ai receptor. From the 
results it can be seen that CGS21680 was not a potent agonist on this tissue. 
CGS21680 has been proposed to be a selective A2 agonist as it is ineffective at
inhibiting dopamine release in the brain (Lupica et al., 1990) and does not induce 
bradycardia in isolated perfused working heart (Hutchison et al., 1989) both of which 
are Ai-mediated effects (Fredholm & Dunwiddie, 1988; Evans et al., 1982). It has 
also been proposed, from ligand binding studies in the central nervous system, that it 
has a higher affinity for A2a rather than A2b receptors since it is equipotent with 
NECA in the striatum which possesses A2a receptors (Jarvis et al., 1989), but is only 
a weak agonist in the hippocampus where A2b receptors predominate (Lupica et al.,
1990).
The results would suggest that the rat duodenum possesses A2b receptors as 
CGS21680 was 250 fold less potent than NECA. In other smooth muscle 
preparations CGS21680 has been shown to display varying affinity depending on the 
smooth muscle preparation or species used. CGS21680 is a potent vasorelaxant of 
precontracted porcine coronary artery being more potent than NECA, however on
I *
rabbit aorta both NECA and CGS21680 are poor agonists causing only a maximum 
20% relaxation (Balwierczak et al., 1991). Also in dog saphenous vein and guinea- 
pig aorta NECA is much more (approximately 60 fold) more potent than CGS21680 
suggesting that in these tissues A2b receptors are present (Hargreaves et al., 1991), 
however in vivo experiments in the dog have suggested the presence of vascular A2a
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receptors as CGS21680 causes preferential lowering of blood pressure (Levens et al.,
1991).
Whilst agonist potency orders are useful in the classification of receptors the use of 
selective antagonists allows a more accurate analysis. Results using the A% selective
antagonist DPCPX, show that at InM concentration-response curves to AMPPCP and 
CPA were shifted to the right whilst those to adenosine and NECA were unaffected. 
The dose-ratios obtained for AMPPCP and CPA suggest a Kd of around 0.2nM for 
DPCPX. This Kd value is in agreement with Kd values obtained from [3H] DPCPX 
binding to Ai receptors in the central nervous system (Bruns et al., 1987) and in the 
periphery (Leid et al., 1988; Cushing et al., 1988) which would suggest that AMPPCP 
and CPA are acting via Ai receptors in rat duodenum. The Kd value however is
somewhat lower than that expected fiom previous isolated tissue studies as it has been 
found by other authors that DPCPX has an apparent lower affinity for Ai receptors in 
these studies when compared to binding studies. For example, in guinea-pig atria a 
Kd of around lOnM has been reported (Collis et al., 1989) and in electrically 
stimulated satorius muscle of the frog the Kd for DPCPX was around 35nM, although 
this has been interpreted to represent an A3 receptor (Sebastiao & Ribeiro, 1989). 
The difference in Kd may be due to species differences as it is known that Pi- 
purinoceptor antagonists have a higher affinity for rat rather than for guinea-pig 
tissues (Ukena et al., 1986b) although Collis et al., (1988) have shown that in isolated 
tissue studies, DPCPX does not have a significantly higher affinity for Ai receptors in
the rat when compared to guinea-pig tissue.
The observation that the concentration-response curves to AMPPCP and CPA were 
shifted by InM DPCPX is consistent with the rat colon muscularis mucosae, where 
responses to AMPPCP and to CPA were also antagonized by InM DPCPX suggesting 
that they are acting via an Ai receptor. However in this tissue responses to adenosine
169
and NECA were also antagonized by InM DPCPX implying that all of the agonists 
were acting via a common receptor (Bailey et 1992). These results are in contrast 
to the rat duodenum where concentration-response curves to adenosine and NECA 
were unaffected by DPCPX (InM) but were shifted by IpM DPCPX. The Kd for
DPCPX against adenosine and NECA was around 0.2pM being similar to that 
obtained in guinea-pig aorta and trachea (Collis et al., 1989; Brackett & Daly, 1991) 
which would suggest that adenosine and NECA are acting via A2 receptors.
The significance of the presence of two Pi-puiinoceptor subclasses, both mediating 
an inhibitory response, is unclear as, in general, in smooth muscle A2 receptors
I
mediate relaxation whereas Ai receptors mediate presynaptic inhibition of 
neurotransmitter release or postsynaptic contractile responses (White, 1988; Kennedy,
1990). Similar anomalies have been shown for other neurotransmitters, for example 
intestinal smooth muscle from many species contains a- and p-adrenoceptors both of 
which mediate an inhibitory response (Biilbring & Tomita, 1987). In several tissues 
the presence of both subclasses of Pi-puiinoceptor has been reported. In guinea-pig 
trachea and aorta and in arterioles from the hamster skin microcirculation both Ai and 
A2 receptors are present however the Ai receptor mediates contraction while the A2
receptor mediates relaxation (Farmer et al., 1988; Stoggall & Shaw, 1990; Stojanov 
& Proctor, 1989). Also in ventricular cardiomyocytes the localization of both Ai and 
A2 receptors has been demonstrated, although it appears that only the A% receptor is 
involved in reducing contractility of the ventricles and the A2 receptor does not 
appear to be functionally significant (Behnke et al., 1990). For two receptor subtypes 
to mediate the same response in one tissue preparation is unusual, and it is not at all 
clear why such an apparently redundant system should have evolved. It is interesting 
to note however that the natural agonist, adenosine, appears to act solely on A2 
receptors, which is surprising since non-selective Pi agonists are generally thought to 
have a higher affinity for Ai rather than A2 receptors (Jacobson, 1990). This may
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indicate that there is a low density of Ai receptors in the rat duodenum which would 
in turn suggest that AMPPCP has a high affinity for Ai receptors. One possible 
explanation for the relaxant A% effect that was observed was that the carbachol used 
to precontract the tissue was stimulating ganglionic nicotinic receptors to induce the 
release of acetylcholine or some other excitatory transmitter and that the Ai receptors
were located presynaptically to oppose this release. However it has previously been 
observed that in rat duodenum the response to the nicotinic agonist 
dimethylphenylpiperazinium (DMPP) was relaxation rather than contraction, possibly 
due to the stimulation of purinergic nerves (Manzini et al., 1985). The studies 
described in this thesis confirmed that DMPP causes relaxation of the rat duodenum, 
although at higher concentrations DMPP-induced relaxations were followed by 
contraction. Hexaméthonium (lOpM) inhibited responses to DMPP but did not 
inhibit carbachol-induced contractions, suggesting that the carbachol was acting 
directly on the smooth muscle. In addition, hexaméthonium did not affect the 
responses to the Ai agonists, AMPPCP and CPA, which again suggests that they were
not acting on presynaptic receptors. In order to substantiate this further 
concentration-response curves to AMPPCP and CPA were obtained with bethanechol 
as the precontracting agent as bethanechol is thought to act solely on muscarinic 
receptors, being devoid of any nicotinic activity (Kaiser & Rzeszotarski, 1987). Both 
AMPPCP and CPA relaxed rat duodenum precontracted with bethanechol (IpM) with 
similar EC50 values to those obtained with carbachol, again implying that the agonists 
are acting postsynaptically (section 3.3.1.).
4.3.2. Rat urinary bladder
Adenosine and NECA each inhibited contractions of the rat bladder induced by 
carbachol (3pM) with NECA being almost 100-fold more potent than adenosine.
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CPA was only weakly active on this tissue and this would therefore suggest that the 
Pl-puiinoceptor mediating inhibition in this tissue is of thé A% class. The observation 
that CGS21680 was also only a weak agonist implies that the A2 receptor is of the 
A2b subtype, as CGS21680 has a high affinity for A2a receptors but has a much lower 
affinity for A2b receptors (Hutchison et al., 1989).
The proposal that the Pi-purinoceptor is of the A2 subtype was confirmed using 
DPCPX, since a high concentration of DPCPX (ipM) was required to antagonize
I
responses to adenosine and NECA. A Kd value of 0.2pM was obtained for DPCPX 
which is similar to that obtained for A2 receptors in other isolated tissue studies 
(Collis et al., 1989; Brackett & Daly, 1991) and also correlates with the Kd value for 
DPCPX in rat duodenum when adenosine and NECA were the agonists used. This 
would suggest that in the rat duodenum and urinary bladder adenosine and NECA are 
acting at a common receptor. The log concentration-response curve to NECA in rat 
urinary bladder however was somewhat flattened by DPCPX (IpM), suggesting that 
it may not be having a solely competitive effect here.
ATP and AMPPCP, which act at P2X-ptninoceptors in this tissue to cause contraction, 
do not appear to have any Pi-puiinoceptor activity as their contractions were not 
enhanced by blockade of Pi-puiinoceptors by DPCPX (IpM). There was a slight 
inhibition of responses to ATP and AMPPCP in the presence of IpM DPCPX and the 
reason for this is unclear, although it is not due to tachyphylaxis to the agonists as 
vehicle alone had no effect on the concentration-response curves.
Therefore in the rat urinary bladder AMPPCP appears to act solely on P2X- 
purinoceptors with no A2 receptor activity. The lack of A2 agonist activity of 
AMPPCP is comparable to its rather weak Pi effect on guinea-pig taenia caeci
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(Hourani et al., 1991), which is also thought to possess A2 receptors (Bumstock et al., 
1984b).
4.4. EFFECT OF PURINES ON RAT VASA DEFERENTIA
There is substantial evidence suggesting that ATP and noradrenaline are co­
transmitters in the vas deferens of many species. Transmural stimulation of the vas 
deferens elicicts a biphasic response, an initial twitch-like response followed by a 
tonic response (Meldrum & Bumstock, 1983). The tonic response is sensitive to a- 
adrenoceptor blockade and is therefore thought to be due to the release of
I
noradrenaline, however the phasic response is resistant to a-adrenoceptor antagonists 
and it has been proposed that this phase of the contraction is mediated by a transmitter 
other than noradrenaline (Ambache & Zar, 1971). Considerable evidence has 
accumulated to suggest that the initial response is mediated by ATP. The phasic 
response is mimicked by exogenous ATP (Sneddon & Westfall, 1984) and is 
abolished after desensitization of Pa-puiinoceptors using AMPCPP (Meldrum & 
Bumstock, 1983). Studies with the putative P2-puiinoceptor antagonist 
arylazidoaminopropionyl-adenosine 5'-triphosphate (ANAPP3) have shown that it 
selectively antagonizes the first component of the neurogenic response (Fedan et al., 
1981; Trachte et al., 1989) but has no effect on responses to noradrenaline, 
acetylcholine, histamine or potassium chloride (KCl) (Hogaboom et al., 1980). Also 
electrophysiological studies have shown that the neurogenic responses in the vas 
deferens is characterized by an excitatory junction potential (e.j.p.) which can be 
mimicked by the application of exogenous ATP, whereas exogenous noradrenaline 
produces no such response (Sneddon & Bumstock, 1984; Sneddon & Westfall, 1984).
I
The release of ATP following transmural nerve stimulation has also been
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demonstrated in many species including the rat (Sperlagh & Vizi, 1988) and guinea- 
pig (Lew & White, 1987).
In the vas deferens ATP and noradrenaline have been reported to "auto-inhibit" 
neurotransmitter release (S^ame & Astrand, 1985) ' although there is some 
controversy as to how ATP acts. Some workers have proposed that the presynaptic 
inhibition of neurotransmitter release by ATP is due to its degradation to adenosine 
which then acts via Pi-purinoceptors, as adenosine is more potent than ATP at 
inhibiting nerve-mediated contractions and the inhibitory actions of adenine 
nucleotides are potentiated, by the adenosine uptake inhibitor dipyridamole and 
antagonized by the Pi-puiinoceptor antagonist theophylline (Clanachan et al., 1977).
I
Others however have suggested that ATP can act p er  se as they have shown that the 
inhibitory action of ATP is not potentiated by 6-S-(p-nitrobenzylthio)guanosine 
(NBTGR) (an adenosine uptake inhibitor) or reduced by adenosine deaminase and the 
relatively stable ATP analogue, AMPPCP also has an inhibitory action (Forsyth et al.,
1991). In this study the inhibitory effect of AMPPCP was completely antagonized by 
8-SPT (30pM) which led them to suggest that it was acting via a novel receptor 
which they termed the Pg-purinoceptor. However studies reported in this thesis have 
shown that AMPPCP is in fact a Pi-puiinoceptor agonist arid do not support the 
proposal of a third purinoceptor subtype (see section 3.2.).
4.4.1. Effect of adenosine and adenosine analogues on field stimulated responses
It is now generally assumed that adenosine mediates inhibition of neurotransmitter 
release and it has been shown that adenosine and adenine nucleotides can reduce theI
release of [3R] noradrenaline and inhibit nerve-mediated contractions (Wakade & 
Wakade, 1978; Sneddon et al., 1984) possibly via Ai receptors (Paton, 1981). The
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results presented in this thesis confirm the inhibitory action of adenosine and its 
analogues on nerve-mediated contractions of rat vas deferens, the analogues having
I
an order of potency of NECA = CPA > adenosine. This order of potency however 
does not fit into the conventional Ai or A2 pattern (Collis, 1990) but is in agreement 
with other studies in the rat vas deferens where a potency order of NECA > CPA > 
2-phenylaminoadenosine (CV1808) has been observed, CV1808 being a selective A2
agonist. In these studies a potency ratio of 65 was obtained for L-PIA to D-PIA, 
which normally indicates the presence of an Ai receptor, however the potency of 
NECA was greater than one would expect if the receptor was of the Ai class (Paton,
1989). This order of potency could be taken as support for the existence of an A3 
receptor subtype, at which NECA and CPA have been proposed to be equipotent 
(Ribeiro & Sebastiao, 1986) however the existence of this receptor subtype is still not 
widely accepted and an alternative explanation is that the rat vas deferens contains 
instead a mixture of presynaptic Ai receptors and postsynaptic A2 receptors.
Huidoboro-Toro & Parada (1989) have previously demonstrated that in rat vas 
deferens adenosine and adenosine analogues inhibit nerve-mediated contractions and 
the release of pHJ noradrenaline with a potency order indicative of an Ai receptor-
mediated effect, as CHA > adenosine > NECA. They also showed however that 
adenosine and its analogues inhibited contractions induced by exogenous ATP and 
noradrenaline with a potency order of NECA > adenosine > CPA suggesting that in 
this case they were acting via postsynaptic A2 receptors. Also Gustafsson et al.,
(1990) reported that L-PIA and NECA could inhibit pH] noradrenaline release, an 
effect that was antagonized by DPCPX (lOnM), but that inhibitory actions of NECA 
on contractile responses were relatively unaffected by this concentration of DPCPX 
suggesting that these effects were mediated by a separate receptor (Gustafsson et al.,
1990).
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Studies with the Ai selective antagonist, DPCPX also gave support to the proposal 
that a mixture of Ai and A2 receptors exists since the present studies have shown that 
whilst InM DPCPX did not antagonize responses to adenosine or NECA it did shift 
to the right the concentration-response curve to CPA with a Kd value for DPCPX of 
around 3nM. This Kd value is similar to that seen for Ai receptors in other isolated
tissue preparations (Collis et al., 1989). Responses to adenosine and NECA were 
inhibited by IpM DPCPX with a Kd value of around 0.37pM indicative of an A2 
receptor-mediated effect (Collis et al., 1989; Brackett & Daly, 1991).
4.4.2. Effect of adenosine and adenosine analogues op responses to exogenous 
ATP and noradrenaline
In order to substantiate the hypothesis that the rat vas deferens contains a mixture of 
Ai and A2 receptors the action of adenosine and adenosine analogues on contractile
responses to exogenous ATP and noradrenaline were investigated. It has previously 
been reported that whilst adenosine inhibits field stimulated responses it has no effect 
on responses to exogenous noradrenaline (Clanachan et al., 1977). Also the A2 
selective agonist CV1808 has been shown to be without effect on nerve-mediated 
contractions of the rat vas deferens or on contractions produced by exogenous 
noradrenaline (Major et al., 1989) implying that the Pi-puiinoceptors are present 
presynaptically and are of the Ai subtype. The results presented here showed, 
however, that both adenosine and NECA dose-dependently inhibited responses to 
exogenous ATP and noradrenaline with NECA being more potent than adenosine in 
each case, which is characteristic of an A2 receptor-mediated effect (Collis, 1990). 
The Ai selective agonist, CPA did not inhibit contractions to exogenous ATP of 
noradrenaline which is in agreement with previous studies (Sneddon et al., 1984; 
Major et al., 1989) and confirms that the inhibitory action of adenosine and NECA is
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via postsynaptic A2 receptors. The lack of effect reported by Major et al., (1989) of 
the A2 selective agonist CV1808 could indicate that these A2 receptors are of the A2b 
subclass, as CV1808 has selectivity for A2a receptors in ligand binding studies (Bruns 
et al., 1986).
Therefore it appears that the rat vas deferens possesses both Ai and A2 receptors. 
The Ai receptors are likely to be located presynaptically to modulate neurotransmitter 
release whereas A2 receptors are present postsynaptically and inhibit smooth muscle
contraction. In this tissue adenosine and NECA appear to exert their effects solely 
through A2 receptors which is perhaps surprising since in general they are thought to 
have a higher affinity for Ai receptors than A2 receptors (White, 1988; Jacobson,
1990). This anomolous result however is similar to that’ seen in the rat duodenum, 
which also possesses a mixture of Ai and A2 receptors, where both NECA and 
adenosine act via the A2 receptor subtype (section 3.3.1.). The finding that the 
natural agonist adenosine appears to act only via postsynaptic A2 receptors to inhibit 
nerve-mediated contractions raises doubts as to whether adenosine is responsible for 
the feedback inhibition of transmitter release in the rat vas deferens. However it 
could be that adenosine is having an inhibitory presynaptic Ai effect but that the 
effect is masked by the A2 mediated response.
4.4.3. Effect of purines on neonatal rat vasa deferentia
The ontogenetic profile for the inhibitory action of adenosine on nerve-mediated 
contractions was investigated to see if the potency of adenosine changed with age. 
The results showed that adenosine was inhibitory at day 15, the earliest day at which 
nerve-mediated contractions could be observed, and that its potency decreased with 
age. These results are comparable to previous findings in the rat urinary bladder
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where adenosine inhibited carbachol contractions via A2 receptors and was much 
more potent in the neonate than in the adult (see section 3.1.4.). However unlike the 
rat urinary bladder where ATP induced contractions via ? 2X"Purinoceptors as early as 
day 2, in the rat vas deferens contractions to ATP were not observed until day 15. It 
is interesting to note that the ontogeny of responses to ATP mirrored those to nerve- 
stimulation, where no nerve-mediated response was apparent until day 15 and after 
day 15 the maximum response increased up to day 25. This ontogenetic profile was 
selective for ATP since noradrenaline contracted the rat vas deferens as early as day 
10 (the earliest day tested) and the maximum response produced by noradrenaline 
decreased with age. These results are in agreement with those of MacDonald & 
McGrath (1984) who showed that the vasa from sexually immature rats (3-4 weeks 
old) were more sensitive to noradrenaline than were the vasa from adults rats, but 
appeared to lack functional adrenergic transmission. The results also suggest that in 
neonatal tissue, ATP is more important as a neurotransmitter than is noradrenaline. 
The importance of ATP as a neurotransmitter in neonatal tissue has also been 
suggested from studies in other tissues including the urinary bladder, where ATP has 
been shown to be more potent in neonatal tissue than in the adult and purinergic 
innervation is apparently functionally more important in the neonate (Zderic et al., 
1990; Keating et al., 1990).
4.5. ONTOGENY OF THE METABOLISM OF PURINES
One of the complicating factors in the study of the pharmacology of ATP is that it can 
be rapidly dephosphorylated via adenosine 5'-^phosphate (ADP) and adenosine 5'- 
monophosphate (AMP) to adenosine by ectonucleotidases present on the surface of 
cells (Pearson & Gordon, 1985). Therefore ATP, as well as having direct effects at
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P2-puiinoceptors, can have an indirect action via Pi-purinoceptors. Also the potency 
of ATP has been shown to be affected on some smooth muscle preparations by 
ectonucleotidase activity since stable ATP analogues are much more potent than ATP 
on tissues such'as guinea-pig urinary bladder (Welford et al., 1987).
The results presented in this thesis have shown that the development of responses to 
ATP and adenosine in rat duodenum and urinary bladder varies with age. This 
variation could be due to a number of factors including a change in either receptor 
number, the second messenger system involved in eliciting the response or the 
degradation and/or uptake of the agonist being studied. The ontogeny of the 
metabolism of purines was therefore studied to see if it also varied with age and if 
there was any correlation with the potency of ATP and adenosine from isolated tissue 
studies.
4.5.1. Rat duodenum: degradation of ATP and AMPPCP
ATP was rapidly degraded by adult rat duodenum to ADP, AMP and inosine, with 
only 10% remaining after a 20 minute incubation period with the tissue. The half-life 
of ATP in these studies was around 5 minutes being similar to that seen for ATP in 
cultured pig aortic smooth muscle cells (Pearson et al., 1980). There was a transient 
accumulation of ADP which peaked at about 5 minutes which is consistent with other 
studies on smooth muscle cells including studies on cultured smooth muscle cells 
(Gordon et al., 1989), guinea-pig taenia coli (Welford et al., 1986), and guinea-pig 
urinary bladder (Welford et al., 1987) whereas the concentration of AMP rose more 
slowly, peaking at around 10 minutes being similar to that observed on guinea-pig 
taenia coli (Welford et al., 1986). Surprisingly no adenosihe was detected at any time 
point studied, the major AMP metabolite being inosine. This is in contrast to other
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studies on arterial smooth muscle cells where it has been shown that the concentration 
of adenosine rises steadily with around 95% of the ATP emerging as adenosine when 
hydrolysis of the nucleotide was complete (Gordon et al., 1989) and is more similar 
to the pattern seen with endothelial cells which are relatively efficient at converting 
adenosine to inosine (Slakey et al., 1986). In cultured pig aortic smooth muscle cells 
it appears that the major inactivation pathway of adenosine is via uptake into the cells 
with the activity of adenosine deaminase being relatively low (Pearson et al., 1978), 
whereas for rat intestine and more specifically rat duodenum the activity of adenosine 
deaminase has been reported to be high (Centelles et al., 1987; Franco et al., 1988) 
and could account for lack of adenosine observed.
The pattern of ATP metabolism in neonatal rat duodenum was similar to the adult 
with a transient rise in ADP concentration and a more gradual increase in the 
concentration of AMP. With 2 and 15 day old rat duodenum however a small amount 
of adenosine was detected with the concentration of adenosine being highest at 2  days 
old suggesting that the activity of adenosine deaminase increases with age.
It has previously been shown that in the rat duodenum relaxations to ATP are 
observed from 'day 15, but that ATP is much less potent at this age than in the adult 
(section 3.1.3.). This reduced potency is not due to a higher nucleotidase activity at 
this age and must therefore be due to another factor. Similarly ATP has been shown 
to contract 2 to 15 day old rat duodenum with ATP being most potent in 2 day old 
and least potent in 15 day old tissue. This increased potency of ATP the day after 
birth is not due to a lack of ectonucleotidases present on the smooth muscle as ATP 
degradation at 2 days was as rapid as for adult tissue.
In order to check that the enzymes responsible for the degradation of ATP were true 
ectonucleotidases, in that they were bound to the membrane, control studies were
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performed in which ATP was incubated in Krebs buffer that had previously contained 
rat duodenum. Surprisingly ATP was rapidly degraded to ADP and AMP at all ages 
when incubated in this medium, suggesting that the enzymes were not membrane 
bound but had leaked into the buffer. The finding that AMP was not further degraded 
to any significant extent in adult and 15 day old tissue indicates that the 5'- 
nucleotidase is however a true ectoenzyme. In contrast, in rat duodenum from 2 day 
old rats the buffer in which tissues had been incubated was capable of degrading ATP 
into inosine, which could indicate that at this age the 5'-nucleotidase is not membrane 
bound. However, 2 day old rat duodenum is extremely fragile and in the time course 
of the experiment it is likely that thin fragments of the tissue were shed into the 
incubating medium which would then be responsible for the pattern of degradation 
seen. In other smooth muscle preparations including cultured smooth muscle cells 
(Pearson et al., 1980) and guinea-pig taenia coli and urinâry bladder (Welford et al., 
1986; 1987) little or no leakage of nucleotidases has been reported.
AMPPCP has been reported to be a stable ATP analogue, resistant to degradation by 
ectonucleotidases (Welford et al., 1986; 1987). Studies on the rat duodenum have 
shown that the potency of AMPPCP at relaxing rat duodenum also varies with age, 
being less potent than the adult at 5 days, least potent at 10 days and most potent at 
day 25 (section 3.1.3.). Some tissues have been reported to contain an ATP 
pyrophosphohydrolase that can convert AMPPCP directly to AMP (Flogaard & Torp- 
Pederson, 1978) and the varying potency of AMPPCP could suggest that AMPPCP is 
being degraded in this tissue. The results show however that only a small proportion 
of the AMPPCP is degraded in adult rat duodenum implying that it is relatively stable 
in this tissue. Studies have also shown that responses to AMPPCP can be antagonized 
by Pi-puiinoceptor antagonists such as 8-SPT and DPCPX (section 3.2. and 3.3.1.), 
however the Pi-puiinoceptor activity of AMPPCP is unlikely to be due to its 
metabolism as degradation was low when compared to ATP which has no Pi-
181
purinoceptor activity.
4.5.2. Rat duodenum: degradation of adenosine
Adenosine was rapidly degraded to inosine by both 2  day old and adult rat duodenum 
with all of the adenosine being converted to inosine within 5 minutes. It was also 
apparent that around 20% of the inosine was metabolized further at both ages. The 
rapid deamination of adenosine in rat duodenum is consistent with the studies by 
Franco et al., (1988) who also showed the activity of adenosine deaminase to be 
relatively high in this tissue. From isolated tissue studies reported in this thesis it has 
been shown that the potency of adenosine at relaxing rat duodenum varies with age 
being less potent than the adult at day 5. It is not possible to conclude from the 
results of adenosine metabolism whether the lack of potency of adenosine in the 
neonate is due to a higher adenosine deaminase activity at this age, although studies 
on the degradation of ATP suggested that the activity of adenosine deaminase was 
similar in both 2 day old and adult tissues with around 45% of the ATP being 
converted to inosine at both ages. Control studies demonstrated that the adenosine 
deaminase also leaks into the medium and is therefore not membrane bound, as in 
both 2  day old and adult rat duodenum adenosine was completely converted to 
inosine by buffer that had previously contained the tissue.
4.5.3. Rat urinary bladder: degradation of ATP and adenosine
Degradation of ATP by the rat urinary bladder was slower than that observed in the 
duodenum at all ages and was slower than that previously reported for guinea-pig 
bladder (Welford et al., 1987). The reduced rate of ATP metabolism could be due to 
a difference in the surface area of tissue available to the buffer as it would be
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expected that in the duodenum the surface area would be increased due to the 
presence of villi. Also the weight of the tissue was greater for 15 day old and adult 
rat duodenum when compared to urinary bladder, however at 2 days the weight of the 
duodenum was the same as for all ages of urinary bladder and yet the rate of 
degradation of ATP was faster for the duodenum even at this age. The main 
degradation products of ATP metabolism in the urinary bladder were ADP and AMP, 
with negligable adenosine accumulating at any age, thus suggesting that 5 '- 
nucleotidase activity is low in this tissue. Again the enzymes responsible for the 
degradation of ATP appear not to be bound to the membrane as ATP was degraded 
by buffer that had previously contained tissue. This was unexpected as in previous 
studies on the degradation of ATP by guinea-pig bladder no such leakage was 
observed (Cusack & Hourani, 1984; Welford et al., 1987). The potency of ATP at 
contracting rat urinary bladder varies with age being similar to the adult at day 2  but 
more potent than the adult at day 10. The ontogenetic profile for ATP however 
mirrored that to AMPPCP, an agonist that has been shown to be resistant to 
degradation in guinea-pig bladder (Welford et al., 1987), which would suggest that 
the changes in potency are not due to changes in nucleotidase activity. The results 
presented here support this suggestion as there was no significant difference in the 
degradation of ATP in 2 day old, 10 day old or adult rat urinary bladder. From 
studies on both ATP and adenosine metabolism it was apparent that no uptake or 
deamination of adenosine occurred in the urinary bladder. This is surprising since it 
has been shown that adenosine has potent pharmacological actions on the urinary 
bladder (Dahlén & Hedqvist, 1980) and therefore it might be expected that a system 
for the inactivation of adenosine would also be present.
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4.6. SUMMARY AND FUTURE WORK
The work presented in this thesis clearly shows that Pj- and p2-purinoceptors are 
present and functional at birth in both the rat duodenum and urinary bladder. The 
results in the rat urinary bladder correlate well with the observation that field 
stimulated responses, where ATP has been proposed as the non-adrenergic, non- 
cholinergic neurotransmitter (Fujii, 1988), are also present at birth (Keating et al.,
1990). In rat vasa deferentia responses to ATP were not observed until day 15, 
however studies showed that nerve-mediated contractions were also not apparent until 
posmatal day 15 giving fiirther support to the proposal that ATP is a co-transmitter in 
this tissue (Meldrum & Bumstock, 1983).
In the rat duodenum low concentrations of ATP were inhibitory at every age studied 
and its potency increased with age. Higher concentrations of ATP (3pM and above), 
however, were excitatory between postnatal days 2 and 15 with the potency of ATP at 
inducing this effect decreasing with age until after day 15 when no contractions to 
ATP were then observed. Both the relaxations and contractions were mediated by 
P2Y-purinoceptors, as 2MeSATP was much more potent than ATP at mediating these
effects. The contractions were not due to ATP-induced prostaglandin synthesis as
indomethacin (25pM) did not antagonize the responses, nor were they due to ATP
acting presynaptically to induce the release of an excitatory neurotransmitter, as
tetrodotoxin (IpM) was also without effect. The presence of an excitatory response
to ATP in 2 to 15 day old rat duodenum but only an inhibitory response after day 15,
may reflect changes in the second messenger system. It would be interesting to study
the development and type of second messenger system involved in mediating the two
responses, as for example, it may be that in 2 to 15 day old rat duodenum ATP causes 
an increase in [Ca^+jj which initially induces relaxation, via the opening of Ca^+-
dependent K+ channels and hyperpolarization of the smooth muscle membrane, but
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that a second transduction mechanism exists whereby if the concentration of Ca^+ 
reaches a certain threshold level it can then cause smooth muscle contraction. It 
would also be interesting to study the ontogeny of non-adrenergic, non-cholinergic 
nerve-mediated responses to see if they followed a similar developmental pattern to 
ATP, i.e. excitatory to inhibitory, which would strengthen the proposal that ATP is 
the non-adrenergic, non-cholinergic neurotransmitter in this tissue (Manzini et al., 
1985). The changes in potency of ATP during development were not due to changes 
in the metabolism of the nucleotide as the rate and pattern of breakdown was similar 
in adult and neonatal tissues. The changes may therefore reflect age-related 
variations in receptor density in this tissue or changes in the sensitivity of the second 
messenger system involved.
Surprisingly, in the rat duodenum the stable ATP analogue, AMPPCP, acted via P%- 
and not P2-purinoceptors, as responses to AMPPCP were antagonized by 8-SPT. The 
Pl-purinoceptor activity of AMPPCP was not due to its breakdown to adenosine as in
this tissue it was shown to be relatively resistant to degradation when compared to 
ATP which had no Pj-purinoceptor activity. From studies with adenosine and 
adenosine analogues and the A^ selective antagonist DPCPX, it was found that a 
mixture of postsynaptic Aj and A2 receptors were present on the rat duodenum, with 
AMPPCP acting on the Aj and adenosine acting on the A2 receptors. Non-selective 
Pi agonists are, in general, thought to have a higher affinity for Ai rather than A2
receptors (Jacobson, 1990), therefore it was interesting to observe that the natural 
agonist adenosine appeared to act solely on A2 receptors. It may be that there is only
a low density of A% receptors in the duodenum and therefore the A2-mediated effect
of adenosine masks any Ai action. Indeed, preliminary radioligand binding studies
with [^H] DPCPX have suggested that there are only a small number of Ai binding
sites in this tissue which would support this suggestion. If only a low density of Ai
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receptors exists then the potent pharmacological actions of AMPPCP would also 
imply that AMPPCP has a relatively high affinity for Aj receptors.
In the rat urinary bladder ATP mediated contraction via P2X“Purinoceptors. The 
variation in potency of ATP with age was not due to differences in degradation of the 
nucleotide as again both the rate and pattern of breakdown was similar in adult and 
neonatal tissue and the differences might therefore be due to changes in receptor
density or in the sensitivity of the second messenger system. AMPPCP also 
contracted rat urinary bladder via P2X“Purinoceptors and had no Pi-purinoceptor
activity in this tissue. Adenosine was inhibitory on the rat urinary bladder its effects 
mediated by A% receptors. The observation that AMPPCP had no Pi-purinoceptor
action in this tissue and no P2Y"purinoceptor activity in the rat duodenum would
suggest that it is selective for P2X and Aj receptors.
In the rat vasa deferentia adenosine inhibited nerve-mediated contractions from day 
15 (the earliest day at which nerve-mediated responses could be observed) with 
adenosine being more potent in the neonate than in the adult. Studies showed that 
both presynaptic Aj and postsynaptic A2 receptors were present in this tissue and that 
adenosine appeared to act via postsynaptic A2 receptors to inhibit smooth muscle 
contraction. It may be that adenosine also acted on Aj receptors but that this effect 
was masked by the A2 response, possibly due to a low density of Aj receptors in this 
tissue. This suggestion could be investigated by studying the A^ receptor density in 
this tissue by radioligand binding studies using [^H] DPCPX.
Therefore, adenosine and ATP have been shown to have potent pharmacological 
actions in both neonatal and adult visceral smooth muscle preparations, which 
suggests that purinoceptor-mediated responses may have some functional 
significance. This study has also highlighted the care needed when using ATP
186
analogues for receptor classification as the stable ATP analogue, AMPPCP, is not 
selective for P2-purinoceptors and can also act as an A^ agonist.
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